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Abstract                        
 
    LUBAC (Linear Ubiquitin Assembly Complex) is a ubiquitin E3 ligase 
complex with crucial roles in the initiation of the innate immune response 
and the activation of the NF-kB signaling pathway. LUBAC displays the 
unique feature to generate the M1-linked ubiquitin chains (also called the 
linear ubiquitin chains).  
 N4BP1 (NEDD4 binding protein 1) is identified as a ubiquitin-binding 
protein and acts as a novel regulator to inhibits LUBAC. However, the 
functional role of N4BP1 in the context of its ubiquitin-binding properties 
remains unclear. In this thesis, biochemical, biophysical and structural 
approaches were employed to study the function of N4BP1.  
    This study has shown that the N-terminal part of N4BP1 is required for 
inhibition of the E3 ligase activity of LUBAC. The KH-like domain displays 
weak inhibition on the LUBAC core catalytic subunit HOIP. However, it is the 
UBA-like domain that is defined as the main inhibitory module. The 
inhibitory effect is modulated by the binding interface regions of N4BP1 and 
HOIP. All three domains of the N-terminal part of N4BP1 work synergistically 
together to mediate the inhibitory effect on HOIP.   
The C-terminus of N4BP1 which contains both the RNAse domain and the 
CUE domain, recognizes linear ubiquitin chains with high specificity. 
Quantitative binding studies have demonstrated that the CUE domain 
differentiates K48-linked di-ubiquitin chains from mono-ubiquitin, M1- and 
K63-linked di-ubiquitin chains. The structure of the CUE domain was 
determined by solution NMR. Key interface residues involved in ubiquitin 
binding were identified by NMR titrations, which allowed the establishment 
of a docking model of the CUE domain in complex with mono-ubiquitin. The 




the CUE domain and the hydrophobic patch which surrounds isoleucine 44 of 
ubiquitin. 
Importantly, it has been shown that the RNAse domain of N4BP1 is 
required to create a binding preference for M1-diUb. The RNAse domain itself 
does not interact with ubiquitin. Instead, the RNAse domain mediates 
oligomerization of N4BP1. This self-association creates a spatial arrangement 
of the CUE domains which is optimized for recognizing linear ubiquitin 
chains with high affinity. 
These findings explain how N4BP1 facilitates its regulatory role in the 
TNFR signaling pathway and expand our knowledge about the functions of 
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Ubiquitination is among one of the most important post-translational 
modifications in eukaryotes. Throughout the last half century, the studies on 
the topic of ubiquitination has massively flourished since the discovery of 
ubiquitin in 1975 (Goldstein et al., 1975). The most well-known function of 
ubiquitination is its key involvements in protein degradation which helped 
Aaron Ciechanover, Avram Hershko and Irwin Rose win the Nobel Prize in 
Chemistry in 2004. Apart from protein degradation, ubiquitination is also 
widely involved in a large diversity of cellular processes, including immune 
signaling, protein trafficking, DNA damage responses and autophagy. 
Dysregulation of ubiquitination could lead to the development of multiple 
diseases, such as neurodegeneration, autoimmune disorder and cancer 
(Popovic et al., 2014). Thus, a better understanding of the functional roles in 
the complex ubiquitination system will greatly help and instruct the 
development of novel drugs and clinical treatments for our whole wellbeing. 
This thesis focuses on characterizing a negative regulator N4BP1 
(NEDD4-binding protein 1) in linear ubiquitination. Linear ubiquitination is 
mediated by the linear ubiquitin assembly complex (LUBAC) which plays 
crucial roles in the initiation of the innate immune response and the 
activation of the NF-kB signaling pathway (Gerlach et al., 2011; Ikeda et al., 
2011; Tokunaga et al., 2011). The involvement of N4BP1 in the NF-kB 
pathway has been reported but lacks in-depth investigation. Recently, 
unpublished cell biological studies have demonstrated that N4BP1 is a 
ubiquitin-binding protein and acts as a novel regulator by inhibiting LUBAC 
under pro-inflammatory conditions (Kliza et al., in preparation).  
To this end, this chapter will provide an overall introduction on the topics 






1.1 Ubiquitin and ubiquitin-related proteins/domains 
1.1.1 Ubiquitin  
Ubiquitin is a small protein that contains only 76 amino acids, with a 
molecular weight at only ~ 8.5 KDa. It is absent in eubacteria and archaea, 
but highly conserved in eukaryotic organisms. There is only 3-residue 
difference between human and yeast ubiquitin, sharing ~ 96% similarity 
(Figure 1.1). 
 
Figure 1.1 Sequence alignments of ubiquitin between human and yeast. The 
identical resides are highlighted in orange. Met1 and the rest of the seven Lys residues are 
indicated with asterisks (*). 
 
Ubiquitin has a compact structure specified as “β-grasp fold”, consisting 
of five β-sheets and one α-helix, with multiple intramolecular hydrogen 
bonds to stabilize the structure. The carboxyl of Gly76, the last residue of the 
ubiquitin, can be covalently attached to the lysine residue of the substrate 
with the help from several enzymes to achieve ubiquitination. L8, I44 and 
V70 form the canonical “hydrophobic patch”, the most common interface 
used in ubiquitin to non-covalently interact with proteins containing 
ubiquitin binding domains (UBDs). Other less commonly used interfaces are 
also found to be critical for the interaction with UBDs, including regions 
centred on F4 or I36 or D58 (Figure 1.2) (Sloper-Mould et al., 2001; Haririnia 





Figure 1.2 The interfaces of ubiquitin for the interaction with UBDs. Ubiquitin is 
shown in the surface mode. The interfaces centered on F4, I36, I44 and D58 are highlighted 
respectively. Figure was generated using Pymol using PDB: 1UBQ. 
 
Throughout ubiquitination, a large variety of ubiquitin chains can be 
formed. There are seven lysine residues in the ubiquitin molecule (K6, K11, 
K27, K29, K31, K48 and K63) of which the amino group from the side chain 
forms an isopeptide bond with Gly76 from another ubiquitin molecule, thus 
elongating the ubiquitin chains with a certain inter-ubiquitin linkage. In 
addition, the first residue Met1 from one ubiquitin was found to be able to 
form a peptide bond with Gly76 from another ubiquitin molecule. Thus, this 
head-to-tail chain elongation produces the so called M1-linked ubiquitin 
chains or linear ubiquitin chains (Figure 1.3). A ubiquitin chain can be 




different linkages to form the “hybrid chain” (described in detail in section 
1.1.2.2 and Figure 1.5).  
Figure 1.3 The structure of representative ubiquitin chains. A. The structure of 
ubiquitin where M1 and seven lysine residues involved in chain formation are highlighted. B. 
The structure of K48-, K63- and M1-linked di-ubiquitin chains. Ubiquitin is pictured in a kite 
shape to display the chain organization. The proximal ubiquitin is coloured in orange and the 
distal ubiquitin is in cyan. Note that G76 is absent in the crystal structure of distal ubiquitin 
in K63-diUb. Figure generated by Pymol using PDB: 1AAR (K48-diUb), PDB: 3H7P 





From the structural view, ubiquitin chains with different linkage types 
show diverse conformations. For example, the K48-linked di-ubiquitin 
adopts a closed conformation in which the two ubiquitin moieties interact via 
the I44 patch (Trempe et al., 2010). Whereas the K63- and M1-linked 
di-ubiquitin adopt a highly extended and flexible structure which is usually 
described as “open conformation” (Komander and Rape, 2012; Weeks et al., 
2009) (Figure 1.3). These different linkages allow ubiquitin chains to 
participate and function in a variety of biological processes and pathways via 
modifying a wide spectrum of substrates. 
 
1.1.2 Ubiquitin-like proteins/domains (UBLs) 
1.1.2.1 Ubiquitin-like proteins 
Apart from ubiquitin, there are several ubiquitin-like proteins adopting 
the same β-grasp topology and widely distributed in eukaryotes to regulate 
various biological processes. These ubiquitin-like proteins include ISG15 
(Interferon Stimulated Gene 15), NEDD8 (Neural Precursor cell-expressed 
developmentally downregulated 8), SUMO (Small Ubiquitin-related 
Modifier), Atg8 (Autophagy gene 8) and Urm1 (Ubiquitin-related Modifier 1) 
etc.  
ISG15 is the first identified UBL. ISG15 is found being strongly induced 
by stimulation from type I interferon and involved in innate immunity in 
response to viral infections. Mature ISG15 is ~ 17KDa and contains two 
domains which both displays the ubiquitin-like fold (Jeon et al., 2010). 
There are four SUMO proteins in vertebrates but only one in yeasts and 
invertebrates. Though SUMO shares poor sequence similarity to ubiquitin, 
strikingly it still adopts the same ubiquitin β-grasp fold. Sumoylation has 
been found to regulate protein stability and redistribution, transcription, 




Among UBLs, NEDD8 (also known as RUB in yeast) shares the highest 
sequence similarity with ubiquitin (58% identity). The best known NEDD8 
substrate is the Cullin protein family that plays as the scaffold in the complex 
Cullin/RING ubiquitin ligases (CRLs). Neddylation of Cullins promotes the 
E3 ligase activity of CRLs. CRLs ubiquitinates a large amount of substrates, 
most of which are involved in the regulation of cell cycle (Van der Veen and 
Ploegh, 2012).   
 
Figure 1.4 Structures of several representative ubiquitin-like proteins reveal 
the conserved β-grasp fold. Figure generated by Pymol using PDB: 1UBQ (Ubiquitin), 
1NDD (NEDD8), 2N1V (SUMO-1), 5TLA (ISG15). 
 
The small ubiquitin-like proteins, together with ubiquitin have greatly 
enlarged the variety of the post-translational modifications via targeting an 
enormous number of substrates. Physiologically, many proteins are tightly 




example, p53 can be regulated by either ubiquitin or ubiquitin-like proteins. 
MDM2, a RING-type E3 ligase, predominantly governs the 
poly-ubiquitination of p53 and thus mediates its degradation via proteasome 
(Freedman et al, 1999). MDM2 also regulates the nuclear export of p53 by 
mono-ubiquitinating p53 (Li et al., 2003). NEDD8 inhibits p53 
transcriptional activity via modifying MDM2 (Xirodimas et al., 2004). It is 
also reported that p53 activity is enhanced while modified with SUMO 
(Gostissa et al., 1999). 
 
1.1.2.2 Ubiquitin-like domains 
Similar to the ubiquitin-like proteins, the ubiquitin-like domains share 
high structure homology to ubiquitin, despite the low sequence conservation. 
But compared to the ubiquitin-like proteins that exist individually as small 
covalent effectors, UBLs are integrated into various multi-domain proteins as 
a certain functional unit (Walters et al., 2004; Grabbe and Dikic, 2009).  
UBLs adopt a similar hydrophobic pocket to interact with binding 
elements such as the UBA domain, but usually less efficient compared to that 
of ubiquitin (Figure 1.5). This might come from the different conformation in 
the β1-β2 loop between UBL and ubiquitin. For example, the equivalent 
ubiquitin L8 located in this loop is absent in the case of Dsk2UBL (PDB: 2BWF), 
resulting in less hydrophobic contact for the interaction. Therefore, the 
binding affinity of Dsk2UBL/Dsk2UBA is ten-fold less than Ub/Dsk2UBA (Lowe 





Figure 1.5 The respective UBA-binding surface on ubiquitin and Dsk2UBL. The 
surface involved in the binding to Dsk2UBA on each molecule is highlighted in red according to 
the comparison summarized by Lowe et al., 2005. The β1-β2 loop in Dsk2UBL that is not 
involved in the binding is indicated by the residues S9 and G10 highlighted in yellow. Figure 
generated by Pymol using PDB: 1UBQ (Ubiquitin), 2BWF (Dsk2UBL). 
 
Other well-characterized UBLs include HOIL-1LUBL and SHARPINUBL in 
the regulation of ligase activity of HOIP from LUBAC. It will be discussed in 
more details in section 1.3.2.  
 
1.1.3 Ubiquitin-binding domains (UBDs) 
Ubiquitin-binding domains (UBDs) are often found in proteins involved 
in the ubiquitin-related processes. To read the diverse “ubiquitin codes”, 
many proteins employ UBDs to conduct ubiquitin-mediated effect. So far, 
more than 20 UBD families have been discovered and grouped into four 
major superfamilies based on their structural folds, including α-helix, Zinc 











UBDs usually interact non-covalently with ubiquitin or ubiquitinated 
substrates in a transient manner, which allows the UBD-containing proteins 
to act in a rapid and timely way in response to certain stimulus. Due to large 
structural heterogeneity of UBDs, the binding mechanisms between UBD and 
ubiquitin show large multiplicities. Thus, the affinity between UBD and 
ubiquitin can vary widely, ranging from ~2 to 500 µM. Most of the UBDs bind 
to the canonical I44 patch of ubiquitin via hydrophobic interactions whereas 
some UBDs bind to other less common surfaces of ubiquitin (eg. the F4, L8 
and I36 patches etc). Moreover, the structural diversity allows some of the 
UBDs to recognize specific ubiquitin chains (Figure 1.6) (Dikic et al., 2009; 
Rahighi and Dikic, 2012; Kliza and Husnjak, 2020). Several examples will be 





Figure 1.6 Schematic representations of different ubiquitin-binding modes by 
UBDs. A. One molecule of UBD binds to one molecule of mono-ubiquitin. B. One molecule 
of UBD binds to two molecules of mono-ubiquitin on different sites. C. A single UBD binds to 
ubiquitin chains. D. Two tandem UBDs from the same protein bind to ubiquitin chains. E. 
Two UBDs form a dimer to interact with ubiquitin chains. 
 
1.1.3.1 The interaction between UBDs and mono-ubiquitin         
    The ubiquitin I44 hydrophobic patch is the most commonly used surface 
for the interaction with UBDs. The binding surface from UBDs can be diverse 
due to their multiple protein folds. Here are some examples.  
The CUE (coupling of ubiquitin conjugation to ER degradation) domain 
belongs to the α-helix superfamily, the largest class of UBD superfamilies. It 
was initially named after the yeast Cue1p (Ponting, 2000). Domains from this 
family have been well-characterized with a compact structure comprising a 
three-helix bundle. The solution NMR structure of the CUE domain from the 
RING-type E3 ligase gp78 (also known as AMFR or RNF45) in complex with 
mono-ubiquitin (PDB: 2LVO) shows that the hydrophobic surface formed by 
α1 and α3 helices from the CUE domain is involved in the binding to 
ubiquitin. The conserved FP motif located in between α1 and α2 is crucial for 
both maintaining the structure in the appropriate fold and the hydrophobic 




CUE domain binds to the proximal or distal ubiquitin from either K48- or 
K63-linked di-ubiquitin chains in a similar fashion as CUE/mono-ubiquitin 
and thus has no binding preference to K48- or K63-linkages. The ITC study 
confirmed that the gp78 CUE domain binds to monoUb or K48- or 
K63-linked di-ubiquitin chains all with comparable Kd of 12.7-14.5 µM (Liu 
et al., 2012). 
The solution structure of the CUE2-1 domain from yeast Cue2 protein in 
complex with mono-ubiquitin has been solved (PDB: 1OTR), but the 
interaction has much lower affinity (Kd value of 155 µM) than that of 
gp78CUE/ubiquitin. Similarly, the CUE2-1 domain mainly binds to the 
well-known hydrophobic I44 patch from ubiquitin but interestingly with 
some extension to residue K48 (Figure 1.7B). The ubiquitin K48A mutation 
completely abolishes the binding ability by the pull-down assay, which 
suggests a possible role that the CUE2-1 domain may play in inhibiting the 
formation of K48-linked ubiquitin chains (Kang et al., 2003). 
 
Figure 1.7 Structures of mono-ubiquitin in complex with gp78CUE (A) or CUE2-1 
(B). gp78CUE and CUE2-1 are shown in green helices. The residues involved in the binding 
interface are highlighted in yellow. The FP motif is colored in red. Ubiquitin is shown in the 




Figure generated by Pymol using PDB: 2LVO (gp78CUE/ubiquitin complex), PDB: 1OTR 
(CUE2-1/ubiquitin complex). 
 
The NZF domain (Npl4 zinc finger domain) is catalogued into the second 
largest class of UBDs, the Zinc finger superfamily. NZF domain is formed by 
four short antiparallel β–strands in which one Zn ion is coordinated by four 
residues (Cys or His). As exemplified by the interaction between the Npl4 
NZF domain and mono-ubiquitin, the NZF domain binds to the I44 
hydrophobic patch of ubiquitin via its TF/Φ motif (where Φ is any 
hydrophobic residue, usually Met) as the canonical ubiquitin-binding site 
(Figure 1.8A). The disassociation constant of the interaction is 126 µM (Alam 
et al., 2004; Wang et al., 2003).  
Apart from the above ubiquitin I44 patch used for the binding, there are 
several exceptions where in some cases UBDs bind to the non-canonical areas 
of ubiquitin. For instance, the A20 ZnF domain from a Rab effector protein 
RABEX5 interacts with the D58-centred patch of ubiquitin with a Kd value of 
~22 µM. A diaromatic patch consisted of Y25 and Y26 from RABEX5 governs 
the main interaction (Figure 1.8B) (Lee et al., 2006). Whereas the ZnF UBP 
domain from the deubiquitinating enzyme IsoT forms a deep hydrophobic 
pocket to accommodate the C-terminus of ubiquitin. In addition, F224 in the 
tip of the loop L2A from this domain interacts with L8 and I36 of ubiquitin. 
The binding has a high affinity (Kd = 2.82 µM) and is crucial for IsoT to 
specifically recognize the unanchored ubiquitin (Figure 1.8C) (Reyes-Turcu et 







Figure 1.8 Structures of the Npl4 NZF domain (A), the RABEX5 NZF domain (B) 
and IsoT NZF UBP domain (C) in complex with mono-ubiquitin respectively. 
Ubiquitin is shown in the surface mode in cyan while the UBDs are shown in the cartoon 
mode. The binding surface of ubiquitin is coloured in red and yellow. The key residues from 
UBDs involved in the binding are shown as sticks in grey. The Zn ion is shown as a grey 
sphere and coordinated by four Cys/His residues highlighted in green. Figures were 
generated by Pymol using PDB: 1Q5W (Npl4NZF/ubiquitin complex), PDB: 2FIF 





The above examples describe the conditions where UBD simply binds to 
mono-ubiquitin in a 1:1 ratio. However, the HRS UIM domain displays a 
double-sided ubiquitin-binding mode where one molecule of the UIM domain 
could bind to both I44 patches of two mono-ubiquitin molecules. The 
ubiquitin-binding occurs simultaneously in the opposite sides of this domain 
(Figure 1.9). SPR study revealed that the disassociation constant of the 
interaction is 190 µM (Hirano et al., 2006). 
 
Figure 1.9 Structures of the HRS NZF domain in complex with mono-ubiquitin. 
Ubiquitins are coloured in cyan while the HRS UIM domain is in orange. I44 residues are 
shown as red sticks. Figure was generated by Pymol using PDB: 2D3G. 
 
On the ubiquitin side, its multiple contact surfaces could also bind to 
more than one UBD at a time. For example, the ubiquitin receptor ZnF216 
and SQSTM1 are both involved in shuttling ubiquitinated proteins to the 26S 
proteasome. A ternary complex model consisted of the two UBDs and 
mono-ubiquitin is proposed (Garner et al., 2011). NMR titrations 
demonstrated that the A20 ZnF domain of ZnF216 binds to the D58-centred 
patch of ubiquitin while the UBA domain of SQSTM1 binds to the I44 patch of 
ubiquitin. Thus, ubiquitin is competent to act as a scaffold to recruit multiple 






1.1.3.2 The binding specificities of UBDs to ubiquitin chains  
Apart from the interaction with mono-ubiquitin, some of the UBDs 
display preference to certain types of ubiquitin chains. Due to the multiplicity 
of both UBDs and ubiquitin chains, the specificity determinants between the 
two binding partners are largely diverged. For some of the UBDs, a single 
domain is capable of recognizing a certain ubiquitin chain type while in other 
cases multiple UBDs cooperatively work together to display chain specificity. 
In addition to the contact with each ubiquitin moiety, some of the UBDs could 
also recognize the linker region from the ubiquitin chain.  
1) Ubiquitin-binding by a single UBD  
    There are observations where a single UBD has multiple 
ubiquitin-binding sites to interact with a certain type of ubiquitin chain. 
TAB2, for example, plays as an adaptor protein binding to K63-linked 
ubiquitin chains to activate the TAK1 kinase complex, thus facilitating the 
activation of the downstream NFκB signaling (Kanayama et al., 2004). The 
NZF domain from TAB2 binds to both I44 hydrophobic patches from the two 
ubiquitin moieties of K63-linked di-ubiquitin. The TF/Φ motif from this 
domain is employed as the canonical ubiquitin-binding site to interact with 
the distal ubiquitin while three conserved residues from the side of the 
domain are responsible for the contact with the proximal ubiquitin (Figure 
1.10A). The TAB2 NZF domain shows distinct binding preference to the K63 
linkage (Kd value of 8 µM for K63-diUb) rather than the linear linkage (Kd 
value of 148 µM for M1-diUb). This specificity lies in that the linear chains 
cannot bend in a similar way to that of the K63 linkage, therefore TAB2 is 
characterized to bind only one ubiquitin moiety in the linear di-ubiquitin 





Figure 1.10 The structure of the TAB NZF domain in complex with K63-linked 
di-ubiquitin (A) and the HOIL-1L NZF domain in complex with M1-linked 
di-ubiquitin (B). Di-ubiquitin chains are shown in cyan in the surface mode where the 
contact surfaces are highlighted in red. The NZF domains are shown in pink, where the four 
Cys residues coordinating the Zn ion are indicated in green. The Zn ion is displayed as a grey 
sphere. The NZF tail of HOIL-1LNZF is coloured in yellow. Figures were generated by Pymol 
using PDB: 2WWZ (TAB2NZF/K63-di-ubiquitin complex), PDB: 3B08 
(HOIL-1LNZF/M1-di-ubiquitin complex).  
 
The NZF domain from HOIL-1L, consisting both the “NZF core” and the 
unique “NZF tail”, binds to linear di-ubiquitin chains with a disassociation 
constant of 17.2 µM, which is ~ 20-fold higher than the K48- or K63-linked 
di-ubiquitin chains. In the HOIL-1LNZF/M1-di-ubiquitin complex (PDB: 
3B08), the NZF core, which is almost structurally identical to the other 




interaction. Another element “NZF tail” offers additional support to enhance 
the specificity. Apart from the canonical hydrophobic binding between the 
NZF TF/Φ motif and the distal ubiquitin I44 patch, another part of the NZF 
core, as well as the NZF tail, contribute several residues which are only 
unique to HOIL-1L to recognize the F4-centred surface of the proximal 
ubiquitin. This binding mode is different from that of the 
TAB2NZF/K63-di-ubiquitin complex, which explains its binding preference to 
the linear linkages (Figure 1.10B) (Sato et al., 2011).  
 
2) Recognizing the linker region of ubiquitin chains 
In addition to the direct contact with both ubiquitin moieties as shown 
above, some of the UBDs could also directly interact with the linker region of 
a certain type of ubiquitin chain.  
As some studies direct UBA-containing proteins in the proteasomal 
degradation machinery (Hofmann and Bucher, 1996; Chen and Madura, 
2002), there are cases where some UBA domains show binding preference to 
K48 linkages. The UBA2 domain from HHR23A (also known as RAD23A), for 
instance, forms a distinctive sandwich-like complex (PDB: 1ZO6) with 
K48-linked di-ubiquitin chain (Varadan et al., 2005). Helix 2 from 
HHR23AUBA2 interacts with the I44 patch from the proximal ubiquitin, while 
helix 3 mainly binds to an extended hydrophobic pocket including the 
C-terminus of the distal ubiquitin and the linker area between the two 
ubiquitin moieties. Additionally, loop 1 of UBA2 binds to residue G47 and 
K48 from the distal ubiquitin to enhance the binding (Figure 1.11).  
Other examples include the DUB domain from the deubiquitinating 
enzyme AMSH-LP, where the catalytic groove from this domain recognizes 
the isopeptide bond in the linker region in K63-linked di-ubiquitin. This 
binding mode thus explains the catalytic specificity of AMSH family to 





Figure 1.11 The structure of the HHR23A UBA2 domain in complex with 
K48-linked di-ubiquitin. HHR23AUBA2 is shown in light blue helices. K48-linked 
di-ubiquitin is shown in the surface mode in yellow. The residues involved in the binding 
interface are highlighted in red. Figure was generated by Pymol using PDB: 1ZO6. 
 
3) Ubiquitin-binding by multiple UBDs  
It is interesting to find that some of the ubiquitin-binding proteins 
contain more than one UBDs. Structural studies have demonstrated that 
multiple UBDs could work together in a specific spatial arrangement to 
recognize certain ubiquitin chain types.  
The crystal structure of the tandem UIM domains from RAP80 in 
complex with K63-linked di-ubiquitin (PDB: 3A1Q) reveals the binding 
mechanism that defines the chain specificity of the protein. RAP80 UIM1 and 
UIM2 domains are tandemly linked via the inter-UIM region to form a 
continuous α-helix, where UIM1 interacts with the proximal ubiquitin while 
UIM2 interacts with the distal ubiquitin. Both UIM domains recognize the 
I44 patch of ubiquitin, but neither of them directly contacts with the linker 
region of K63-diUb. From the complex structure, the inter-UIM region does 
not recognize the linker region either. However, the length of the inter-UIM 
region is critical for the binding specificity in a precise way where it arranges 




ubiquitin moieties simultaneously. Experimental evidence has shown that 
either increasing or reducing the residues in the inter-UIM region will fully 
abolish the interaction. It is thus described as a “molecular ruler” as it could 
“measure” the distance between the two ubiquitin moieties (Figure 1.12) (Sato 
et al., 2009).  
 
Figure 1.12 The structure of the RAP80 UIM domain in complex with 
K63-linked di-ubiquitin. RAP80UIM is shown in light blue and grey helices. K63-linked 
di-ubiquitin is shown in the surface mode in orange. The residues involved in the binding 
interface are highlighted in red and pink. Figure was generated by Pymol using PDB: 3A1Q. 
 
    The NEMO UBAN domain has been characterized to selectively interact 
with M1-linked ubiquitin chains with high affinity (Kd value of 1.6 µM for 
M1-diUb). The structural study has shown that the UBAN domain displays a 
coiled-coil arrangement and forms a parallel homodimer to interact with two 
M1-linked di-ubiquitin molecules (PDB: 2ZVO) (Figure 1.13) (Rahighi et al., 
2009). The two ubiquitin moieties in the M1-linked di-ubiquitin have distinct 
interaction with the UBAN dimer. The distal ubiquitin contacts with both 
UBAN protomers via the canonical I44 patch and the C-terminal tail (from 
R72 to R74). The C-terminal tail is part of the linker region, demonstrating 
the ability from the UBAN domain to recognize the M1 linkage. In contrast to 
the major hydrophobic interaction between the distal ubiquitin and UBAN, 




employed for mostly polar interactions with only one of the UBAN protomers. 
The I44 patch from the proximal ubiquitin is not involved in the interaction.  
 
Figure 1.13 The structure of the NEMO UBAN domain in complex with 
M1-linked di-ubiquitin. NEMOUBAN is coloured in purple and shown in the dimer form. 
Two M1-linked di-ubiquitin molecules are coloured in cyan and green respectively. The key 
residues involved in the interaction are coloured in pink and shown in one of the di-ubiquitin 
molecules where I44, R72-R74 from the distal ubiquitin are highlighted as sticks. Figure was 














1.2.1 Ubiquitination cascade 
To achieve ubiquitination, three different enzymes team up in a cascade 
to generate the correct and precise modification of the substrate with 
ubiquitin (or chains) (Figure 1.14). These enzymes include the E1 
ubiquitin-activating enzyme, the E2 ubiquitin-conjugating enzyme and the 
E3 ubiquitin ligase.  
At the first step, E1 hydrolyses ATP to form a ubiquitin-adenylate 
intermediate (Ub-AMP) at the C-terminus of ubiquitin. Ub-AMP is then 
attacked by the side chain from E1 catalytic Cys, forming a high-energy 
thioester bond (“~” is used hereafter) between the two molecules, coupled 
with the adenylation of the second ubiquitin (Schulman and Harper, 2009). 
The activated ubiquitin from E1~Ub is subsequently delivered onto the E2 
active site Cys by a transthiolation process, forming the E2~Ub conjugate (Ye 
and Rape, 2009). E3 ubiquitin ligases play crucial roles in substrate 
recognition and ligation with ubiquitin to achieve the final step of 
ubiquitination. Depending on their catalytic mechanism, some E3 ubiquitin 
ligases will accept the activated ubiquitin from E2 to form an E3-ubiquitin 
thioester intermediate (E3~Ub) and subsequently transfer ubiquitin to the 
substrate, such as the HECT- and RBR-type ligases. In contrast, RING-type 
E3 ligases work as a bridge between ubiquitin charged E2 and the substrate, 
where the ubiquitin transfer is performed directly from E2 to the substrate.  
(Zheng and Shabek, 2017).        
In humans there are only two E1 ubiquitin-activating enzymes, 30 E2 
ubiquitin-conjugating enzymes and more than 600 E3 ligases in human 
(Brazee et al., 2016). Therefore, different E2/E3 combination can catalyze the 






Figure 1.14 Schematic of the ubiquitination cascade and de-ubiquitination. 
Ubiquitination consists of 3 steps: ①: ubiquitin activation by E1; ②: E2 conjugation; ③: E3 
ligation. Step ④ indicates the de-ubiquitination process catalyzed by DUB. 
 
Ubiquitination can be reversed by a group of enzymes called 
deubiquitinating enzymes (DUBs) (Figure 1.14). DUBs cleave ubiquitin 
chains into oligomers or monomers or process the ubiquitin precursor into 
the mature ubiquitin. Most important of all, DUBs catalyze the removal of 
the ubiquitin or chains from the substrate, thus reversing its fate. Some of the 
DUBs can also catalyze the cleavage of ubiquitin-like proteins attached to the 
substrates (Ramakrishna et al., 2011; Reyes-Turcu et al., 2009). 
Taking together, the dynamic ubiquitin modification is under strict and 
precise control by both ubiquitination and de-ubiquitination, to guarantee 






1.2.2 Cellular function of ubiquitination  
The versatility of ubiquitination allows its involvements in almost every 
aspect of the biological processes. In addition to the simple 
mono-ubiquitination, there are many different means of poly-ubiquitination 
(Figure 1.15). A single substrate can be multi-mono-ubiquitinated at several 
sites or modified by chains with certain linkages. Less frequently, substrates 
can be ubiquitinated by a hybrid of two or more linkages on one chain or even 
branched chain. Most of them require the specific recognition by UBDs, 
therefore, to greatly diversify their functions. Accumulating evidence has 
demonstrated that a combination and collaboration of multiple types of 
ubiquitin chains is needed in the precise regulation of some intricate 
pathways, such as the TNF-induced NFκB pathway (Rittinger and Ikeda, 2017; 
Spit et al., 2019). Due to relatively higher enrichment in the cells, K48 and 
K63 linkages are widely studied throughout decades. However, the functional 
roles of K6, K11, K27, K29 and K33 linkages are still lack of systematic 
investigation. 
Apart from the linkage, the ubiquitin chain length is also an important 
determinant for the selective recognition by UBDs, but still poorly understood 
due to the lack of powerful tools. It is previously known that a minimum of 
K48-linked tetra-ubiquitin chain is required for the recognition by the 
proteasome (Pickart, 2000). Until recently, a novel biochemical method, 
Ub-ProT (Ub chain protection from trypsinization), was developed to 
determine the ubiquitin chain length from substrates. Using this method, it 
was found that EGFR was mainly modified with K63-linked chains of 4-6 
ubiquitin moieties upon activation by EGF (Tsuchiya et al., 2018). In another 
study, the Ub chains with defined length and linkage were used as baits to 
identify ubiquitin-binding proteins in a global scale. For example, it has been 
shown that the K29- and K33-linked ubiquitin chains with shorter length 




enzymes, while longer chains with at least 6 ubiquitin moieties have the 
tendency to bind metabolite interconversion enzymes (Lutz et al., 2020). 
With the emerging techniques, it will surely help us exploring the function of 
ubiquitin length in a lot more detail. 
In the below section, A brief functional introduction in the context of only 
linkages will be summarized.  
 
Figure 1.15 Examples of different means of ubiquitination. A. Mono-ubiquitination. 
B. Multi-mono-ubiquitination. C. Modification by homogenous ubiquitin chain. D. 
Modification by hybrid ubiquitin chain. E. Modification by branched ubiquitin chain. 
 
Mono-ubiquitination 
The studies on mono-ubiquitination are mostly centred on H2A and H2B, 
revealing its close association with gene expression, transcription, DNA 
replication and DNA repair etc. hPRC1L is an E3 ligase complex that 
specifically targets mono-ubiquitination on H2A and mediates Polycomb 
target gene silencing (Wang et al., 2004). The reduced level of 
mono-ubiquitinated H2A (uH2A) decreases the stability of the nucleosomes, 
implicating its possible roles in regulating transcriptional repression (Zhu et 
al., 2007; Weake and Workman, 2008).  
In contrast to the negative regulatory roles of uH2A, mono-ubiquitinated 
H2B (uH2B) is suggested to activate gene expression in a crosstalk with 
histone methylation, where the mono-ubiquitination of H2B is prerequisite 
for the methylation of histone H3K4 and H3K79 (Sun et al., 2002; Weake and 




methyltransferase complex Set1/COMPASS and transcribed chromatin is 
stabilized by uH2B, therefore the activity of Set1/COMPASS is facilitated to 
further activate gene expression (Racine et al., 2012). uH2B also promotes 
DNA repair via increasing the methylation of H3K4 on the DNA broken site in 
response to DNA damage (Faucher et al., 2010).  
 
K48-linked ubiquitination 
The K48-linked poly-ubiquitination is the most abundant ubiquitin 
modification. The study is centred on the ubiquitin-proteasome system (UPS). 
In this system, K48-linked ubiquitin chains act as “degradation tags” to 
covalently attach to the target protein through the ubiquitination process and 
mediates protein degradation via the 26S proteasome (Thrower et al., 2000; 
Komander and Rape, 2012). Once targeted with K48-linked chains, the 
substrate is recognized by the 19S regulatory particle of the proteasome and 
then digested into short peptides in the 20S subunit. The ubiquitin is then 
free from the substrate and can be reused again (Ciechanover and Schwartz, 
1998).  
The proteosomal degradation via K48 linkage not only eliminates 
undesired proteins, but also participates in several signaling pathways. For 
example, in the canonical NFκB pathway, the K48-mediated IκBα 
degradation is required in order to release the NFκB dimer p50/p65 into the 
nucleus, therefore initiating effector gene transcription. Similarly, in the 
non-canonical NFκB pathway, the p52 precursor p100 is targeted for partial 
proteasomal degradation and then processed into mature p52. p52 then 
forms a complex with Rel-B to activate gene expression in the nucleus (Liu 
and Chen, 2011; Pamukcu et al., 2011).   
Interestingly, K48 linkage is also suggested to carry 
proteolysis-independent functions. As exemplified by the transcription factor 




chains. However, as a result, the transcriptional activity of Met4 is inhibited 
but not degraded (Kaiser et al, 2000). Later detailed mechanism reveals that 
the UBD domain of Met4 limits the length of K48-linked chains formed on 
Met4, preventing its recognition by the proteasome (Flick et al., 2006).  
 
K63-linked ubiquitination 
In contrast to the close relation between K48 linkage and proteosomal 
degradation, K63-linked poly-ubiquitination acts as a regulatory signal and is 
mostly involved in non-proteolytic processes, such as DNA damage response, 
autophagy, innate immunity and protein trafficking. 
When recruited to the DNA damage sites, the RING-type E3 ligase RNF8, 
together with an E2 enzyme Ubc13, catalyzes K63-linked ubiquitin chains 
onto H2A and H2AX. The K63-linked chains mediate the recruitment of 
multiple effectors for the DNA repair, implying key roles in DNA damage 
response (Bennett and Harper, 2008; Chen and Sun, 2009).  
It has been reported that the K63-linked ubiquitination of Beclin-1 
mediated by TRAF6 regulates TLR4-induced autophagy during inflammatory 
responses (Shi and Kehrl, 2010). 
Notably, K63 linkage participates in various processes via kinase 
activation. RNF128 catalyzes the K63-linked ubiquitination of kinase TBK1, 
thus inducing the activation of TBK1 and the subsequent IFN-β production in 
antiviral immune response (Song et al., 2016). TRAF6 also targets the 
serine/threonine protein kinase Akt with K63-linked ubiquitination, required 
for Akt phosphorylation and membrane recruitment (Yang et al., 2009). 
Surprisingly, K63-linked ubiquitination was recently found to act as a 
substrate-specific marker and is indirectly involved in proteasomal 
degradation. K63-polyubiquitinated TXNIP catalyzed by ITCH triggers the 
recruitment of UBR5 while UBR5 subsequently forms K48 branches on the 





K6-linked ubiquitin chain has the least abundance among all the linkages. 
Currently it is reported to take part in DNA repair and mitochondria 
homeostasis. Its involvements in DNA repair are mostly related to BRCA1. 
The heterodimer BRCA1/ BARD1 acts as an E3 ligase and auto-ubiquitinates 
BRCA1 with K6-linked poly-ubiquitin chains (Wu-Baer et al., 2003). It was 
found that BRCA1 and BRCA1-dependent K6-linked chains are recruited to 
the DNA damage sites, implicating their participation in DNA repair (Morris 
and Solomon, 2004). Another study reveals that the mutated BRCA1 lacking 
the E3 activity for auto-ubiquitination is relatively unstable, suggesting a role 
of K6 linkage in substrate stability (Reid et al., 2008).  
An E3 ligase Parkin assembles K6-, K11- and K63-linked ubiquitin chains 
when stimulated by mitochondrial damage (Cunningham et al., 2015). 
Mitochondrial autophagy (mitophagy) was found to undergo serious delay 
when wild-type ubiquitin is replaced with Ub-K6R or Ub-K63R in the cells 
using a ubiquitin replacement strategy (Ordureau et al., 2015).  
Recently, a HECT-type E3 ligase HUWE1 was demonstrated to modify 
Mfn2 with K6 linkages, but the specific function of this modification on the 
substrate is yet unidentified (Michel et al., 2017).  
 
K11-linked ubiquitination 
K11-linked ubiquitination is also involved in proteasomal degradation. 
The E3 ligase APC/C, together with two E2 enzymes UbcH10 and Ube2s, 
accounts for the K11-linked poly-ubiquitination on Cyclin B1, thus mediating 
its degradation by the proteosome to facilitate the mitosis progress. It 
suggests that K11-linked ubiquitination plays as a degradative signal in 
regulating cell cycle (Kirkpatrick et al, 2006; Jin et al, 2008; Garnett et al, 




Interestingly, Ube2s is also found to catalyze the K11-linked ubiquitin 
chain formation on β-Catenin, but β-Catenin is stabilized instead (Li et al., 
2018). An E2 family, UbcH5, has been demonstrated to increase the 




The studies on K27 linkage reveal its possible participation in mitophagy, 
innate immunity and DNA damage. Parkin-mediated K27-linked 
ubiquitination targets VDAC1 and VDAC1 is essential for 
PINK1/Parkin-directed mitophagy (Geusler et al., 2010). Double-strand 
breaks (DSBs) induce major K27-linked ubiquitination on chromatin. 
RNF168 is the specific histone E3 ligase in charge of this catalysis. 
RNF168-dependent K27-linked ubiquitination on Histone H2A/H2A.X is 
required for activating DNA damage response. It has been observed that 
BRCA1 and 53BP1 cannot be recruited to the DNA damage sites when K27 
linkage is absent (Gatti et al., 2015).  
The knowledge on K27 linkage involved in innate immunity has been 
enlarged by recent research. In reaction to DNA stimulation from virus such 
as HSV-1, AMFR-INSIG1 complex acts as an E3 ligase to modify STING with 
K27-linked chains. It facilitates the recruitment of TBK1 by STING to form 
the STING-TBK1 complex, which further activates the transcriptional factor 
IRF-3. IRF-3 then induces the expression of type I interferons and 
pro-inflammatory cytokines (Wang et al., 2014). Upon HSV-1 infection, 
RNF185-mediated K27-linked ubiquitination on cGAS facilitates the 
enzymatic activity of cGAS. The formation of 2’3’-cGAMP catalyzed by cGAS 
acts as a second messenger to active the downstream STING signaling (Wang 






The function of K29 linkage in lysosomal degradation has been 
demonstrated. In the Notch pathway, AIP4, the human orthologue of mouse 
HECT-type E3 ligase ITCH, directly interacts with DTX and ubiquitinates 
DTX with K29-linked ubiquitin chains for lysosomal degradation (Chastagner 
et al., 2006). In another study, NEMO and p65 are targeted with K29-linked 
ubiquitin chains by TRAF7 for lysosomal degradation, suggesting that K29 
linkage also participates in the NFκB signaling pathway (Zotti et al., 2011).  
There are also examples that K29 linkage is related to non-proteolytic 
functions. Apart from catalyzing the formation of K48 linkage, Smurf1 is able 
to modify Axin with K29-linked chains, egatively regulating Wnt/β-Catenin 
signaling. As a result, Axin lost the ability to interact with the Wnt coreceptors 
LRP5/6 (Fei et al., 2013).  
 
K33-linked ubiquitination 
K33 linkage is suggested to play as an inhibitory role, especially in T-cell 
activation. It is reported that the ubiquitination of AMPK-related kinases 
mediated by K29 and K33 linkages inhibits their phosphorylation and 
activation by LKB1 (Al-Hakim et al., 2008). Two E3 ligases Cbl-b and ITCH 
work cooperatively to target K33-linked ubiquitination on T-cell receptor 
TCR-ζ. Then phosphorylation of TCR-ζ and its association with the signaling 
kinase Zap-70 are reduced, which further inhibits the T cell activation (Huang 
et al., 2010). Zap-70 was also found to be modified with K33 linkage by Nrdp1, 
resulting in the inactivation of Zap-70, thus terminating early TCR signaling 
in CD8+ T cells (Yang et al., 2015).  
K33 linkage is also involved in protein trafficking. CUL3-KLHL20 is an 
E3 ligase that catalyzes the attachment of K33-linked ubiquitin chains on 
Crn7, which promotes Crn7 targeting to the trans-Golgi network (TGN) 




The functional studies on linear ubiquitination will be discussed in the 
next section. 
1.2.3 Linear ubiquitination 
To date, the linear ubiquitin assembly complex (LUBAC) is the only 
known E3 ligase that mediates the formation of linear ubiquitin chains. 
Initially, it was found that LUBAC was composed of two components HOIP 
(HOIL1-interacting protein, also known as RNF31) and HOIL-1L 
(Haem-oxidized IRP2 ubiquitin ligase-1, also known as RBCK1) (Kirisako et 
al., 2006). Then SHARPIN (Shank-associated RH domain-interacting protein) 
was discovered as part of the complex to regulate the NF-κB pathway and 
apoptosis (Ikeda et al., 2011). LUBAC soon drew wide attention in the 
ubiquitin research field.  
 
Figure 1.16 Schematic of the architectures of the three subunits of LUBAC as 
well as the interactions between the UBL and UBA domain (© 2017 Liu et al., by 
permission). 
 
LUBAC is characterized as a 600-KDa protein complex although the 
exact stoichiometry of the three components is not yet defined. HOIP and 
HOIL-1L are both identified as RBR-type E3 ligases, of which HOIP is the 
main catalytic subunit in the complex (Figure 1.16). HOIL-1L and SHARPIN 
function as important regulators for HOIP ligase activity. Although HOIL-1L 
is also capable of synthesizing linear ubiquitin chain, the in vitro ligase 




The mechanism of linear ubiquitin chain elongation (in the absence of 
physiological substrates) by HOIP has been studied by structural approaches. 
It will be discussed in section 1.3.2.2. In terms of linear ubiquitination of a 
real substrate, such as NEMO, the catalysis requires key regulators from the 
LUBAC complex. It has been shown that HOIL-1L is not only required for 
releasing the auto-inhibition of HOIP (please see section 1.3.2.1), but also 
facilitating HOIP to initiate mono-ubiquitination on NEMO. Rather than the 
en block transfer of linear ubiquitin chains to the substrate, this priming 
mono-ubiquitination is followed by the processive linear chain extension by 
HOIP (Smit et al., 2013).  
    The multiple and essential roles of LUBAC in inflammation and immune 
signaling have been extensively investigated. A large number of studies show 
that dysregulation of LUBAC is associated with autoinflammation and 
immunodeficiencies. 
    The canonical NF-κB pathway is well known to mediate key 
pro-inflammatory gene expression, playing an important role in both 
adaptive and innate immunity (Lawrence, 2009; Hoesel and Schmid, 2013). 
LUBAC is now known for its close involvement in the activation of the NF-kB 
pathway induced by various stimuli such as TNF, PGN, CD40-L, LPS, IL-1β 
etc (Ikeda et al., 2011; Gerlach et al., 2011; Damgaard et al., 2012, 2013). The 
synthesis and covalent attachment of linear ubiquitin chains to key elements 
in the upstream signaling pathways of NF-kB are a prerequisite for NF-kB 
activation. These important upstream pathways are related to both immune 
response and apoptosis, such as the TNFR-signaling pathway (Reviewed in 
detail by Rittinger and Ikeda, 2017 and Spit et al., 2019). 
The TNFR-signaling pathway is one of the most well-characterized 
pathways in NF-kB activation (Figure 1.17). In this pathway, the binding of a 
proinflammatory cytokine TNFα to the transmembrane TNF receptor (TNFR) 




including TRADD, TRAF2, RIP1 and cIAP1/2 are recruited to the trimeric 
TNFR to form the “TNFR complex I” (Barnhart and Peter, 2003). E3 ligase 
cIAP1/2 mediates the K63-polyubiquitination of the protein kinase RIP1, 
which then allows the recruitment of the kinase TAK1/TAB complex to RIP1. 
The phosphorylation of the IKK complex by TAK1/TAB is required for IKK 
activation. cIAP1/2 also auto-ubiquitinates itself with K63-linked ubiquitin 
chains, which is essential for recruiting LUBAC. LUBAC subsequently targets 
linear ubiquitin chains to NEMO, one of the subunits in the IKK complex 
(Haas et al., 2009; Gyrd-Hansen and Meler, 2010). The UBAN domain of 
NEMO shows high affinity to M1 linkages and thus facilitates the activation of 
kinase IKKα/β, another two components of the IKK complex, to 
phosphorylate IkBα (Rahighi et al., 2009). IkBα is an inhibitor to the 
heterodimeric transcriptional factor NF-kB. Once IkBα is phosphorylated, it 
is recognized by the E3 ligase SCF-βTrCP for K48-mediated proteasomal 
degradation, therefore releasing the inhibitory state of NF-kB. The liberated 
NF-kB transcriptional factor is then translocated into the nucleus, allowing 
the gene expression of pro-inflammatory factors, such as cytokines, 
chemokines, and adhesion molecules (Lawrence, 2009; Liu and Chen, 2011; 





Figure 1.17 Schematic representation of NF-kB activation by the TNFR signaling 
pathway.  
 
Similarly, in PGN-induced NOD2 immune signaling, E3 ligase XIAP 
ubiquitinates RIP2 and recruits LUBAC for the downstream activation of 
NF-kB (Damgaard et al., 2012; Damgaard et al., 2013).  
LUBAC is fine-tuned by multiple factors among which N4BP1 
(NEDD4-binding protein 1) was newly identified as a novel regulator by 
negatively regulating LUBAC activity (Kliza et al., in preparation). The 






1.3 Ubiquitin E3 ligases  
1.3.1 Classification of ubiquitin E3 ligase families 
The ligation between ubiquitin and the substrate catalyzed by E3 ligase is 
the final step of ubiquitination. A large number of E3 ligases have been 
identified and the diversity enables their involvements in targeting specific 
substrates. E3 ligases can be classified into 3 main families, the RING-, 
HECT- and RBR-type E3 ligases (Figure 1.18) (Morreale and Walden, 2016).  
 
Figure 1.18 Schematic representation of the ubiquitin transfer mechanisms by 
the three ubiquitin E3 ligase families. A. RING-type E3. B. HECT-type E3. C. RBR-type 
E3. Ubiquitin moieties that link to E2 or E3 via thioester are shown in pale red. Ubiquitin 
moieties that link to substrates via isopeptide bond are shown in solid red. Dashed arrow 
indicates the ubiquitin transfer process. 
 
1.3.1.1 RING (Really Interesting New Gene)-type E3 ligases 
The RING-type E3 family has more than 600 members. It is 
characterized by containing either the RING domain or the U-box domain. 
Both domains bind to E2 and share similar fold. As shown in Figure 1.19, the 




coordinated (Metzger et al., 2014). The U-box domain does not coordinate Zn, 
instead the fold is maintained by hydrogen bonds and salt bridges (Ohi et al., 
2003).   
RING-type E3s bind to both substrate and ubiquitin-charged E2 
(Ub~E2), thus acting as a scaffold to facilitate the direct ubiquitin transfer 
from Ub~E2 to the substrate. Therefore, the aminolysis reaction that results 
in the formation of isopeptide bond between ubiquitin and the substrate is 
conducted by E2 (Figure 1.18).  
 
Figure 1.19 Structure of the RING/U-box domain. A. Schematic of the RING domain 
organization for Zn-coordination (© 2014 Metzger et al., by permission, Licence No: 
4882050067905). The residues that coordinate Zn are shown in yellow with number 1-8. X 
represents any residue. B. Crystal structure of the RING domain from c-Cbl (PDB: 1FBV). The 
residues that coordinate Zn are indicated in red. C. Solution structure of the U-box domain 





As mentioned in section 1.1.2.1, the Cullin protein family could interact 
with some RING-type E3 ligases to form the Cullin/RING ubiquitin ligases 
(CRLs). CRLs are highly diversified due to multiple protein combinations. 
Taking the SCF complex (Skp, Cullin, F-box containing complex) as an 
example, it plays key roles in the regulation of cell cycle by targeting proteins 
for 26S proteasomal degradation. The SCF complex is composed of four 
subunits among which Cullin serves as a scaffold to organize RBX1, Skp1 and 
Skp2. RBX1 is the RING-type E3 ligase for E2-binding while the F-box 
protein Skp2 is responsible for substrate recognition. Skp1 is the adaptor 
protein that links Skp2 to Cullin (Figure 1.20).  
 
Figure 1.20 Structure of the SCF complex. The complex is shown in the surface mode. 
Figure was generated by Pymol using PDB: 1LDK. 
 
The interaction between the dimerized RING domain from RNF4 and 
the stable E2-Ub conjugate provides some insights into the activation of the 
ubiquitin-charged E2 by the RING-type E3 ligase (Figure 1.21, right panel). 
To help form the crystal, a stable UbcH5A-Ub conjugate is used where the 
catalytic C85 of UbcH5A is mutated to lysine to form a stable isopeptide bond 
with G76 of Ub, in order to mimic the thioester between C85 and G76. As 
seen from the complex structure (PDB: 4AP4), each RNF4 RING domain 




moieties from the dimer. This induces the conjugated ubiquitin folded back 
onto UbcH5A, in comparison to the structure where ubiquitin non-covalently 
binds to the E2 (Figure 1.21, left panel). The interaction extends the contact 
between the ubiquitin C-terminus and the E2 active site, which thus 
facilitates the nucleophilic attack from the ubiquitin C-terminal glycine to the 
incoming substrate (Plechanovová et al., 2012). 
 
Figure 1.21 Structure of the RING/U-box domain. Left panel. Structure of UbcH5A 
non-covalently bound to ubiquitin (PDB: 3PTF). The catalytic C85 of UbcH5A is indicated in 
a red sphere. Right panel. Structure of the dimerized RNF4 RING domain in complex with 
two stable UbcH5A-Ub conjugates (PDB: 4AP4) where the C85 is mutated to lysine 
(indicated in a red sphere) to form a non-hydrolysable isopeptide bond with G76 of Ub. The 
UbcH5A/ubiquitin complexes from both structures are shown in the same position for a 






1.3.1.2 HECT (Homologous to E6AP Carboxyl Terminus)-type 
E3 ligases 
The HECT-type E3 family features the HECT domain, which is 
composed of the N terminal lobe and the C terminal lobe with a flexible linker 
in between the two lobes. HECT domain utilizes the N lobe to recruit Ub~E2 
while the catalytic Cys residue from the C lobe accepts the ubiquitin from E2 
via the transthiolation reaction to form the Ub~E3. Finally, the ubiquitin 
charged E3 catalyzes the aminolysis reaction by transferring ubiquitin to the 
substrate to form the stable isopeptide bond (Figure 1.18).  
Early structural studies of the E2 enzyme UbcH7 in complex with the 
HECT domain from E6AP (PDB: 1C4Z) shows that the distance between the 
catalytic Cys from both molecules is ~ 40 Å in the absence of ubiquitin, which 
is far from achieving efficient transthiolation (Figure 1.22A) (Huang et al., 
1999). Later, the crystal structure of Ub~UbcH5B-HECTNEDD4L complex was 
resolved (PDB: 3JW0), giving new insights into the ubiquitin transfer 
mechanism (Kamadurai et al., 2009). In this structure, the ubiquitin-loaded 
E2 brings its active Cys in close proximity at less than 8 Å to that of HECT. It 
indicates that drastic conformational changes upon binding facilitate the 
ubiquitin transfer from E2 to E3 (Figure 1.22B).  
 
Figure 1.22 Structure of the HECT domain in complex with E2. A. Structure of 
UbcH7-HECTE6AP complex (PDB: 1C4Z). B. Structure of Ub~UbcH5B-HECTNEDD4L complex 




distance between the catalytic Cys from E2 and E3 is indicated by the dashed lines. Figure 
were generated by Pymol according to the respective PDB structure entry. 
 
1.3.1.3 RBR (RING-in-between-RING)-type E3 ligases 
The RBR-type E3 ligases are discovered much later. It consists at least 14 
members in human and yet the function from most of them is still unclear. 
Among them, the most studied proteins include Parkin, HHARI (also known 
as ARIH1), HOIP and HOIL-1L (Figure 1.23A).  
Parkin mediates a variety of ubiquitination processes including 
mono-ubiquitination, K6, K11, K48- and K63-linked polyubiquitination, to be 
associated with mitochondrial autophagy (mitophagy), Parkinson’s disease 
etc (Chung et al., 2001; Vives-Bauza et al., 2010; Cunningham et al., 2015). 
Independently, Parkin was also found to act as a transcriptional suppressor 
to regulate p53 expression by interacting with p53 promoter (Da Costa et al., 
2009). HHARI has been reported to participate in cellular proliferation, DNA 
damage response, neuronal differentiation etc (Aguilera et al., 2000; 
Elmehdawi et al., 2013; von Stechow et al., 2015). HOIP and HOIL-1L are 
components of LUBAC, playing key roles in innate immunity and 
inflammatory reactions (See section 1.1.2.3). 
    1) The RBR domain 
RBR-type E3 ligases are more like a RING/HECT hybrid. As the name 
suggests, the RING1 and RING2 domain are separated by the IBR 
(in-between-RING) domain. All the three domains in RBR coordinate Zn 
ions. Although RBR ligases contain a RING domain, the catalytic mechanism 
of this E3 is in an HECT-like fashion. The RBRRING1 domain, which adopts a 
similar structure to the canonical RING domain in a cross-brace fold, 
recognizes and recruits E2~Ub. While the catalytic Cys is localized in the 
RBRRING2 domain to accept the activated ubiquitin from E2. The RBRRING2 




to the RBRIBR domain (Figure 1.23B, C) (Morreale and Walden, 2016; Dove 
and Klevit, 2017). 
 
Figure 1.23 An overall view of the RBR-type E3 ligases (© 2017 Dove and Klevit, 
by permission, Licence No: 4882040764839). A. Domain structures of representative 
RBR E3s. Red stars indicate the active Cys site. B. The RBRRING1 domain from HHARI (PDB: 
5UDH) is structurally similar to the canonical RING domain from BRCA1 (PDB: 1JM7). C. 
The RBRRING2 domain adopts similar fold to the RBRIBR domain (both domains are from 
HHARI, PDB: 5UDH). Dark gray circles in B and C indicate Zn ions. 
 
Though the similar structure between the RBRRING1 domain and the 
canonical RING domain, the conformation state of E2~Ub upon binding to 
RBR- or RING-type E3 is very different. As exemplified in Figure 1.21, 
E2~Ub adopts a closed state when attached to the canonical RING domain, 
increasing the reactivity of E2 toward the Lys sidechain amino group from 
the substrate. In this closed conformation, ubiquitin is in contact with E2, 
resulting in the burial of its hydrophobic patch. With the help from 
RING-type E3 ligases, ubiquitin is then transferred directly from E2 to the 
substrate. In contrast, in the case of HHARI, HOIP and RNF144A, E2~Ub is 




hydrophobic patch is exposed, facilitating the transthiolation process from 
E2~Ub to E3~Ub (See the example from Figure 1.26B,C,D) (Dove and Klevit, 
2017).  
    2) Auto-inhibition of RBR-type E3s 
Auto-inhibition is a common feature within the RBR-type E3 family. 
However, the mechanisms of auto-inhibition between RBR-type E3s are 
quite diverse due to their various domain organizations. Correspondingly, 
the release of the auto-inhibition is organized in different ways.  
Two examples for autoinhibition from HHARI and Parkin are shown in 
Figure 1.24. In the apo form of HHARI, the catalytic Cys from the RING2 
domain is partially buried in the interface between RING2 and the Ariadne 
domain. RING1 is far away from RING2 at a distance of ~ 90 Å. Note that 
though upon E2~Ub binding, HHARI is still in its auto-inhibited state. The 
catalytic center of HHARI is ~ 54 Å away from that of E2 (UbcH7), 
suggesting an unsuitable conformation for catalysis at this state (Duda et al., 
2013; Yuan et al., 2017). As for Parkin, the UPD/RING0 domain buries the 
catalytic Cys from RING2 at the interface. REP, the linker between IBR and 
RING2 obstructs E2 binding to RING1 (Wauer and Komander, 2013; Trempe 
et al., 2013). The auto-inhibition implicates that appropriate conformation 
rearrangement is required for RBR-type E3s to induce full activity before the 
ubiquitin transfer. 
    The release of the auto-inhibitory state varies, and most was discovered 
by functional studies. For instance, the RBR ligase activity of HHARI is 
activated by binding to the neddylated Cullin-RING ligase (CRL) complexes 
(Kelsall et al., 2013). Parkin phosphorylation by kinase PINK1 is required in 
order to release its auto-inhibition when responses to mitochondrial damage 
(Eiyama et al., 2015; Pickrell et al., 2015). The UBA domain from HOIP 
auto-inhibits its catalytic RBR domain (Stieglitz et al., 2012). The UBL 




HOIP (Discussed in more details in section 1.3.3.1) (Gerlach et al., 2011; 
Ikeda et al., 2011; Kirisako et al., 2006; Tokunaga et al., 2009, 2011). 
 
Figure 1.24 The structure of HHARI (PDB: 4KBL) and Parkin (PDB: 4K95) in 
their respective auto-inhibition state (© 2017 Dove and Klevit, by permission, 
Licence No: 4882040764839). The catalytic Cys in each RING2 domain is indicated as a 
red sphere while Zn ions are indicated as dark circles.  
 
1.3.2 HOIP 
    Apart from the above general introduction of the RBR-type E3 ligases, as 
the study of the ligase activity of HOIP is one of the topics in this thesis, a 





1.3.2.1 Auto-inhibition of HOIP 
As mentioned in section 1.1.2.3, HOIP plays the main catalytic role in 
LUBAC. Similar to other RBR members, the catalytic RBR domain from the 
apo HOIP is auto-inhibited by its UBA domain (Stieglitz et al., 2012). The 
structure of auto-inhibited HOIP is still unavailable. Current studies reveal 
that the UBL domains from both HOIL-1L and SHARPIN share high sequence 
and structure similarity (Figure 1.25A). They can both bind to the UBA 
domain of HOIP, thus releasing HOIP from auto-inhibition. Binding of 
HOIL-1L and SHARPIN is therefore required to transform HOIP into a 
catalytic competent state (Gerlach et al., 2011; Ikeda et al., 2011; Kirisako et 
al., 2006; Tokunaga et al., 2009, 2011).  
Despite the high similarity, the two UBL domains interact with HOIPUBA 
in different manners, revealed by the structures of corresponding complexes 
(Yagi et al., 2012; Liu et al., 2017). SHARPINUBL interacts with the N-terminal 
HOIPUBA, while HOIL-1LUBL contacts the C-terminus of HOIPUBA (Figure 
1.25B). Furthermore, adding both SHARPINUBL and HOIPUBA together to 
HOIP synergistically activates HOIP, resulting in a stronger catalytic capacity 
to synthesize linear ubiquitin chains compared to the interaction with only 
one of the two proteins (Liu et al., 2017). Recently, the crystal structure of the 
trimeric complex HOIPUBA/SHARPINUBL/HOIL-1LUBL has been solved, which 
elucidates how the UBA domain of HOIP interacts with both UBL domains 
simultaneously (Fujita et al., 2018). The LUBAC-tethering motifs (LTMs) 
from both SHARPINUBL and HOIL-1LUBL form a single globular domain, 
which provides extra supports to stabilize the LUBAC trimeric complex 





Figure 1.25 Structure insight into the release of HOIP auto-inhibition by the 
UBL domain from SHARPIN and HOIL-1L. A. HOIL-1LUBL and SHARPINUBL shares 
high similarity in structure (© 2017 Liu et al., by permission). B. HOIL-1LUBL and 
SHARPINUBL binds to different areas in HOIPUBA (© 2017 Liu et al., by permission). C. The 
LUBAC-tethering motifs (LTMs) from SHARPIN and HOIL-1L form the TD domain in the 
trimeric LUBAC core to stabilize LUBAC complex (PDB: 5Y3T) (© 2018 Fujita et al., by 
permission). 
 
1.3.2.2 Catalytic mechanism of HOIP 
Similar to the HECT-type E3 ligase, the RBR-type E3 ligase itself 
determines the linkage type of the synthesized ubiquitin chains. In the case of 
the isolated HOIPRBR domain (including the C-terminal extension), no 
ubiquitin chains are formed when N-terminal His-tagged mono-ubiquitin is 
used as the substrate, indicating that the Met1 from the ubiquitin is involved 
in the chain formation. In the in vitro ubiquitin assay, the HOIPRBR domain 




HOIPRBR and ubiquitin (RBR~Ub). Cys885 in the RING2 domain is 
identified as the key catalytic residue responsible for the ligase activity 
(Stieglitz et al., 2012). 
    The structure of the HOIP RING2L domain (the RING2 domain 
including the C-terminal LDD domain) in complex with ubiquitins has been 
solved at 1.6 Å resolution (PDB: 4LJO) (Figure 1.26A) (Stieglitz et al., 2013). 
The LDD domain together with the zinc-finger forms a ubiquitin-binding 
platform to non-covalently interact with the acceptor ubiquitin (Ubacc). It 
specifically positions the α-amino group of Met1 from the acceptor ubiquitin 
to the HOIP catalytic core. The thioester is formed between the C-terminal 
Gly76 carboxyl group of the donor ubiquitin (Ubdon) and the Cys885 thiol 
group from HOIP RING2. The α-amino group of the first residue Met1 in the 
acceptor ubiquitin is protonated by His887, the catalytic base from HOIP, 
therefore the acceptor ubiquitin is capable of being the nucleophile reagent to 
attack the above thioester. The reaction results in the simple peptide bond 
formation between the donor and acceptor ubiquitin. Being the critical 
catalytic base, His887 is pH-dependent. The H887A mutant can restore its 
function in higher pH conditions.  
The crystal structure of HOIPRBR with UBcH5B~Ub transfer complex has 
been solved to further provide structural evidence to the ubiquitin transfer 
process from E2 to HOIP (PDB: 5EDV) (Lechtenberg et al., 2016). In a single 
asymmetric unit, the RING1-IBR domain from one HOIP molecule and the 
RING2L domain from another HOIP molecule forms a “clamp-like” structure, 











Figure 1.26 Structure insight of the catalytic mechanism of HOIP. A. The crystal 
structure of the HOIPRING2L/Ub Ub transfer complex (PDB: 4LJO). Ubdon: the donor 
ubiquitin. Ubacc: the acceptor ubiquitin. G76 from the donor ubiquitin, M1 from the acceptor 
ubiquitin and the catalytic C885, H887 from HOIP are highlighted. B and C. The crystal 
structure of the HOIPRBR/E2~Ub transfer complex (PDB: 5EDV). Uballo: the allosteric 
ubiquitin. Ubact: the activated ubiquitin from E2~Ub. Uballo and RING1-IBR are not shown 
in Figure C. To mimic the thioester bond between E2 and Ub, the catalytic C85 from E2 
(UBcH5B) was mutated to lysine in order to form a stable isopeptide bond with G76 from 
ubiquitin. G76 from the activated ubiquitin, C85K from E2 and the catalytic C885, H887 
from HOIP are highlighted. D. Schematic illustration of the structure from Figure B. Both 
RING2L domains from Figure A and C are placed in the same position for a better 





The mechanism underlying the activation of HOIP RBR domain and the 
following ubiquitin transfer from E2 to HOIP has been proposed 
(Lechtenberg et al., 2016). First of all, the auto-inhibition state of HOIP is 
released by HOIL-1L, enabling ubiquitin (or linear chains) binding to the RBR 
domain. The binding of a ubiquitin (Uballo) to the RING1 domain allosterically 
rearranges the conformation of the RING1-IBR arm, facilitating the 
engagement of E2~Ub onto RING1 and RING2L. The interaction between the 
activated ubiquitin from E2~Ub and the RING2L domain further stabilizes 
the E2~Ub engagement. Therefore, the E2~Ub is clamped into the HOIP RBR 
domain in an appropriate position which brings the active Cys from HOIP in 
close proximity to the E2~Ub thioester, thus enables the ubiquitin transfer to 
HOIP.  
It is worth noticing that when comparing the structure of the 
HOIPRING2L/Ub Ub transfer complex (PDB: 4LJO, Figure 1.26A) with this 
HOIPRBR/E2~Ub transfer complex (Figure 1.26C), the acceptor ubiquitin- 
binding regions in RING2L is overlapped with that from E2, which indicates 
that the two transfer states of HOIP are mutually exclusive. In other words, 
once finishing the delivery of the activated ubiquitin to HOIP, E2 must exit 
from the complex to spare room for the acceptor ubiquitin in order to achieve 
the subsequent linear chain formation catalyzed by HOIP. Similarly, to keep 
this turnover, the growing chain or the ubiquitinated substrate has to later 











1.4 An introduction to the RNAse-containing proteins 
The functional study of N4BP1 (NEDD4 binding protein 1) as an 
inhibitor on LUBAC ligase activity and as a linear ubiquitin receptor is the 
major topic of this thesis. Initially, from a phylogenetic study, N4BP1 has 
been implicated as an RNAse due to the NYN (N4BP1, YacP-like Nuclease) 
domain it contains (Figure 1.27) (Anantharaman and Aravind. 2006), 
In the NYN phylogenetic tree, there are several proteins whose domains 
are structurally close to N4BP1. It’s worth noting that NYN domain in these 
proteins is fused to several other domains related to ubiquitin binding such 
as the CUE domain, the UBA domain etc, indicating the possibility involved 
in the ubiquitin-related processes. Among them, some structural studies are 
available for KIAA0323 (also called KHNYN) and MCPIP1 (also known as 
Regnase-1 or Zc3h12a).  
The nomenclature of the NYN domain reported in different literature is 
very promiscuous. For example, the NYN domain from MCPIP1 was named 
alternatively as the NCD or NCR or PIN domain from different studies. The 
NYN domain from N4BP1 is usually named as the RNAse domain. To avoid 
confusion, due to that the NYN domain functions as an RNAse, it will be 
uniformly named as the RNAse domain for N4BP1, KHNYN and MCPIP1 in 
this thesis hereafter. In this section, the three representative 





Figure 1.27 Phylogenetic trees of the proteins containing the RNAse (NYN) 
domain (© 2006 Anantharaman and Aravind, by permission). Note that 
KIAA0323 is KHNYN. Though MCPIP1 is not shown in the tree, another MCPIP family 
member (KIAA1726 or MCPIP3) is present. The NYN domain will be called as RNAse 
domain hereafter in this thesis. 
 
1.4.1 N4BP1 (NEDD4 binding protein 1)  
    N4BP1, as the name suggests, was first identified to interact with Nedd4, 
a HECT-type E3 ligase by yeast two-hybridization. In vivo experiments have 
demonstrated that N4BP1 can be mono-ubiquitinated by Nedd4 (Murillas et 
al., 2002). Further study has shown that N4BP1 can be also 
poly-ubiquitinated by Nedd4 and then undergoes proteasomal degradation 
(Sharma et al., 2010). Interestingly, sumoylation on N4BP1 was identified in 
the same study and this modification negatively regulates its 
poly-ubiquitination. The sumoylated N4BP1 cannot be poly-ubiquitinated 




N4BP1 also interacts with another HECT-type E3 ligase ITCH, but not a 
substrate of ITCH. Instead, N4BP1 binding to the ITCH WW2 domain 
reduces the affinity of ITCH to other substrates (eg. p73, p63 and c-Jun) in a 
competitive manner, thus diminishing the poly-ubiquitination of these 
substrates (Oberst et al., 2007).  
Several binding partners of N4BP1 have been identified by pull-down 
experiments combined with mass spectrometry in the wild-type 
neuroblastoma. Among them, CEZANNE, a deubiquitinating enzyme 
involved in the NF-kB pathway is significantly enriched. CEZAANE removes 
the ubiquitination modification on TRAF3, thus helping TRAF3 escape from 
being degraded. The recruitment of CEZANNE by N4BP1 results in the 
stabilization of TRAF3, suggesting that N4BP1 plays as a negative regulator 
in the NF-kB pathway (Spel et al., 2018).  
 
Figure 1.28 The domain structure of the full-length mouse N4BP1 studied in this 
thesis. KH: K Homology. UBA: Ubiquitin association. UBM: Ubiquitin binding motif. CUE: 
coupling of ubiquitin conjugation to ER degradation domain. 
 
Recently, the RNAse activity of N4BP1 has been demonstrated. The 
expression of N4BP1 can be induced by type-I interferons (IFNs), which 
suggests a role in defending the infection from viruses. In primary T cells and 
macrophages, N4BP1 acts as a suppressor to HIV-1 on account of its RNAse 
activity, while D623 is identified as the key catalytic residue for the activity 
(Yamasoba et al., 2019). It is also reported that N4BP1 is negatively regulated 
by MALT1. MALT1 cleaves N4BP1 at its R509 site, which results in the 
inactivation of N4BP1, thus further promoting the reactivation of latent 




Apart from the above findings, N4BP1 was recently discovered as a linear 
ubiquitin receptor from a yeast-two hybrid (Y2H) screening aiming for 
identifying linear ubiquitin binding domains (LUBIDs) by our collaborators 
(K. Kliza, K. Husnjak et al.,).From the cell biological studies, N4BP1 is 
recruited to the TNFR complex upon TNFα stimulation. Cell lines which are 
deficient for N4BP1 showed significantly increased levels of TNFα-induced 
NF-κB transcription activity as well as the accumulation of linear 
ubiquitinated substrates. The C-terminus of N4BP1 recognizes linear 
ubiquitin chains with high specificity from in vitro pull-down experiments, 
but the mechanism behind the ubiquitin selectivity is still unknown. It is also 
found that the N4BP1 N-terminus interacts with HOIP, the LUBAC catalytic 
subunit that mediates linear ubiquitin chain synthesis. Therefore, N4BP1 is 
proposed to be a negative regulator of the TNFR signaling pathway possibly 
by regulating LUBAC activity, but the mechanism requires in-depth 
investigation. Interestingly, N4BP1 can be cleaved by CASP8 into N- and 
C-terminal fragments during apoptosis. The N-terminus of N4BP1 could still 
negatively regulate the TNFR signaling pathway while the C-terminal 
cleavage fragment undergoes proteasomal degradation (Kliza et al., 
unpublished data).  
    
1.4.2 KHNYN (KH and NYN domain-containing protein) 
KHNYN was initially described in the phylogenetic study of the NYN 
domain (as shown in Figure 1.27) and predicted to have the RNAse activity 
(Anantharaman and Aravind. 2006). So far, KHNYN is still poorly 
characterized.  
Recently, KHNYN is reported to interact with the zinc finger antiviral 
protein (ZAP). ZAP is responsible to recognize and bind to CpG dinucleotide 
region in viral RNA but lacks the nuclease activity. KHNYN is thus recruited 




KHNYN is also found to be associated with NEDD8. KHNYN binds to 
neddylated cullins (including CUL1 to CUL4) and is independent on 
ubiquitination. Unmodified cullins lost the binding ability to KHNYN, 
indicating the direct interaction between NEDD8 and KHNYN. Later, the 
C-terminal domain from KHNYN was identified to be responsible for the 
binding. Therefore, this domain is named as CUBAN (Cullin-Binding domain 
Associating with NEDD8) (Castagnoli et al., 2019). 
CUBAN domain shows significant binding affinity to NEDD8 rather than 
ubiquitin. It is worth noticing that N4BP1 was also screened from the same 
research by phage lambda display, but N4BP1 interacts with ubiquitin 
instead of NEDD8. The binding behaviour is completely opposite to that of 
KHNYN, indicating the different binding modes between the two proteins. 
CUBAN domain alone (PDB: 2N5M) adopts a three-helix bundle 
arrangement which is commonly shared with other UBDs. However, the 
location of the second helix is in an opposite plane, making CUBAN 
structurally distinguished from UBDs such as the CUE domain or the UBA 
domain (Figure 1.29A).  
The co-structure of the KHNYN C-terminus CUBAN domain with 
NEDD8 has been solved by solution NMR (PDB: 2N7K). Polar and 
hydrophobic interactions are mainly involved in the interaction between the 
two molecules. In addition, the higher chemical shift perturbations (CSPs) of 
the residues in the loop1 area from CUBAN suggest spatial rearrangement 
upon binding to NEDD8. Although NEDD8 I44A mutant has completely 
abolished the binding with CUBAN, the co-structure shows no direct contact 
between the NEDD8 I44 hydrophobic patch and CUBAN (Figure 1.29B) 
(Castagnoli et al., 2019). It was suggested that the strong CSP changes of 
those indirect residues (including I44) are coming from the “far effect” that 
was propagated from the intramolecular disturbance when the binding event 




Additional dynamic properties were analysed by NMR titrations at 
different CUBAN: NEDD8 ratio. At the early stage where there is only 
insufficient NEDD8 added to CUBAN, the hydrophobic interaction plays the 
dominant role in the binding. While increasing NEDD8 to the same ratio to 
CUBAN, the perturbations were extended to larger surface areas with the 
involvement from several polar and neutral residues. Although the perturbed 
CUBAN surfaces are quite similar upon either NEDD8 or ubiquitin at the 
final 1:1 ratio, the intermediate evolvement seems quite limited in the case of 
CUBAN/ubiquitin where only a few hydrophobic residues are perturbed at 
the early binding stage (Santonico et al., 2019). 
 
Figure 1.29 The structure of KHNYNCUBAN domain as well as the complex with 
NEDD8. A. Overall structure comparison among the KHNYN CUBAN domain (PDB: 
2N5M), the gp78 CUE domain (PDB: 2EJS) and the UBA domain from the NSFL1 cofactor 
p47 (PDB:1V92). B. The solution NMR structure of the CUBAN/NEDD8 complex (PDB: 
2N7K). The residues involved in the interaction are shown in sticks and highlighted in pink 
(from CUBAN) and red (from NEDD8) respectively. The residues from the I44 hydrophobic 
patch of NEDD8 are coloured in yellow. Figures were generated by Pymol according to the 




1.4.3 MCPIP1 (MCP-1-induced protein 1) 
MCP-1-induced protein (MCPIP) family, as the name suggests, was first 
found being highly induced by MCP-1 in human peripheral blood monocytes 
(Zhou et al., 2006). The MCPIP members feature a novel CCCH-zinc finger 
motif, among which MCPIP1 is significantly induced by LPS in the 
macrophage activation process. MCPIP1 overexpression inhibits the 
promoter activity of TNFα when induced by LPS or p65, suggesting a 
negative role in regulating NF-κB activation in macrophages (Liang et al., 
2008). MCPIP1 functionally suppresses T and B cell activation. Deficiency of 
MCPIP1 in mice results in developing autoimmune diseases. MCPIP1 was 
also found to be the substrate of MALT1 under T cell receptor (TCR) 
stimulation. The cleavage at R111 site by MALT1 releases the inactivation 
states of T cells (Uehata et al., 2013).   
The RNAse activity of MCPIP1 has been identified. It degrades cytokine 
mRNA such as IL-6, IL-12β by targeting their 3’-UTR regions (Matsushita et 
al., 2009; Xu et al., 2012). The crystal structure of the MCPIP1 RNAse 
domain (PDB: 3V33) displays a conserved catalytic centre when 
superimposed with the PIN domain from SMG6 (PDB: 2HWW) (Figure 
1.30A, B). The catalytic centre is located within a negatively-charged pocket 
which consists of several conserved acidic residues. Among them, the single 
mutations of D141, D225, D226 and D244 result in complete loss of the 






Figure 1.30 Crystal structure of the MCPIP1 RNAse domain (© 2012 Xu et al., by 
permission, Licence No: 4881950673039). A. Overall structure of the RNAse domain 
(PDB: 3V33). B. Superimposition of the MCPIP1RNAse domain with the SMG6PIN domain 
(PDB: 2HWW). C. Electrostatic surface of MCPIP1RNAse domain. The catalytic center 
featuring several conserved acidic residues (D141, N144, D225, D226, D244 and D248) are 
located in the negatively-charged pocket. Positively-charged residues are indicated in blue 
while negatively-charged residues are indicated in red.  
 
    Further study shows that the head-to-tail dimerization of the RNAse 
domain is critical to exert the RNAse activity of MCPIP1 in vitro. Several 
single point mutations on the dimer interface break the dimerization and 
have shown no activity towards IL-6 mRNA (Figure 1.31A). The N-terminal 
domain (NTD) was found to help increase the RNAse activity. The direct 
interaction between the NTD domain and the RNAse domain was revealed by 
NMR. According to the above structural characterization, the regulation of 
the RNAse activity of MCPIP1 has been proposed: The NTD domain binding 
to the RNAse domain stops the formation of the head-to-tail RNAse oligomer, 
thus only the RNAse dimer is functioning to carry out the RNAse activity 





Figure 1.31 Oligomerization of MCPIP1RNAse domain is critical for its RNAse 
activity. A. Dimer structure of the MCPIP1 RNAse domain (PDB: 5H9V). The two RNAse 
molecules are coloured in yellow and blue respectively. Key residues that maintain the dimer 
states are highlighted in red sticks. B. Proposed working model of the regulation of MCPIP1 
RNAse activity by domain-domain interaction and dimerization. 
 
Apart from the regulation on the mRNA level, surprisingly, the 
deubiquitinating activity from the same RNAse domain in MCPIP1 was also 
discovered. Sequence analysis reveals that MCPIP1RNAse domain contains 
both the Cys box and Asp box, which are usually characterized in Cys 
protease. The sequence alignments of the Cys box between MCPIP1 and 
UCHL1 shares 39% homology and the catalytic Cys is conserved. MCPIP1 
could cleave K48- and K63-linked polyubiquitin chains in vitro. Furthermore, 
MCPIP1 is able to remove the ubiquitin modification on TRAFs (including 
TRAF2, TRAF3 and TRAF6), thus negatively regulates JNK and NF-κB 
activity. This finding demonstrates its crucial roles in inflammatory signaling 
pathways on the protein level (Liang et al., 2010).  
Because of its newly identified deubiquitinating activity, the MCPIP 
family is then grouped into the 6th member of DUB family (Fraile et al., 2012). 
It is interesting to investigate the possible relations between the dual catalytic 




1.5 Objective of this thesis 
The study of N4BP1 is the central topic of this thesis. As mentioned in 
section 1.4.1, N4BP1 is identified as a novel linear ubiquitin receptor that 
negatively regulates the TNFα signaling pathway. It is hypothesized that the 
role of N4BP1 being a negative regulator is mediated by inhibiting the E3 
ligase activity of LUBAC core subunit HOIP as well as substrate recruitment 
under pro-inflammatory conditions. 
    Based on the above knowledge and hypothesis, the study in this thesis will 
characterize both in depth the inhibition module and the specific 
ubiquitin-interacting module from N4BP1 by combining multiple approaches 
including biochemistry, biophysics and structural biology (Figure 1.32). This 
study will further expand our understanding of the physiological functions of 
N4BP1 in inflammatory and innate immunity. 
 
Figure 1.32 Schematic representation of the possible involvements of N4BP1 in 













































Nuclear magnetic resonance (NMR) spectroscopy is one of the most 
powerful and modern techniques to characterize the molecular structures 
ranging from small organic chemicals, polymers to large biomolecules 
(polypeptides or proteins). In addition, NMR is also applied to study 
chemical reactions, molecular dynamics etc. Thus, it has been widely used in 
areas including chemical, material, biological and medical sciences. There is 
another important branch from NMR application, called magnetic resonance 
imaging (MRI), which has been developed into an essential and 
indispensable technique for medical diagnosis. 
The NMR phenomenon was first discovered by American physicist 
Isidor Isaac Rabi. He was awarded the Nobel Prize in Physics in 1944. Then 
the development and application of NMR have highlighted several key 
moments in the Nobel Prize history. The development of the methods for 
NMR measurements helped two American scientist Felix Bloch and Edward 
Mills Purcell win the Nobel Prize in Physics in 1952. The applications of 
high-resolution NMR spectroscopy in chemistry were significantly developed 
by Swiss scientist Richard Robert Ernst, who was awarded the Nobel Prize in 
Chemistry in 1991. The contributions to the development of solution NMR 
for determining biomacromolecules by Swiss scientist Kurt Wüthrich helped 
him win the Nobel Prize in Chemistry in 2002 (Boesch, 2004; Shampo et al., 
2012).     
In the structural biology field, there are many advantages for applying 
NMR spectroscopy to study protein structures. For example, the protein is 
measured in solution conditions, which are close to its native physiological 
states. Compared to crystallography, sample preparation for biomolecular 
NMR does not require the time-consuming crystal screening procedure. 
NMR is also an ideal approach to study the dynamics of protein folding, 




protein-protein interactions, providing rich information on the binding 
behaviour, such as disassociation constant (Kd), perturbed surface etc.  
Needless to say, NMR also has its limits in characterizing biomolecules. 
The proteins are usually uniformly labelled with isotopes (15N or 13C or both) 
by recombinant expression. Considering the high cost of the isotopes, it 
requires the protein to be expressed at a reasonable level in minimal media. 
The protein is also required to be stable and properly folded. The protein size 
is usually limited in NMR study due to the increasing difficulties to resolve 
the crowded signals from a complex spectrum. Small proteins (<20kDa) are 
ideal for NMR, though there are cases where the structures of large proteins 
were successfully solved, it requires advanced spectrometers equipped with 
more powerful magnets. As much more signals acquired from a large protein, 
analyzing the complex multi-dimensional spectra can be challenging.  
2.2 Basic NMR theory 
Nuclear magnetic resonance (NMR) is the phenomenon where a nucleus 
in a magnetic field transits between discrete energy levels at a certain 
radiation frequency when exposed to electromagnetic radiation. NMR uses 
radio frequency (RF) radiation. A nucleus with a spin quantum number I≠0 
is NMR-active, thus NMR has selectivity towards certain nuclear types.  
2.2.1 Nucleus energy splitting and resonance 
    The nucleus is positively charged. For a nucleus with a non-zero spin 
quantum number, its spin generates a magnetic field. Therefore, it has a 
magnetic moment µ and can be considered as a very tiny magnetic bar 
(Figure 2.1A). When no external magnetic field is applied, nuclei are spinning 
at random orientations. However, when the external magnetic field (referred 
as “B0” hereafter and usually conventionally placed along the z-axis) is 
present, the nuclei will either align with the magnetic field or align against 
the magnetic field B0, thus displaying different spin states with different 





Figure 2.1 Schematic representations of the nucleus energy splitting (I=1/2) in 
an applied magnetic field. A. A nucleus with a spin quantum number I≠0 has the 
property to spin and thus has a magnetic moment µ. It can be considered as a very tiny 
magnetic bar. B. Larmor precession of nuclei in the applied magnetic field B0. B0 is usually 
conventionally applied along the z-axis. C. Energy splitting of the nuclei (I=1/2) when the 
external magnetic field Bo is applied. 
 
 
We also need to know that the nucleus does not completely align parallel 
or antiparallel with the applied magnetic field. The nucleus will also precess 




top. This is called Larmor precession and its characteristic frequency is thus 
called Larmor frequency ν (Figure 2.1B). The Larmor frequency is unique to 
each nucleus. 
The most studied nuclei for NMR include 1H, 13C and 15N etc. The spin 
quantum numbers of these nuclei are all at 1/2. The number of spin states in 
an applied magnetic field is thus 2I+1=2. Taking proton (1H) as an example, 
in an applied external magnetic field B0, proton energy splits into 2 sublevels 
and thus protons display two spin states and populate into two species 
(Figure 2.1C). The two populations follow the Boltzmann distribution. There 
is only a tiny excess of the number of the lower energy species than the 
higher energy species. From a macroscale view, it would result in the bulk 
magnetization of a group of nuclei aligning parallel with B0 at equilibrium.  
To excite the protons from the lower energy state to the higher energy 
state, the RF radiation at the proton Larmor frequency ν must be applied to 
exactly fulfil the energy gap ΔE between the two states (Equation 1). Nuclei 
can only absorb the energy from RF radiation that is equal to ΔE in order to 
resonate. The energy transition during this spin flip can be recorded in an 
NMR spectrum. 
               ΔE= γ!"# B0 = hν                (1)  
                 ν = γ"# B0                   (2) 
Where: 
h is the Plank’s constant (6.626×10-34 Js) 
γ is the gyromagnetic ratio of the nucleus 
Bo is the applied magnetic field 
ν is the Larmor frequency of a certain nucleus 
2.2.2 Chemical shift 
The discussion from above is the simplest case where the proton is 




surrounded by various chemical environments, mostly from electrons. In an 
applied external magnetic field B0, electron spins opposite to the nucleus. 
Hence, a small magnetic field Be from the electron is induced, opposite to B0 
(Figure 2.2). This results in a reduced total external magnetic field Beff for the 
nucleus (Equation 3). This is called the shielding effect.  
 
Figure 2.2 Schematic representation of the shielding effect from the electron to 
the nucleus. Electron is shown as a small red ball. The red arrow indicates the magnetic 
field Be generated by the spinning electron.  
 
ρ is the shielding constant in the below equation. Due to the shielding 
effect, the Larmor frequency of a nucleus will be changed, which is described 
by the chemical shift. Even for the same nucleus, the different surrounding 
electron distributions would result in different chemical shifts, providing 
important information on its local chemical environments. Thus, it has 
become a key parameter for structure determination. 
                    Beff=B0-Be=(1-ρ) B0                  (3) 
Replacing B0 with Beff in Equation 1 will result in an increased value of 
Bo in order to fulfil the resonance. 
                     B0 = "$#	('())γ                     (4) 
According to Equation 4, the chemical shift (represented by the Larmor 
frequency ν here) is proportional to the external magnetic field B0. It will 
result in various chemical shift values if the same nucleus is placed in NMR 
spectrometers with different magnetic field strengths. To avoid this 




standard chemical (usually using TMS) in the below form (Equation 5). Thus, 
chemical shift δ is a ratio without unit. It is usually expressed in ppm.    
δ = !"#$%&'−!)'*	
!)'*
                   (5) 
Where: 
δsample is the absolute resonance frequency of the sample 
δref is the absolute resonance frequency of the standard 
2.2.3 J-Coupling 
J-coupling (also called spin-spin coupling or scalar coupling) is the 
indirect interaction between two magnetically active nuclei, through 
chemical bonds. Considering a nucleus (I≠0) as a small magnetic bar, its 
magnetic moment could affect a neighbouring nucleus (I≠0) and vice versa. 
This mutually leads to the energy splitting for both nuclei in the magnetic 
field, resulting in the splitting of the NMR signals (Figure 2.3).  
The strength of the coupling is expressed as the constant J, which is the 
frequency difference between the split signals. J constant is the intrinsic 
property of the nucleus and is independent of the external magnetic field. 
J-coupling usually occurs as far as three bonds. Thus, it provides distance 
and dihedral angle information of two coupled nuclei.   
J-coupling is the basic principle of some key multidimensional NMR 
experiments, for example, double resonance HSQC and triple resonance 
approaches such as HNCA, HN(CO)CA etc. These experiments are based on 
the magnetization transferred between certain types of nuclei via J coupling, 
providing selective nuclear correlations that are important for protein 





Figure 2.3 Schematic representation of an example of J-coupling between two 
protons. The energy levels of Hα are affected by the spin states from a nearby Hβ, as 
described as J-coupling, resulting in the splitting of the Hα NMR signals. JHH is the 
J-coupling constant. 
 
2.2.4 The Nuclear Overhauser Effect (NOE) 
Different from the J-coupling where the nuclei interact indirectly 
through bonds, two spin-active nuclei also have the direct interaction 
through space. This is described as dipolar coupling. Key factors involved in 
dipolar coupling include the distance between two nuclei as well as their 
orientations etc. Therefore, the dipolar coupling provides information on the 
geometric structure of the molecule.   
Based on dipolar coupling, the NOE effect is discovered and has been 




described as the changes of the signal strength from an observed nucleus 
when a nearby nucleus (usually within 5 Å) is excited or saturated by radio 
frequency. The NOE strength η is directly correlated to the distance d 
between two nuclei:  
                  η ∝ 1/d6                                           (5) 
The NOE effect is particularly important for the NOESY (Nuclear 
Overhauser Effect Spectroscopy) experiments. In the simplest 
two-dimensional H-H NOESY experiment (Figure 2.4), magnetization is 
exchanged between all the protons that have the NOE effects. That is to say, 
any protons close enough to a certain proton of interests are visible in the 
NOESY spectrum. It provides rich distance information on the 
intramolecular or even intermolecular structure.  
 
Figure 2.4 Schematic representation of the interactions between a group of 
close protons detected in H-H NOESY. Arrows indicate the magnetization transfer 
between protons that have NOE effects. Atom signals visible in the NOESY spectrum are 






2.3 One-dimensional 1H NMR  
One-dimensional 1H NMR experiment is the simplest and most 
commonly used experiment in the starting stage of sample characterization. 
The natural abundance of 1H makes it the most sensitive element for NMR 
detection. In a modern Fourier-Transform (FT) NMR spectroscope, a 
single-pulse sequence is applied to obtain the 1D 1H NMR spectrum (Figure 
2.5). After the 90° RF pulse is applied, the bulk magnetization of the protons 
flips to the x-y plane compared to its original direction (along the z-axis). The 
signals of magnetization are recorded in the relaxation process where the 
bulk magnetization is returning to the z-axis over this period. This process is 
called Free Induction Decay (FID). The FID signals are further transformed 
from the time domain to the frequency domain by Fourier transformation in 
order to generate the conventional spectrum that is usually seen from an 
NMR spectroscope.    
1D 1H NMR spectrum of a small organic compound has only a few 
signals and is easy to resolve due to the simplicity of the structures. However, 
when it comes to even a small protein, a large number of signals are 
overlapped, thus the complexity of the spectrum is greatly increased and 
difficult to solve. To collect as much structural information as possible, 
multi-dimensional heteronuclear NMR spectroscopy has been developed, 
including double and triple resonance experiments. 
However, it is still useful to roughly evaluate the protein quality by 1D 
NMR, for example, how well the protein is folded. It is helpful to verify the 






Figure 2.5 Schematic representations of the process of 1D NMR experiment 
applied with a single 90° pulse. A 90° RF pulse was applied to the nuclei to induce the 
bulk magnetization (M) flipping to the x-y plane. The Free Induction Decay (FID) signals 
over time in the magnetization relaxation process are recorded and then Fourier-transferred 
to the frequency domain.  
 
2.4 two-dimensional HSQC 
HSQC (Heteronuclear Single Quantum Correlation) experiment is the 
double resonance approach to detect the correlation between two different 
nuclear species. As a two-dimensional NMR experiment, the chemical shift of 
1H is usually recorded in the direct dimension, while 15N or 13C is in the 




1H/15N-HSQC is perhaps the most widely used 2D NMR spectrum which 
collects all the H-N correlations via J-coupling, including the backbone 
amide groups and those from the side chains of Trp, Asn and Gln. Therefore, 
each signal in 1H/15N-HSQC can be assigned to a certain residue (except 
those from the side chains). Due to fewer numbers of NH groups than CH 
groups of a protein, 1H/15N-HSQC spectrum is less crowded than 
1H/13C-HSQC. Together with its high sensitivity, 1H/15N-HSQC is considered 
as the fingerprint of a protein and usually the first 2D NMR measurement to 
start with. Figure 2.6 shows the 1H/15N-HSQC profile of ubiquitin with full 
assignments acquired from this study.  
 
Figure 2.6 The 1H/15N-HSQC spectrum of 15N-labelled ubiquitin. The assignment 
for each residue is indicated (expect the side chains). The dashed lines link the signals from 
the side chains. The insertion in the right corner indicates the J coupling in the NH group. 
Atom signals visible in the spectrum are coloured in red. 1H/15N-HSQC spectrum was 
acquired from this study. The signals were assigned according to the previously reported 




1H/15N-HSQC can be combined with three-dimensional 15N-NOESY to 
obtain the proton-proton constraints for structure calculation. The NH strip 
of each residue in 15N-NOESY can be identified from 1H/15N-HSQC. Then any 
protons that have the NOE effects with the sidechain protons in this NH strip 
can be detected. Likewise, 1H/13C-HSQC or triple resonance experiments can 
also be combined with 13C-NOESY to help obtain the structure constraints.  
 
2.5 Three-dimensional NMR experiments and protein 
assignment theory  
Heteronuclear triple resonances are widely used for protein assignments 
by solution NMR. The sample is usually uniformly labelled with 13C and 15N, 
and all the three nuclei are involved in specific NMR detection, resulting in a 
three-dimensional spectrum. Triple resonances provide rich information to 
assist in solving the protein structure. 
2.5.1 Triple resonance experiments for protein backbone 
assignments 
Taking HNCA, one of the most used triple resonance experiments for 
protein backbone assignments as an example, the three dimensions of this 
experiment are 1H, 15N and 13C respectively. The spectrum can be seen as 
many 2D 1H/15N-HSQC planes (Figure 2.7B, x-z plane) extending along the 
third axis 13C (Figure 2.7B, y-axis). Thus, each 2D plane contains the signals 
at a certain 13C value. When compact all the 2D 1H/15N-HSQC planes into one 





Figure 2.7 Schematic representation of an HNCA experiment. A. The Cα signals of 
residue i and i-1 are both visible in the HNCA spectrum. Atom signals visible in the spectrum 
are colored in red. B. A 3-dimensional view of the signals in the HNCA spectrum. The (x,y,z) 




spectrum by compacting all the x-z planes together. The value of the 13C in y-axis cannot be 
indicated in this view and thus absent in the coordination. D. Three NH strips at different 15N 
values (α, β and γ) identify the residue sequence by matching the same signals from different 
strips. 
 
To analyze the HNCA spectrum in a better way, each 2D 1H/13C plane 
(Figure 2.7B, x-y plane) is usually taken out at a certain 15N value (Figure 
2.7B, z-axis) at one time. In each such plane, the signals can be isolated in the 
form of an “NH strip” (Figure 2.7D). For a certain NH strip of residue i in the 
HNCA spectrum, the Cα signals of residue i and i-1 are both visible, while the 
intensity from residue i is stronger than that from i-1 (Figure 2.7A and D). 
The chemical shift of the Cα signal of a certain residue provides a unique 
coordination in the 3-dimensional space. By looking for and comparing the 
NH strips in pairs, the context of two adjacent residues can be identified. 
Under ideal circumstances, a spectrum like HNCA is enough to identify a 
series of strips in the correct order of the actual protein sequence. However, 
multiple factors would possibly affect the resolution of the spectrum in the 
real experiment. For instance, a bad signal-to-noise ratio would increase the 
difficulty to distinguish some of the residues. Some signals can be also 
overlapped. The flexible area of the protein usually displays weak signals.    
To help assign the Cα signal from each residue, HN(CO)CA can be used 
in conjugation with HNCA (Figure 2.8A). For a certain NH strip of residue i 
in the HN(CO)CA spectrum, only the Cα signals of residue i-1 are visible. If 
overlay the same NH strip from the two spectra, Cα from residue i-1 can be 






Figure 2.8 Schematic representation of an HN(CO)CA experiment in 
conjugation with HNCA. A. The Cα signal of residue i-1 is visible in the HN(CO)CA 
spectrum. Atom signals visible in the spectrum are colored in red. B. By overlapping the same 
NH strip from HNCA and HN(CO)CA, The Cα signal of residue i-1 can be identified. 
 
There are other spectrum combinations to help with the protein 
backbone assignments. As shown in Figure 2.9A, CBCA(CO)NH and 
CBCANH can be conbined together to help identify both Cα and Cβ from 
residue i-1. It can also work with HNCA/HN(CO)CA to confirm the 
assignment of Cα. Similarly, carbonyl CO can be identified by combining 





Figure 2.9 Schematic representation of different combinations of triple 
resonance experiments to assist protein backbone assignments. A. The Cα and Cβ 
signals can be identified in CBCA(CO)NH and CBCANH experiments. Signals from residue i 
and i-1 are both visible in CBCANH while only signals from residue i-1 are visible in the 
CBCA(CO)NH. B. Carbonyl CO can be identified in HNCO and HN(CO)CA experiments. 
Signals from residue i and i-1 are both visible in HN(CO)CA while only signals from residue 
i-1 are visible in HNCO. Atom signals visible in the spectrum are colored in red. C. A 






2.5.2 Triple resonance experiments for protein side 
chain assignments 
There are also specifically developed triple resonance experiments to 
identify the sidechain C and H groups. The most commonly used 
experiments include HBHA(CO)NH, HCCH-TOCSY etc.  
As shown in Figure 2.10A, the Hα and Hβ signals from residue i-1 
correlate to the NH group from residue i in HBHA(CO)NH. With the help 
from the 1H/15N-HSQC spectrum, the NH strip of each residue can be found 
in HBHA(CO)NH and the proton signals in this strip are actually from the 
preceding residue. HBHA(CO)NH is quite sensitive and usually recorded 
prior to HCCH-TOCSY. 
 
Figure 2.10 Schematic representations of HBHA(CO)NH and HCCH-TOCSY 
experiments. A. The Hα and Hβ signals from residue i-1 are visible in HBHA(CO)NH. B. 
Sidechain proton signals from residue i and i-1 are both visible in HCCH-TOCSY. Atom 
signals visible in the spectrum are colored in red.  
 
HCCH-TOCSY (1H-13C-13C-1H Total Correlation Spectroscopy) is a more 
complex experiment where the proton resonances from residue i and i-1 can 
be both detected (Figure 2.10B). These proton signals correlate to the 
backbone or sidechain carbon signals. For example, in a CH strip of a certain 




the sidechain proton signals from this residue and the preceding residue are 
visible in this strip. The Hα and Hβ assignments from HBHA(CO)NH and the 
Cα and Cβ assignments from the previous backbone experiments can be 
combined with HCCH-TOCSY to help complete almost all the sidechain 
assignments.      
 
2.6 Protein dynamic studies by NMR titrations 
The advantage of using NMR technique to study protein-ligand or 
protein-protein interactions is that the thermodynamic (Kd), kinetic (kon and 
koff) and structural (chemical shifts and NOEs) information of the interaction 
can be well-characterized (Williamson, 2013). In particular, the fast 
dynamics of a process can be detected by NMR. Another advantage is that a 
broad range of interaction strengths (from nM to mM) can be detected by 
NMR, thus it is possible to study weak interactions by this approach. In 
addition, the characterization is under solution conditions with an atom-level 
resolution, making NMR an ideal and powerful tool for protein dynamic 
studies. 
A series of 1H/15N-HSQC experiments are usually employed in the 
protein-ligand or protein-protein interactions. The protein of interests can be 
labelled with 15N, in order to be visible in HSQC. Upon the addition of an 
unlabelled binding partner (i.e. a ligand or a protein) at different ratios, the 
changes of a variety of physical parameters from the protein can be 
monitored via NMR through the titration process. The dynamics of the 
binding partner can be also characterized vice versa.  
In a simple one-step interaction, in the presence of a binding partner 
(represented as L here), the line width and Larmor frequency of the signal 
from a certain residue might be changed compared to the free-bound state (P) 
(Figure 2.11). These changes are dependent on the exchange rate kex between 





Figure 2.11 Schematic representation of a single step interaction observed from 
NMR titration. P indicates the free-bound state of the protein of interests. PL indicates the 
bound state. L represents a binding partner. Δ%N is the chemical shift difference of 15N. Δ%H is 
the chemical shift difference of 1H. 
 
The chemical shift difference Δ" of a signal can be calculated based on 
the weighted average of Δ"H and Δ"N. The interaction can be roughly grouped 
into three regimes depending on the strength of the exchange rate (Figure 
2.12). In the case of slow exchange (kex << Δ"), the original signal starts to 
decrease and then gradually reappears in a new position during the titration 
process. While for a fast exchange (kex >> Δ"), the signal moves progressively 
to a new position without much change in the signal intensity. The 
intermediate exchange is in between the two extreme cases and the line 
shape and intensity are not changed linearly (Waudby et al., 2016). A series 
of Δ" collected from the titration can be plotted as a function of L/P ratio, in 





Figure 2.12 Three exchange regimes in the NMR titration process. Left panel: 1D 
projections of the 15N (or 1H) signals from a residue in 1H/15N-HSQC spectra during titrations. 
Right panel: the moving patterns of the signal from a residue in 1H/15N-HSQC spectra during 
titrations. P indicates the free-bound state of the protein of interests. PL indicates the bound 
state. L represents the binding partner. 
 
 If the structure and NMR assignment of the protein (or ligand) are both 
available, a list of Δ" can be generated summarizing the chemical shift 
perturbation (CSP) for the binding event. CSPs can be mapped to the 
structure of the protein or ligand to help identify the binding site or binding 
interface. The information can be used to establish the computational 
docking model between the two binding partners.  
Apart from the NMR titrations by recording HSQC spectra, NOESY 
experiments are also sometimes employed to detect intermolecular NOEs 
that may occur in the binding interface. This could further help identify the 







                           CHAPTER III                         
 

























General equipment                       Manufacturer/Source 
Balance (ED2202S-CW)  Sartorius 
Digital Block Heater JENCONS-PLS 
Mini-PROTEIN® Tetra Electrophoresis System Biorad 
P-1 Peristaltic Pump Pharmacia Fine Chemials 
pH Meter (3510) JENWAY 
Tactrol 2 Autoclave Priorclave 
T100TM Thermal Cycler Biorad 
ThermoMixer C Eppendorf 
Vacuum Filtration Device Millipore 




Avanti J-30I  Beckman Coulter 
Centrifuge 5810R Eppendorf 
Centrifuge 5424 Eppendorf 
Universal 320R Hettich 
Columns 
HiLoad® 16/600 Superdex® 75 pg (SEC) GE Healthcare 
HiLoad® 26/600 Superdex® 75 pg (SEC) GE Healthcare 
HiLoad® 16/600 Superdex® 200 pg (SEC) GE Healthcare 
HiLoad® 16/600 Superdex® 200 pg (SEC) GE Healthcare 




HiTrap® HP SP (cation exchange) GE Healthcare 
HisTrapTM HP (Ni-affinity) GE Healthcare 
Mono Q 5/50 GL (anion exchange) GE Healthcare 
PD-10 (desalting) GE Healthcare 
Resource S (cation exchange) GE Healthcare 
Self-packed Ni-NTA column (Ni-affinity) 
(~10 mL, filled with GSH SepharoseTM 4 Fast 
Flow) 
GE Healthcare 
Self-packed Ni-NTA column (Ni-affinity) 
(~10 mL, filled with Ni SepharoseTM 6 Fast 
Flow) 
GE Healthcare 
Self-packed TALON column (Co-affinity) 
(~20 mL, filled with TALON resin) 
GE Healthcare 
SuperoseTM 12 10/300L (SEC) GE Healthcare 
Superdex® 200 Increase 10/300 GL (SEC) GE Healthcare 
Imagers 
ChemiDocTM Touch Imaging System  Biorad 
Typhoon TRIOVariable Mode Imager Biorad 
ITC 
MICROCAL PEAQ-ITC Malvern 
Incubators 
Excella E25 shaker  New Bruswick 
Innova 44R shaker New Bruswick 
Protein purifiers 
AKTA PrimeTM GE Healthcare 




AKTA PurifierTM GE Healthcare 
Spectrometers 
Cary 100 UV-Vis spectrophotometer Aglient 
WPA Biowave II Spectrophotometer Biochrom 
DS-11+ Spectrophotometer DeNovix 
SPR 
Biacore S200 GE Healthcare 
3.1.2 Consumables 
Amicon® Utra-15 Centrifugal Filters (3K/10K) Merk Millipore 
NuPAGE Novex 4-12% Bis-Tris Gel 
 (12/17-wells) 
Invitrogen 
Mini Dialysis Kit (1 kDA cut-off, 250 µL) GE Healthcare 
Mini-PROTEAN® TGX Stain-Free™ Precast 
Gels 
Biorad 
RunBlue™ 4-12% Bis-Tris Gel (9cm×10cm) Expedeon 
Series S Sensor Chip CM5 GE Healthcare 
Shigemi NMR tube Bruker 
SnakeSkinTM Dialysis Tubing Thermo Scientific 
Syringe filter (0.2 µm) Fisherbrand 
VIVASPIN 500 (3,000 MWCO) Sartorius stedim biotech 
3.1.3 Chemicals 
Ampicillin sodium Apollo Sceintific 
BoltTM MES SDS Running Buffer (20×) Novex 
cOmpleteTM protease inhibitor cocktail tablets  ROCHE 





DTT Apollo Sceintific 
gibco®100X MEM vitamin solution Thermo Fisher Scientific 
Instant Blue™ Expedeon 
Kanamycin sulphate Apollo Sceintific 
(L)-glutathione (reduced form) Apollo Sceintific 
Lumitein Protein Gel (1×) Biotium 
MES Run Buffer (20×) Expedeon  
Miller’s LB Broth  Melford  
15NH4Cl CIL  
NuPAGE® LDS Sample Buffer (4×) Novex 
PMSF Melford 
Quick-Load® Purple 1 kb Plus DNA Ladder NEB 
RunBlue™ TriColor Prestained Protein 
Ladders 
Expedeon 
TCEP-HCl Apollo Sceintific 
Other general cheimicals are purchased from Apollo Sceintific, Fisher 
Scientific, Melford, Sigma or VWR.   
3.1.4 Kits 
Amine Couping Kit GE Healthcare 
GeneJET plasmid Miniprep Kit Thermo Scientific 
GST Capture Kit GE Healthcare 
PCR clean up kit NEB; QIAGEN 
QIAprep Spin Miniprep Kit QIAGEN 





KOD Hot Start DNA Polymerase Novagen 
NEBuilder® HiFi DNA Assembly MasterMix NEB 
OneTaq MasterMix NEB 
Q5 Polymerase MasterMix NEB 
Restriction Enzymes  
(NdeI-HF, EcoRI-HF, BamHI, DpnI) 
NEB 
3.1.6 Backbone plasmids used in this thesis 
 






3.1.7 E. coli Competent cells 
BL21 (DE3) competent E. coli Self-made 
NEB® 5-alpha Competent E. coli (High Efficiency) NEB 
Rosetta DE3 competent E. coli Self-made 











3.2.1 Microbiology-related methods 
3.2.1.1 General E. coli culture induction 
    For E. coli expression strains carrying pGEX-4T1, pGEX-6P1, pET47b or 
pET49b-derived vectors, the corresponding LB culture was incubated at 
37°C/220 rpm until OD600 reached to ~0.8. Then the culture was induced by 
0.1-0.5 mM IPTG at 20°C/180 rpm for ~16 h. 
To improve protein yield, pCold-I and pCold-TF vectors were used in this 
study. Both vectors carry the cold-shock Protein A (cspA) promoter, allowing 
the synthesis of the recombinant protein at a low temperature (15°C) in E.coli. 
Under such condition, the expression of host proteins is suppressed and the 
protease activity is decreased, which helps increase the purity and yields of 
the recombinant proteins. pCold-TF vector additionally expresses the 48-kDa 
trigger factor (TF), a prokaryotic ribosome-associated chaperone protein, as a 
soluble tag fused to the expressed protein of interest. It facilitates 
co-translational folding of nascent polypeptides, thus reducing misfolding 
and insolubility of the protein (pCold™ TF DNA user manual, TAKARA). 
To this end, for E. coli expression strains carrying pCold-I or 
pCold-TF-derived vectors, the corresponding LB culture was first incubated 
at 37°C until OD600 reached to 0.5-0.8. Then the culture was cold-shocked in 
the ice/water mixture until the temperature reduced to ~15°C and further 
kept in 15°C for 30 min without shaking. Later, IPTG was added at the final 
concentration of 0.1-0.5 mM for induction at 15°C/180 rpm for ~24 h. 
3.2.1.2 E. coli growth in M9 media for isotopic labelling 
Protocol 
    A small LB culture (~5 mL) was inoculated with a tiny amount of E. coli 
glycerol stock from -80°C to recover the strain overnight. On the second day, 
the above recovered culture was re-inoculated into a new 5 mL LB medium 




mL M9 media as starting culture. The M9 starting culture was incubated 
overnight at 37°C/220 rpm. The OD600 should be 2-3 the next day. Then 25 
mL starting culture was added into 1 L M9 media for incubation at 37°C/220 
rpm. Note that for a 5L flask, only incubate at most 1L culture to supply 
enough aeration for good baterial growth. In the case of growing E.coli 
Rosetta DE3 strains to express His-tagged N4BP1 CUE domain, IPTG was 
added to a final concentration of 1 mM when OD600 reached to ~ 0.8 at 37°C 
and then the induction was conducted at 20°C overnight.  
M9 media 
To make 1 L M9 media, dissolve 6 g Na2HPO4, 3 g KH2PO4 and 0.5 g NaCl 
in 800 mL water and pH to 7.4, then make up to 1 L and transfer into a 5L 
conical flask for autoclave. Take ~ 40 mL above buffer to dissolve the 
following reagents, filter through the 0.2 µM membrane and add back to the 
bulk media: 
D-glucose (D-13glucose if 13C labelling is needed) 2 g 
NH4Cl (15NH4Cl if 15N labelling is needed)  0.7 g  
gibco® 100X MEM vitamin solution 10 mL 
0.1 M FeSO4 100 µL 
1M CaCl2 10 µL 
1M MgSO4 2 mL 
     Add antibiotics to the culture before inoculation. 
3.2.1.3 Making E. coli competent cells 
Protocol 
    A small 1 mL LB culture with corresponding antibiotic was made from the 
E. coli (XL2 or BL21 or Rosetta DE3 strains) glycerol stock overnight. Then it 
was used to inoculate a new 10 mL overnight pre-culture. On the next day, 1 
mL pre-culture was added to 100 mL LB media and incubated at 37°C/250 




transferred into 2×50 mL polypropylene falcon tubes and left on ice for 15 
min, then centrifuged at 4°C for 5 min at 5K rpm. The pellet was collected and 
gently resuspended (avoid vortexing or excessive pipetting) in 25 mL 
pre-chilled TfbI Buffer and left on ice for 15 min. It was then centrifuged at 
4°C for 5 min at 5K rpm. The pellet was collected again and gently 
resuspended in 4 mL pre-chilled TfbII Buffer. Small aliquots (100 µL each) 
were made and flash frozen in liquid nitrogen. Aliquots stored at -80°C can be 
used for transformation for up to 6 months. 
Buffers used in this protocol 
TfbI Buffer: Dissolve 0.294 g Potassium Acetate, 0.989 g MnCl2·4H2O, 0.745 
g KCl, 0.147 g CaCl2·2H2O, 15 mL glycerol in 100 mL Milli-Q H2O. Filter 
sterilize with 0.2 µm syringe filter before use.  
TfbII Buffer: Dissolve 0.209 g MOPS, 1.1 g CaCl2·2H2O, 0.075 g KCl and  
15 mL glycerol in 100 mL Milli-Q H2O. Filter sterilize with 0.2 µm syringe 
filter before use.  
3.2.2 Molecular biology-related methods 
3.2.2.1 Gene cloning  
    Gene cloning was conducted by using Q5 polymerase (NEB), following 
manufacturer’s instructions. If the PCR product only shows single band with 
correct size from the TAE agarose gel, the PCR product can be directly 
purified by PCR Clean-up Kit (NEB). If not, the corresponding band is cut 
from the gel, then the DNA is purified by gel extraction using the Gel 
Extraction Kit (Qiagen).  
3.2.2.2 Gene ligation 
    Inserting genes into the corresponding plasmid was all achieved by the 
In-Fusion cloning technology using NEBuilder® HiFi DNA Assembly 
MasterMix (NEB).  
    In brief, the gene specific primer for gene amplification is designed with 




vector. By PCR, both ends of the gene was added with the corresponding 15 bp 
vector sequence. With the help from the In-Fusion enzymes, the gene 
fragment was incorporated into the linearized vector by homologous 
recombination of the overhangs. A typical reaction is as follows: 
 
Reaction components Volume 
2Í NEBuilder® HiFi DNA Assembly MasterMix 5 µL 
DNA insertion ~ 200-300 ng 
Linearized plasmid  ~ 100 ng 
H2O  top up to 50 µL 
     
    The reaction was incubated at 50°C for 30 min using a PCR thermocycler. 
Then 2 µL reaction was taken for the transformation into XL2 or DH5α 
competent cells. Positive strains were selected under corresponding antibiotic 
resistance and confirmed by sequencing. 
The detailed information of the primers is listed in Appendix IV. 
3.2.2.3 Site-directed mutagenesis (SDM) 
    1) Primer design 
The method to achieve the site-directed mutagenesis in this thesis is 
generally amplifying the whole plasmid by using a pair of primers which carry 
the mutation. The primer design is based on the online design website 
(https://www.agilent.com/store/primerDesignProgram.jsp) from Agilent 
following the instruction step by step. 
The detailed information of the primers for SDM is listed in Appendix IV. 
    2) PCR 
KOD Hot Start DNA Polymerase (Novagen) was used to amply the whole 
plasmid carrying the point mutation. The typical elongation time is ~25 s/kb. 
The reaction system and condition are shown below. Usually a 2Í50 µL 




TAE agarose gel to make sure a visible PCR product is generated. 
 
PCR reaction 
Reaction components Volume 
10ÍKOD buffer 5 µL 
25 mM dNTPs 5 µL 
25 mM MgSO4  3 µL 
10 µM Fwd Primer 2 µL 
10 µM Rev Primer 2 µL 
Plasmid template (20 ng/µL) 1 µL 
KOD polylmerase 1 µL 
PCR H2O top up to 50 µL 
 
PCR program 
Temperature Time (min)  
95°C 02:00  
95°C 01:00  
50°C 01:00  
70°C 02:30 go to step 2 (25Ícycles) 
70°C 05:00  
4°C Pause or forever  
 
    3) DpnI digestion and transformation 
The rest of the PCR product (85 µL) was incubated with 3 µL Dpn I (NEB) 
for digestion at 37°C for 3-4 h or overnight. The DNA was purified by the PCR 
Clean-up Kit (NEB) with an elution of ~ 20 µL. Then 2 µL DNA was taken for 
the transformation into the XL2 or DH5α Competent Cells. Positive clones 





3.2.3 Protein-related methods 
3.2.3.1 General protein purification 
A. GST-tagged protein purification and tag removal  
Protocol 
    The E. coli cell pellet was defrosted and resuspended with ~ 100 mL 
Resuspension Buffer, followed by sonication at 75% amplitude with a 
60s-on/60s-off pulse on the ice, for 4-5 repeats. The lysate was centrifuged at 
20K rpm for 30 min at 4°C. The supernatant was then loaded onto the GSH 
column (pre-equilibrated with 5 CV Washing Buffer 1). The column was 
washed with Washing Buffer 1 (high salt) to remove most of the impurities 
until the UV absorption reached a steady baseline. The column was then 
washed with Washing Buffer 2 (low salt) to reduce the salt concentration. 
Finally, the GST-tagged protein with eluted with Elution Buffer containing 20 
mM GSH. The protein elution is usually concentrated to 5~10 mL for GST-tag 
removal. 
To remove the GST tag, the protein was transferred into a dialysis bag 
(SnakeSkinTM Dialysis Tubing, Thermo Scientific) and incubated with the 
corresponding protease (usually thrombin or HRV-3C protease according to 
the linker sequence). Then the dialysis bag was dialysed against ~1.5 L 
Dialysis Buffer for overnight cleavage as well as dialyzing GSH out of the 
sample. If using thrombin, the cleavage is usually conducted at 22°C or R.T. If 
using HRV-3C protease, cleavage can be done at 4°C. 
After dialysis, the GST column was equilibrated with Washing Buffer 2. 
The overnight cleavage mixture was loaded through the GSH column again to 
remove most of the free GST and the un-cleaved GST-tagged protein. In 
theory, the flowthrough contains mostly the tag-free protein. This 
flowthrough was again concentrated until the volume was reduced to desired 
(usually 1-5 mL depending on the loop size for the gel filtration). A gel 




chromatography (SEC) and equilibrated with SEC Buffer. The protein sample 
was loaded onto the column from the loop and eluted with SEC buffer for the 
separation. The corresponding peaks from the chromatography were tested 
by SDS-PAGE and the fractions with pure target protein were pooled to the 
desired concentration. 
Small protein aliquots were made and flash-frozen in the liquid nitrogen 
and then kept in -80°C. 
Buffers used in this protocol 
Resuspension Buffer: 500 mM NaCl, 100 mM Tris-HCl (pH 7.4), 1 mM DTT 
Washing Buffer 1: 500 mM NaCl, 100 mM Tris-HCl (pH 7.4), 1 mM DTT  
Washing Buffer 2: 150 mM NaCl, 100 mM Tris-HCl (pH 7.4), 1 mM DTT 
Elution Buffer: dissolve 0.6 g glutathione (GSH) into 100 mL washing buffer 
2, check and adjust the pH to 7-8 if necessary  
Dialysis Buffer: Washing Buffer 2 
SEC Buffer: 150 mM NaCl, 50 mM HEPES (pH 7.6), 1 mM DTT 
B. His-tagged protein purification and tag removal 
Protocol 
The E. coli cell pellet was processed using the same procedure as 
described above. The supernatant after sonication and centrifuging was 
loaded onto the TALON or Ni-NTA column (pre-equilibrated with 5 CV 
Equilibration Buffer). The column was then washed with Equilibration Buffer 
until the UV absorbance reached a steady baseline. To elute the target protein, 
the column was washed with 0-100% gradient elution from Equilibrium 
Buffer to Washing Buffer with 5-10 CV. The peak fractions were tested by 
SDS-PAGE and concentrated to desired. The following tag removal and 
separation by SEC is the same as what’s described in section 3.2.3.1B.  
Buffer used in this protocol 
Equilibration Buffer: 300 mM NaCl, 50 mM Tris-HCl or HEPES, if necessary, 





Washing Buffer: Equilibrium Buffer containing 250 mM imidazole  
C. On-Column Cleavage 
Apart from the cleavage in the dialysis process, in some cases, the tag can 
be removed by on-column cleavage.  
The E. coli lysate was prepared in the same way as stated above. Then the 
supernatant from the cell lysate after centrifuging was incubated with the 
pre-equilibrated resin on an orbital rotator for 2-4 h at 4°C. The resin was 
then collected on an empty column and washed several times with the 
corresponding buffer to clean off the impurities as much as possible. Later, 
the resin was resuspended with 1-1.5 CV buffer containing the corresponding 
protease (usually thrombin or HRV-3C protease) and incubated on an orbital 
rotator for the cleavage overnight at 4°C. In theory, given enough incubation, 
the tag would be kept attached to the resin and the free-tagged protein would 
be released into the buffer. To collect the buffer containing the tag-free 
protein, the resin was collected on the empty column again and the 
flowthrough was concentrated for further purification steps.    
3.2.3.2 Purification of ubiquitin and variants  
There are several different types of ubiquitins used in this study as 
summarized in Table 3.1, including K48/K63/M1-linked di-ubiquitin chains 
(K48/K63/M1-diUb), M1-linked tetra-ubiquitin chains (M1-tetraUb) and 
ubiquitin mutants such as K48A, K48R and M-Cys-Ub (A Cys residue was 
introduced in between M1 and Q2 of ubiquitin). The purification of tagged 
ubiquitin proteins follows the standard method as described in section 
3.2.3.1.  
Here the purification of tag-free ubiquitin and K48/K63-diUb chains will 






Table 3.1 Ubiquitin-related proteins used in this thesis 
Name Tag Tag removed Purification method 
Ub WT Tag-free - SEC 
Ub K48A GST Yes GSH*/SEC 
Ub K48R GST Yes GSH*/SEC 
M-Cys-Ub GST Yes GSH*/SEC 
K48-diUb Tag-free - IEX 
K63-diUb Tag-free - IEX/SEC 
M1-diUb  His No His*/SEC 
M1-tetraUb  GST Yes GSH*/SEC 
NEDD8 GST Yes GSH*/SEC 
     His*: Affinity chromatography by TALON or Ni-NTA column   
     GSH*: Affinity chromatography by GSH column 
     SEC: Size-exclusion chromatography  
     IEX: Ion exchange chromatography by Resourse S column  
 
A. Tag-free ubiquitin purification 
    Ubiquitin has high tolerance to acidic environment, therefore it can 
remain soluble at pH 4.0 while most of the other proteins will be precipitated. 
This is the general method to isolate ubiquitin from a relatively large amount 
of culture.  
    For 15N-labelled ubiquitin, the general purification procedure is almost 
the same, the only difference is to grow the culture in 15N-M9 media in order 
to label the protein. 
    1) Purification of ubiquitin by acid-precipitation 
    The E. coli pellet from the LB culture was collected and resuspended in ~ 
60 mL SEC buffer (150 mM NaCl, 50 mM HEPES, pH 7.4) and then sonicated 
at 75% power for 4×1 min. Then the lysate was centrifuged at 4°C/20K rpm 




into 4.0 by adding 1M HCl dropwise in order to precipitate most of the 
impurities. The protein mixture was centrifuged at 4°C/20K rpm for 30 min 
to collect the supernatant, most of which contained ubiquitin with only a few 
impurities. The pH was then adjusted back to 7.4. This neutralized 
supernatant was concentrated to 2-5 mL using a 3K concentrator (Merk 
Millipore) in order to load onto the SEC column. It’s better to exchange the 
protein buffer into SEC buffer via the concentrator to decrease the salt 
strength that was introduced by adjusting the pH.  
    2) Size-exclusion chromatography (SEC) 
    Usually 2 mL concentrated neutralized sample was loaded onto the SEC 
column (HiLoad® 16/600 Superdex® 75 pg, GE Healthcare) and eluted with 
the SEC buffer. Ubiquitin is only ~ 8.5 KDa, thus eluted at a very late stage. 
The corresponding peaks from the chromatography were tested by 
SDS-PAGE and the fractions with pure ubiquitin were pooled to the desired 
concentration. Protein aliquots were flash frozen in the liquid nitrogen and 
then kept in -80°C. 
B. The synthesis of K48-linked diUb chains 
    1) Enzymatic formation of K48-diUb chains  
The K48-linked ubiquitin chains cannot be synthesized simply by 
bacterial expression. Instead, an E2 enzyme CDC34 is required to specifically 
make the K48-linked ubiquitin chains in combination with E1 (Ube1) in vitro.  
The reaction is prepared in the reaction buffer (50 mM HEPES pH 7.6, 
150 mM NaCl, 50 mM MgCl2) as follows. DTT is not allowed in the reaction. 
ATP addition is the last step to initiate the reaction. The reaction is usually 
incubated overnight at 25°C. To improve the yield of K48-diUb chains, the 








Component Final concentration 
Ube1 1 µM 
CDC34 10 µM 
Ub 250 µM 
ATP 10 mM 
 
    2) Purification by IEX (cation exchange) 
The 5.0 mL reaction above was mixed with equal amount of 50 mM NaAc 
(pH 4.0) to precipitate Ube1 and CDC34. Then the mixture was incubated on 
a 60°C heating block for 30 min followed by centrifuging at 20K rpm for 20 
min to remove the protein precipitation. The supernatant, enriched with 
ubiquitin chains, was then loaded onto the 1 mL Resource S column (GE 
Healthcare) using the sample pump from the AKTA PureTM system (GE 
Healthcare). Before loading the sample, the Resource S column was 
pre-equilibrated with 50 mM NaAc (pH 4.0). Then the proteins were eluted 
with 300 CV salt gradient (0-1.0 M NaCl in 50 mM NaAc pH 4.0) with 
2mL/fraction. Usually before reaching to 0.5 M NaCl, all the attached protein 
can be washed out from the column. The K48-diUb is usually the second peak 
after elution started. The corresponding fractions were pooled and exchanged 
into the desired buffer required for the downstream experiments. 
C. The synthesis of K63-linked diUb chains 
   1) Enzymatic formation of K63-diUb chains  
Similar to the synthesis of K48-linked diUb chains, the K63-diUb chains 
can be synthesized in vitro by two E2 enzyme UBE2V1 and UBC13 working 
together in combination with E1 (Ube1).  
The reaction is prepared in the reaction buffer (50 mM HEPES pH 7.6, 
150 mM NaCl, 50 mM MgCl2) as follows. DTT is not allowed in the reaction. 




incubated overnight at 25°C. To improve the yield of K46-diUb chains, the 
reaction time can be optimized to reduce the production of higher Mw chains. 
 
Component Final concentration 
Ube1 1 µM 
UBE2V1 10 µM 
UBC13 10 µM 
Ubiquitin 250 µM 
ATP 10 mM 
 
    2) Purification by cation exchange 
    The purification of K63-diUb chains is almost the same to that of 
K48-linked diUb chains. Note that the K63-diUb separated by cation 
exchange is usually contaminated with higher Mw chains. A further SEC 
(Superdex® 200 Increase 10/300 GL) step was applied to polish the proteins.  
3.2.3.3 15N/13C-labelled tag-free CUE purification 
Protocol 
    The cell pellet harvested from ~ 3 L E. coli culture in M9 media was 
resuspended in TALON buffer and then processed by sonication. The 
supernatant from the lysate was mixed with the pre-equilibrated ~15 mL 
TALON resin at 4°C for ~5 h to get better incubation. Then the resin was 
collected on the column and washed with TALON buffer. The resin was 
re-suspended and incubated with ~ 2 CV TALON buffer containing 150 µL 27 
mg/mL HRV-3C protease for the on-column cleavage overnight at 4°C.  
    The second day, the resin was collected on the column and the 
flowthrough was enriched mostly with the cleaved protein. The flowthrough 
was pooled to ~ 2 mL and then loaded onto the SEC (HiLoad® 16/600 
Superdex® 75 pg, GE Healthcare). The proteins were eluted with NMR buffer. 




at a very late stage. The peak fractions were confirmed by SDS-PAGE and the 
pure fractions were pooled to ~ 300 µL at 500-800 µM including 10% D2O 
and 0.05% NaN3 for NMR assignments as well as the NMR titrations. 
Buffer used in this protocol 
TALON buffer: 300 mM NaCl, 50 mM Tris-HCl, 0.5 mM TCEP-HCl  
NMR buffer: 22 mM phosphate, 55 mM NaCl, pH 7.0, 1mM DTT 
3.2.3.4 Purification of chimeric RNAse and RNAseCUE  
Protocol 
The procedures to purify chimeric RNAse or RNAseCUE were optimized 
into 3 steps. The protein was first purified by TALON affinity chromatography 
as described in section 3.2.3.1 except that the protein was directly eluted with 
Washing Buffer containing 250 mM imidazole. The peak fractions were 
combined and pooled to 2.5 mL for desalting using the pre-equilibrated PD10 
column (GE Healthcare) by IEX Buffer A. The 3.5 mL elution was then loaded 
to the pre-equilibrated Mono Q column (1 mL, GE Healthcare). The column 
was washed with 0-100% gradient elution from IEX Buffer A to IEX Buffer B 
with a total 100 CV. The pure chimeric protein was eluted at a salt 
concentration of ~100 mM NaCl. The peak fractions from IEX were combined 
and pooled to ~100-200 µL for analytical size-exclusion chromatography 
using SuperoseTM 12 10/300L (GE Healthcare). Protein was eluted with GF 
buffer. 
Buffer used in this protocol 
IEX buffer A: 20 mM HEPES (pH 8.5), 20 mM NaCl, 1 mM DTT 
IEX buffer B: 20 mM HEPES (pH 8.5), 1 M NaCl, 1 mM DTT 
GF Buffer: 150 mM NaCl, 50 mM HEPES (pH 8.5), 1 mM DTT 
Note: All the buffers above contain 0.5% Triton X-100. 
3.2.3.5 Protein quantification 
Protein concentration was measured on a DS-11+ Spectrophotometer 




nm was applied to the Beer-Lambert’s law for the concentration calculation. 
                                   A = ε·c·l                               (1) 
Where:  
A is the absorbance value 
ε is the molar extinction coefficient of the measured protein (M-1 cm-1) 
c is the protein concentration (M) 
l is the path length (1 cm) 
The AKTA protein purifier also monitors the purification progress at 280 
nm by the UV detector based on the above principle. Note that for the 
analytical size-exclusion chromatography in section 3.2.5.1, Triton X-100 was 
used in the buffer. It is known that Triton X-100 also has strong absorption at 
280 nm. To minimize the interference from Triton X-100, a background 
subtraction was performed before analysing the protein sample. The SEC 
column was equilibrated with the buffer until the UV absorbance reached 
steady. The UV absorbance was then manually adjusted to 0 by the AutoZero 
function from the UNICORN software. 
3.2.3.6 SDS-PAGE 
Protein samples were mixed with equal amount of NuPAGE® LDS 
Sample Buffer (2×, containing 0.5 M DTT) and denatured at 95°C for 10 min. 
Usually a 10 µL sample was loaded to the RunBlue™ 4-12% Bis-Tris Gel 
(Expedeon). The protein gel was run in 1×MES Running Buffer (Expedeon) at 
140V for ~ 1.5 h. Then the gel was stained with Instant Blue™ (Expedeon) for 
~ 10 min to visualize the protein bands. The gel image was taken by the 
ChemiDocTM Touch Imaging System (Biorad). 
3.2.3.7 Proteins purified in this thesis 
Table 3.2 summarizes the basic information and purification methods of 
the proteins used in this thesis. The tag of some of the proteins were kept for 
certain applications, such as SPR immobilization or to help increase the 












CDC34 27.6 No His*/SEC 
Chimeric N4BP1 RNAse domain 23.0 No His*/SEC 
Chimeric N4BP1 RNAse + CUE domain 36.1 No His*/SEC 
HOIL-1L (1-478) 54.5 Yes GSH*/SEC 
HOIP (697-1072) 45.3 No His*/SEC 
HOIP (300-1072) 86.9 Yes GSH*/SEC 
HRV-3C protease 19.9 No GSH*/SEC 
N4BP1 (1-311) 34.8 Yes GSH*/SEC 
N4BP1 (1-342) 37.9 Yes GSH*/SEC 
N4BP1 (1-392) 43.9 Yes GSH*/SEC 
N4BP1 CUE domain (850-893) 
(including WT and F862G/P893A) 
53.9 No GSH*/SEC 
5.2 Yes His*/SEC 
N4BP1 KH-like domain (1-144) 17.9 No His*/IEX 
N4BP1 RNAse domain (613-774) 71.1 No His*/SEC 
N4BP1 RNAse + CUE domain (613-893) 84.2 No His*/SEC 
N4BP1 UBA-like domain (312-392) 11.5 No His*/SEC 
N4BP1 UBM-like domain (144-311) 21.2 No His*/SEC 
UBC13 20.3 No His*/SEC 
UbcH5c 16.7 Yes GSH*/SEC 
Ube1 117.8 No His*/SEC 
UBE2V1 22.6 No His*/SEC 
     His*: Affinity chromatography by TALON or Ni-NTA column   
     GSH*: Affinity chromatography by GSH column 
     SEC: Size-exclusion chromatography  





3.2.4 Biochemical methods 
3.2.4.1 Generation of Cy5-labelled ubiquitin 
Ubiquitin is labelled with Cy5 maleimide dye (GE Healthcare) for 
fluorescence detection in the ubiquitination assay. Cy5 maleimide dye usually 
reacts with the cysteine thiol group for the labelling. A Cys residue was 
introduced in between M1 and Q2 of ubiquitin (M-Cys-Ub) to enable 
labelling.  
    M-Cys-Ub was dialyzed against the Labelling Buffer (150 mM NaCl, 50 
mM HEPES pH 7.6) overnight before the reaction. A 5 to 10-fold excess of 
Cy5 Maleimide (dissolved in DMSO) was added into 2 mM M-Cys-Ub in the 
Labelling Buffer containing 0.5 mM TCEP-HCl. The reaction was conducted 
in the dark at R.T. for 2 h. To terminate the reaction, 20 mM glutathione was 
added to inactivate the excess dye. The free dye was then removed via a 5 ml 
HiTrap desalting column (GE Healthcare). The Cy5-labelled ubiquitin was 
further purified by SEC (HiLoad® 16/600 Superdex® 75 pg, GE Healthcare).  
3.2.4.2 Ubiquitination assay 
A typical in vitro ubiquitination assay usually contains E1, E2 and E3. 
Tag-free mono-ubiquitin is commonly used as the substrate. A tiny amount of 
Cy5-labelled ubiquitin (~ 1 µM) is added to the reaction in order to participate 
in forming the chains, thus, the chains can also be labelled with Cy5. The 
reaction was prepared in the assay buffer (50 mM HEPES pH 7.6, 150 mM 
NaCl, 50 mM MgCl2). Note that DTT is not allowed in the reaction. ATP was 
the last component added to initiate the reaction. The reaction temperature is 
25°C.   
If using the longer HOIP protein construct (including the UBA domain) 
for the assay, HOIL-1L is needed to release the auto-inhibition of HOIP. 
Generally, the final concentration of HOIL-1L in the reaction is 5 µM. To test 
the inhibition effect from N4BP1, the corresponding N4BP1 construct is 




Component Final concentration 
E1 (Ube1) 1 µM 
E2 (UbcH5c) 10 µM 
E3(HOIP) 1 µM 
WT Ubiquitin 100 µM 
Cy5-Ubiquitin 1 µM 
ATP 10 mM 
 
The samples were collected at different time points during the reaction 
process and mixed with equal amount of NuPAGE® LDS Sample Buffer (2×, 
containing 0.5 M DTT) and denatured at 95°C for 10 min. Usually 10 µL 
sample was loaded to the NuPAGE Novex 4-12% Bis-Tris Gel (Invitrogen). 
The protein gel was run at 140V for ~ 1.5 h. After the eletrophoresis, the gel 
was directly scanned at an excitation wavelength of 633 nm and an emission 
wavelength of 670 nm in a Typhoon TRIOVariable Mode Imager (Biorad) to 
image the Cy5-labelled ubiquitin. To image the total protein bands, the gel 
was further stained with Instant Blue™ (Expedeon) for ~ 10 min. The gel 
images were analyzed by the Image Quant TL software (GE Healthcare). 
3.2.5 Biophysical methods 
3.2.5.1 Protein molecular weight determination 
    1) Analytical size-exclusion chromatography  
    In order to characterize the oligomeric states of the protein, 
analytical size-exclusion chromatography was performed. The SEC column 
used in this thesis is SuperoseTM 12 10/300L (GE Healthcare). The void 
volume (Vo) of this column is 7.2 mL. Six standard proteins with known Mw 
were loaded respectively to the pre-equilibrated column and eluted with the 
GF Buffer (150 mM NaCl, 50 mM HEPES (pH 8.5), 1 mM DTT, 0.5% Triton 
X-100). Note that Triton X-100 was added to the buffer in order to reduce 




Triton X-100 concentration has been optimized to 0.5%. Due to that Triton 
X-100 was used in the buffer, a background subtraction was performed as 
follows before loading the protein onto the column. The SEC column was 
thoroughly equilibrated with the GF buffer until the UV absorbance reached 
steady. The UV absorbance was then manually adjusted to 0 by the AutoZero 
function from the UNICORN software. It is known that 0.5% Triton X-100 
exists as micelles at ~90 KDa (CMC=~0.02%). But there was no particular 
peak of Triton X-100 in any profile of the standard proteins (for example 
Carbonic Anhydrase or Thyroglobulin), indicating that the column was 
well-equilibrated and the background had been successfully subtracted.  
The standard proteins were taken from the Gel Filtration Markers Kit 
(29,000-700,000 Da, Sigma). The loading volume for each protein was all at 
200 µL. The total loading amount for each standard protein is as follows: 
 
Protein Mw (Da) Loading amount 
Carbonic Anhydrase, bovine erythrocytes  29,000 1.5 mg 
Albumin, bovine serum 66,000 5 mg 
Alcohol Dehydrogenase, yeast 150,000 5 mg 
β-Amylase, sweet potato 200,000 5 mg 
Apoferritin, horse spleen 443,000 5 mg 
Thyroglobulin, bovine 669,000 5 mg 
 
The elution volume (Ve) of each protein peak (with maximum UV 
absorption) from the gel filtration profile was recorded. The calibration curve 
was plotted using the elution volume/void volume ratio (Ve/Vo) versus the 
protein molecular weight (in the logarithmic form). It was then linearly fitted. 
The protein of interest can be analyzed in the same way to obtain the Ve/Vo 
ratio from the gel filtration profile. Then the molecular weight of the protein 




    2) SEC-MALLS 
SEC-MALLS (Size-exclusion chromatography coupled 
multiple-angle laser light scattering) is the technique to determine the 
absolute molecular mass of a protein separated by SEC.  
Protein was prepared at 0.5, 1.0, 2.0 mg/mL and then 100 uL of each 
concentration was separately applied to the pe-equilibrated SEC column 
(Superdex® 200 Increase 10/300 GL, GE Healthcare) using the buffer 
containing 150 mM NaCl, 50 mM HEPES pH 7.6, 0.5 Mm TCEP-HCl and 3 
mM NaN3. The scattered light intensity of the elution from SEC was recorded 
at 16 different angles by the Dawn HELEOS-II and rEX Optilab systems and 
the concentration was measured using the rEX Optilab differential 
refractometer (Wyatt Technology). The average molecular mass was 
calculated by the ASTRA software (Wyatt Technology). Experiments and data 
analysis were performed with the kind help from Dr. Simone Kunzelmann 
(The Francis Crick Institute). 
3.2.5.2 Isothermal Titration Calorimetry (ITC)  
A physical interaction or chemical reaction is always accompanied with 
the release or absorption of heat. ITC (Isothermal Titration Calorimetry) is 
the ideal technique with high sensitivity to study the above thermodynamics 
especially for biomolecules. During titration, ITC directly monitors the 
enthalpy changes (ΔH°), binding affinity (Ka) and binding stoichiometry (N) 
in the binding process. Thus, the Gibb’s free energy (ΔG°) and the entropy 
changes (ΔS°) can be calculated according to the below equations. Apart from 
the above thermodynamic parameters, ITC could also provide kinetic 
parameters (Km, Kcat etc). This powerful technique has been widely used in 
quantitatively characterizing interactions among protein, nucleotide, lipid etc 






The relation between the several parameters is as follows: 
                          ΔG°=-R·T·lnKa                            (2) 
                          ΔG°= ΔH°-T·ΔS°                           (3) 
Where: 
ΔG° is the Gibb’s free energy (kcal/mol) 
R is the universal gas constant (1.987 cal·K-1·mol-1) 
T is the absolute temperature in Kelvin 
Ka is the association constant (M-1) 
The dissociation constant Kd is converted from Ka as shown below:  
                              Kd=1/Ka                              (4) 
Modern ITC calorimeters usually employ the power compensation 
method. In the resting state, the sample cell and the reference cell are kept in 
identical temperature thus no power difference is detected. When the 
titration starts, injectant is titrated from the syringe into the sample cell 
which contains the titrand. The enthalpy in the sample cell is changed over 
the titration process. The heat controller of the sample cell then quickly 
adjusts the temperature to maintain constant with the reference cell. This 





Figure 3.1 The simplified structure of an ITC instrument (© 2008 Freyer and 
Lewis, by permission, Licence No: 4900970610059). Three major components are 
shown: the reference cell, the sample cell and the syringe. 
 
The raw data directly acquired from the instrument records the power 
(µCal/s) versus time during the titration (Figure 3.2A). It is then processed in 
the form of an isotherm curve where each injection peak is integrated and 
plotted against molar ratio between injectant and titrand (Figure 3.2B). Thus, 
several important binding parameters can be calculated when an appropriate 





Figure 3.2 An example of an exothermic reaction from an ITC measurement 
showing the raw data (A) and the isotherm (B). Figure taken from 
https://2bind.com/itc/. 
 
To fit the isotherm curve, a binding model must be assumed and then an 
iterative nonlinear regression procedure is used. Due to that all the ITC data 
in this thesis were using the one-site binding model by the MicroCal 
PEAQ-ITC Analysis Software, here the below data fitting procedure is 
described only for this model (Freyer and Lewis, 2008; MicroCal PEAQ-ITC 
analysis software user manual (MAN0576-01-EN-00)). Equation 5 and 6 
describe the relationships between the equilibrium and mass balance in the 
system. Substituting [L] from Equation 6 into Equation 5 allows the 
calculation of the fraction of binding site j occupied by the ligand. 
                            Θj = [,].+	'/[,].+	                       (5) 
                       Lt =[L]+Pt# (%j	&j),-./                         (6)  
Where:  
Θj is the fraction of binding site j occupied by the ligand 
Kj is the binding constant of process j 
Lt is the total ligand concentration 
[L] is the free ligand concentration 




nj is the total stoichiometric ratio for process j 
Equation 7 describes the total heat content Q of the system. Derived from 
Equation 7, The differential heat ΔQi (the heat for the injection, i represents 
the injection number) can be thus derived shown as Equation 8. 
                      Q=PtV0# (%j	&j()j),-./                         (7)   
                            ΔQi=Qi-Qi-1                                           (8)   
Where: 
Q is the total heat content 
V0 is the initial volume of the sample cell 
ΔHj is the molar enthalpy change for process j 
    Parameter nj, Kj and ΔHj are initially estimated by the software and then 
the nonlinear regression is performed to fit for ΔQi from each injection and 
compared with the experimental data. The error function is calculated to 
improve the values of nj, Kj and ΔHj for the next round of iteration. The 
procedure is repeated until no significant improvement is achieve.   
Protocol 
All the protein samples were dialysed against ITC buffer (50 mM HEPES 
pH 7.4, 50 mM NaCl, 0.5 mM TCEP-HCl) overnight at 4°C using the Mini 
Dialysis Kit (1 KDa cut-off, GE Healthcare) before measurements. The titrand 
in the cell is usually prepared at a range of 100-500 µM. The injectant 
concentration in the syringe is usually 10-15 fold greater than the titrand. The 
measurement temperature is 25°C unless specified, with a reference power at 
10 µCal/s. Stir speed is 750 rpm. Initial delay is 60s. Standard 19-injection 
titration program is as follows: 
1st injection: 0.4 µl/injection, duration: 0.8s, spacing time: 150 s. 
The rest of the injections: 2 µl/injection, duration: 2s, spacing time: 120 s. 
Depending on the titrand or injectant types as well as the concentration, 
the parameters from the titration programs can be adjusted or modified to get 




PEAQ-ITC calorimeter (Malvern). The data is processed and analyzed using 
the MicroCal PEAQ-ITC Analysis Software with a one-site binding model 
(Version: 1.21). 
3.2.5.3 Surface Plasmon Resonance (SPR)  
BiacoreTM systems (GE Healthcare) take the advantage of surface 
plasmon resonance (SPR) to quantitatively measure the interaction between a 
wide range of molecules from small chemicals to biomolecules such as nucleic 
acids, proteins etc. This label-free technique provides kinetics and affinity 
parameters and has been widely used in drug and antibody screening.  
 
Figure 3.3 The basic SPR detection principle. A SPR sensor chip is a small piece of 
glass coated with a layer of thin gold film. Ligand is immobilized on the gold sensor surface. 
Analyte is in the mobile phase and running through the ligand surface under measurement 
mode. Θ indicates the resonance angle (SPR angle) at different surface conditions. Figure 
slightly modified from http://weistron.com.cn/. 
  
Surface plasmon resonance is a physical phenomenon that occurs in the 




chip for the BiacoreTM system is used as an example. The chip is a small piece 
of glass coated with a thin film of gold as shown in Figure 3.3. When the 
incident light is passing from the optically denser medium (i.e. the glass) to 
the less dense medium (i.e. the gold film), if the incident angle reaches to (or 
beyond) the critical angle, total internal reflection occurs on the interface. 
Under a certain incident angle and wavelength, the free electrons (the 
“surface plasmon”) on the gold surface are excited by the incident light and 
absorb the energy from the incident light, thus the surface plasmon resonance 
occurs. Because of the energy absorption, the reflected light intensity is 
greatly reduced. The incident angle under such condition is called the 
resonance angle or SPR angle. When mass changes on the sensor surface, the 
local refractive index of the gold layer is changed and results in changes of the 
SPR angle. 
The molecule immobilized on the sensor surface is usually defined as the 
ligand while its binding partner in the mobile phase is defined as the analyte. 
Molecules such as proteins can be immobilized on the surface via covalent 
chemical reactions, or via a capture molecule (such as antibody) to 
non-covalently interact with the protein with high affinity.  
The directly recorded SPR signal over time is displayed in a sensorgram 
(Figure 3.4). The signal intensity is expressed as response and measured in 
resonance units (RU). It is directly proportional to the biomolecule mass 
concentration on the chip surface.  
 




For an actual measurement, the analyte at a certain concentration is 
applied over the ligand surface on the sensor chip at constant flow. The 
association event between the ligand and the analyte increases the mass of the 
surface, thus results in the increase of the response. For the dissociation event, 
vice versa. 
The Kon and Koff can be resolved from the association and dissociation 
stage in the sensogram. However, in some cases, the kinetics are too fast to 
measure, instead the Kd can be resolved by the steady-state method. Here we 
only described affinity determination at the steady state.  
As shown in the sensogram, the steady state phase indicates the 
equilibrium of analyte association and dissociation with the ligand at a certain 
analyte concentration. When the ligand surface is fully saturated by the 
analytes, the response reaches to maximum (Rmax). The response at the 
equilibrium state under serial analyte concentrations follows the below 
equation: 
                        Req=Ka·c·Rmax/(Ka·c+1)                        (9) 
Where: 
Ka is the equilibrium (steady state) association constant  
Req is the response intensity in the equilibrium (steady state) 
c is the corresponding concentration of the analyte (monoUb or diUb 
chains) 
The equilibrium (steady state) dissociation constant KD is converted from 
Ka as shown below:  
                             KD=1/Ka                              (10) 
 
Protocol 






    1) GST-tagged protein immobilization 
To determine the KD between GST-tagged CUE domain (hereafter as 
GST-CUE) with ubiquitin and chains, GST-CUE was immobilized onto the 
CM5 sensor chip through the polyclonal anti-GST antibody. The CM5 chip 
was first immobilized with the antibody by amine coupling using a GST 
capture kit and an amine coupling kit (both from GE Healthcare) following 
manufacturer’s instructions. The polyclonal anti-GST antibody carries a 
minor fraction of high affinity sites that are difficult to regenerate. To avoid 
capture of GST-CUE on these sites, prior to the immobilization with 
GST-CUE, the high affinity site of the antibody was blocked with recombinant 
GST.  
GST-CUE was diluted to 5 µg/mL with 1×HBS-T+ buffer (150 mM NaCl, 
10 mM HEPES pH 7.4, 0.05% Tween 20) and loaded to the sample channel in 
the CM5 chip at a flow rate of 10 µL/min for 1 min. A reference channel was 
also prepared without loading the protein as control.  
    2) TF-tagged protein immobilization 
To determine the KD between TF-tagged RNAse or RNAseCUE proteins 
with ubiquitin and chains, the proteins were directly immobilized onto the 
CM5 sensor chip by amine coupling using an amine coupling kit (GE 
Healthcare). For amine coupling, the protein needs to be positively charged in 
the buffer below its pI for successful immobilization. In our case, the 
TF-tagged protein stocks (50 µg/mL) were diluted to 5 µg/mL with 10 mM 
Sodium Acetate at pH4.0, 4.5, 5.0, 5.5 respectively for the pH scouting. pH4.5 
was found to perform the best immobilization. Then the TF-tagged proteins 
were immobilized onto the corresponding sample channels at pH4.5 at a flow 
rate of 10 µL/min for 20 s. 
    3) Measurements and data analysis 
The analytes (ubiquitin and chains) were dialyzed against 1×HBP-T+ 




prepared on a 96-well plate. Then the analytes were flowed through the chip 
at a flow rate of 40 µL/min with 20 s association and 20 s dissociation. The 
signal from the reference channel was subtracted from the signal obtained 
from the sample channel. 
The corresponding data points were collected at the steady state stage as 
demonstrated in Figure 3.4 and analyzed by employing the steady-state 
method described above. The data were fitted using Equation 9 by Matlab.  
Experiments and data analysis were performed with the kind help from 
Dr. Simone Kunzelmann (The Francis Crick Institute). 
3.2.5.4 NMR measurements 
The basic NMR theory is introduced in Chapter II. 
The protein samples are all kept in the NMR buffer (pH 7.0) containing 
10% D2O and 0.05% NaN3. Protein concentration is 300-500 µM. 300 µL 
sample was filled in the Shigemi NMR tube (Bruker) for the NMR 
measurements. 
    1) NMR measurements for protein assignments 
The 2D and 3D NMR spectra of the 15N/13C-labelled tag-free CUE domain 
were measured in a Bruker Avance III HD 700 spectrometer equipped with a 
5mm 1H/13C/15N triple-resonance PFG cryoprobe in the Medical Research 
Council (MRC) Biomedical NMR Centre (The Francis Crick Institute).  
15N-HSQC, HNCA, HN(CO)CA, HNCACB, CBCA(CO)NH, HNCO, 
HN(CA)CO, HBHA(CO)NH and HCCH-TOCSY spectra were recorded 
respectively at 303.15 K under the kind instructions from Dr. Alain Oregioni.  
    2) NMR titrations 
    The titrations between the 15N-labelled CUE domain with non-labelled 
di-ubiquitin chains was measured in a Bruker AvanceNEO 600 spectrometer 
equipped with a 5mm 1H/13C/15N inverse triple resonance probe in the high 
field Nuclear Magnetic Resonance laboratory of QMUL. A series of 15N-HSQC 




    The titrations between the 15N-labelled CUE domain with non-labelled 
mono-ubiquitin and the titrations between 15N-labelled di-ubiquitin chains 
with the non-labelled CUE domain were measured in a Bruker Avance III HD 
700 spectrometer equipped with a 5mm 1H/13C/15N triple-resonance PFG 
cryoprobe in the Medical Research Council (MRC) Biomedical NMR Centre 
(The Francis Crick Institute). A series of 15N-HSQC spectra were recorded 
under the kind instructions from Dr. Alain Oregioni. 
The CUE domain titrated with ubiquitin 
For the titration between the CUE domain and mono-ubiquitin, a series 
of 0-4.0X titration pairs are made by addition of mono-ubiquitin (stock at 
13.17 mM) to the 15N-labelled CUE domain (stock at 0.39 mM). 
For the titration between the CUE domain and M1-diUb, a series of 
0-5.0X titration pairs are made by addition of M1-diUb (stock at 4.05 mM) to 
the 15N-labelled CUE domain (stock at 0.4 mM). 
For the titration between the CUE domain and K48-diUb, a series of 
0-2.0X titration pairs are made by addition of K48-diUb (stock at 2.72 mM) 
to the 15N-labelled CUE domain (stock at 0.4 mM). 
For the titration between the CUE domain and K63-diUb, a series of 
0-1.35X titration pairs are made by addition of K48-diUb (stock at 1.465 mM) 
to 15N-labelled CUE domain (stock at 0.4 mM). 
Ubiquitin titrated with the CUE domain 
For the titration between mono-ubiquitin and the CUE domain, a series 
of 0-4.0X titration pairs are made by addition of the CUE domain (stock at 
5.27 mM) to 15N-labelled mono-ubiquitin (stock at 0.43 mM). 
For the titration between M1-diUb and the CUE domain, a series of 
0-3.0X titration pairs are made by addition of the CUE domain (stock at 1.66 




For the titration between K48-diUb and the CUE domain, a series of 
0-5.0X titration pairs are made by addition of the CUE domain (stock at 1.66 
mM) to 15N-labelled K48-diUb (stock at 0.22 mM). 
For the titration between K63-diUb and the CUE domain, a series of 
0-3.0X titration pairs are made by addition of the CUE domain (stock at 1.66 
mM) to 15N-labelled K63-diUb (stock at 0.3 mM). 
    3) NMR data analysis 
The 1D NMR raw data were processed by the Topspin software (Bruker). 
All the 2D and 3D NMR raw data were first processed by NMRPipe software 
for data conversion and phase correction. Then the processed spectra were 
analyzed by CCPNMR software for backbone and side-chain assignments. A 
total of 97% of the potential backbone (disregarding the proline residues) and 
87% of the potential side-chain resonances were assigned (the first 3 
N-terminal residues from the tag are ignored). 
The HSQC titration spectra were analyzed by CCPNMR software and 
visualized by NMRviewJ software. Based on the protein assignments, the 
chemical shift values ("N and "H) were extracted from the spectra and 
integrated to the chemical shift perturbation Δ" according to the below 
equation in order to make the CSP list and map to the structure surface. 
               Δ" = (("H bound-"Hfree)2 + (("N bound-"Nfree)/a)2)1/2                (11) 
                a = ("Nmax- "Nmin)/	("Hmax- "Hmin)                    (12) 
The CSPs were mapped to the protein structure surface by the Chimera 
software (Version 1.14). The Kd of each residue was calculated by fitting the 
chemical shift data via the MestReNova software using the advanced tool 
AFFINImeter-NMR. It also provides an average Kd for the whole titration 
process. AFFINImeter-NMR applies the stoichiometric equilibrium (SE) 
models for the NMR titration analysis. For a simple interaction between 
molecule A and B as shown below, the equilibrium constant can be described 




                           a×A+b×B « AaBb        
                            Kab= 
[AaBb]	
[A]a[B]b	                  (13) 
For a particular observable X, such as the chemical shift perturbation Δ", 
it is related to the formation of AaBb complex in a volume V and follows the 
below equation where Xmn is the molar contribution of AmBn to the observable 
X: 
                      X=# ,mn[.m/n]10,23,4.5                        (14)  
The formation of AmBn can be calculated by Equation 13 where Kmn is the 
global stoichiometric equilibrium constant corresponding to the formation of 
AmBn:  
                        [AmBn]=Kmn[A]a[B]b                (15) 
The total concentration of A and B is distributed between the existing free 
fractions and the complex formed as follows: 
                    [A]T=# 2[.m/n]0,23,4.5                       (16)  
                    [B]T=# %[.m/n]0,23,4.5                        (17)  
Where: 
[A]T and [B]T are the total concentration of A and B 
m and n is the numbers of molecule A and B in the AaBb complex 
Xmn and Kmn can be obtained by fitting using the above equations to the 
experimental data via AFFINImeter-NMR (Piñeiro et al., 2019).  
    The above analysis was performed with the kind instructions from Dr. 
James Garnetts (King’s College London) and Dr. Alain Oregioni (The Francis 
Crick Institute).  
    4) Solution NMR structure calculation  
    The backbone chemical shift data (Cα, Cβ, C’, N, Hα and HN) from the 
complete chemical shift list (Appendix I) was saved in a TALOS format and 
then submitted to the CS-ROSETTA server (Rosetta version 3.8; 




parameters. A total of 20,000 models were generated. The top 10 models with 
the lowest energy were chosen as the final ensemble. Structural statistics 
(Appendix V) were calculated using several servers including wwwPDB, 
MolProbity and PROSESS. Favorable Ramachandran statistics were observed, 
with 100% of residues in most favored (98%) regions and 0% in outlier 
regions. The whole calculation procedure was performed with the kind 
instructions from Dr. James Garnetts (King’s College London). 
    5) Establishment of the docking model  
The N4BP1CUE/ubiquitin model was built with HADDOCK 2.4 using the 
default parameters (https://wenmr.science.uu.nl/haddock2.4). The active 
residues for the ambiguous interaction restraints (AIRs) were defined on the 
basis of the CSP lists generated from NMR titrations and the relative solvent 
accessible surface area (SASA) of the residues. The relative SASA was 
calculated using GetArea (http://curie.utmb.edu/getarea.html). The CSPs 
and SASA values were combined for the final selection with an in-house R 
script. The structure for the mono-ubiquitin used here is PDB: 1UBQ. The 
structure of N4BP1CUE is the top 1 model generated from CS-ROSETTA. The 
whole modelling process was performed with the kind help from Dr. Arianna 
Fornili (QMUL). 
3.2.6 Bioinformatic methods 
3.2.6.1 Protein sequence analysis  
Pairwise protein sequence alignment was performed by EMBOSS Neddle 
(https://www.ebi.ac.uk/Tools/psa/emboss_needle/). Multiple protein 
sequence alignment was performed by ClustalW 
(https://www.genome.jp/tools-bin/clustalw) or MEGA (Version 10.0.5) 
using the default MUSCLE method. Results were visualized by Bioedit. 
3.2.6.2 Protein structure analysis  
The protein structure prediction was performed by submitting the 




(http://www.sbg.bio.ic.ac.uk/~phyre2/html/page.cgi?id=index) using the 
intensive modelling mode or by the de novo protein structure prediction 
server trRosetta (https://yanglab.nankai.edu.cn/trRosetta/). 
Phyre2 is highly dependent on the known protein structures in order to 
build the predicted models. The query protein sequence is applied to the 
multiple sequence alignments (MSAs) to predict secondary structure. It is 
further combined as a query hidden Markov model (HMM) for the scanning 
against the HMM database of known structures. The top alignments will be 
used to establish the initial backbone models where the insertion and 
deletions will be further corrected by loop modelling. For the final step, the 
side chains are added to build the final model (Kelly et al., 2015). Apparently, 
if homology is poor or undetectable between the query and the sequence of a 
known structure, the modelling will be very unreliable or even fail.  
As a newly-developed protein prediction method, trRosetta makes use of 
MSAs to predict relative distances and orientations of not only residue pairs 
but also inter-residues of the protein based on a deep residual-convolutional 
network. Then the predicted distances and orientation information is used to 
build the de novo protein structure with more accuracy following the 
constrained minimization protocol via Rosetta (Yang et al., 2020). Rosetta 
performs Monte Carlo search through space of conformations to find minimal 
energy conformation instead of using homologous structures as templates 
(Rohl et al., 2004). 
Protein structure comparison was performed by submitting the query 
protein structure to the Dali server for the comparison against the Protein 
Data Bank (PDB) (http://ekhidna2.biocenter.helsinki.fi/dali/).  
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Chapter 4.1  






























4.1.1 Introduction: The N-terminus of N4BP1 
As mentioned in section 1.4.1, N4BP1 can be cleaved by CASP8 into N- 
and C-terminal fragments. The N-terminus but not the C-terminus still 
retains the ability to negatively regulate the TNFR signaling pathway. N4BP1 
could also interact with LUBAC core catalytic subunit HOIP. Since LUBAC is 
a key component in the TNFR signaling pathway as well as the only known E3 
ligase that catalyzes linear ubiquitin chain formation, a possible inhibitory 
role of N4BP1 on the LUBAC E3 ligase activity was proposed and will be 
investigated in this chapter.  
The N-terminus of N4BP1 can be divided into three domains by 
bioinformatic analysis (Figure 4.1.1A). The KH-like domain is predicted to be 
involved in RNA-binding, in line with the reported function of N4BP1 in RNA 
degradation. The UBM-like and UBA-like domain are both putative UBDs, 
which implicate the possible involvement of N4BP1 in ubiquitin-related 
processes.  
So far, only the structure of KH-like domain has been solved (PDB: 
6Q3V). However, the literature is still in the “to be published” state. As can be 
seen from Figure 4.1.1B, interestingly, the whole crystal structure consists of 
N4BP11-188 which almost contains both the KH-like domain (N4BP16-144) and 
UBM-like domain (N4BP1160-200) defined here. From the structure, the 
KH-like domain has a “di-KH” organization, where two subdomains (KH_1 
(N4BP11-67) and KH_2 (N4BP170-142)) share highly similar fold (RMSD=0.401) 
though with poor sequence similarity (Figure 4.1.1C).  
The interaction between N4BP1 and the LUBAC subunit HOIP has been 
previously identified by pull-down assays (Figure 4.1.1D, E) (Kliza et al., 
unpublished data). The identified binding regions of the two proteins are 






Figure 4.1.1 Current background knowledge of N4BP1 N-terminus. A. The domain 
structure of the N-terminus and full length N4BP1. Please see Figure 1.28 for N4BP1 domain 
annotation. B. Crystal structure of N4BP1 KH-like domain (PDB: 6Q3V). The two 
subdomains are indicated as KH_1 (N4BP11-67) and KH_2 (N4BP170-142). UBM domain 
(N4BP1143-188) is also indicated. C. Superimposition of KH_1 and KH_2. D. N4BP1133-342 is 
identified as the minimum HOIP-binding region. E. HOIP299-438 is identified as the minimum 
N4BP1-binding region. 
4.1.2 Experimental design    
In order to get mechanistic insights into the inhibitory role of N4BP1 in 
the ligase activity of LUBAC, in vitro ubiquitination assay was performed 
(Figure 4.12A). Different N-terminal N4BP1 constructs were examined in a 
series of HOIP-mediated linear chain synthesis (Figure 4.1.2B). N4BP1 was 
also incubated with HOIP constructs of various length (Figure 4.1.2C). The 
comparison of linear ubiquitin chain synthesis activity derived from different 
HOIP constructs in combination with various N4BP1 domains will help 





Figure 4.1.2 Experimental design of Chapter 4.1. A. Schematic representative of the 
in vitro ubiquitination assay. N4BP1 was added into the HOIP-mediated linear ubiquitin 
synthesis system containing monoUb, E1 (Ube1), E2 (UbcH5c), E3 (HOIP). monoUb was 
labelled with Cy5 in order to visualize the newly-synthesized linear ubiquitin chains. B. The 
N4BP1 constructs used in this thesis. C. The HOIP constructs used in this thesis. Binding 
regions between N4BP1 and HOIP are indicated in the full-length protein respectively. LDD: 
linear ubiquitin chain determining domain. NZF: novel zinc finger. PUB: PNGase/UBA or 
UBX-containing proteins. RBR: RING-in-between-RING. UBA: ubiquitin-associated. ZF: 





4.1.3.1 The N4BP1 KH-like domain displays a weak inhibitory 
effect on the E3 ligase activity of HOIP catalytic domain 
    An in vitro ubiquitination reaction system containing the minimal key 
components including ATP, mono-ubiquitin, Ube1 (E1), UbcH5c (E2), HOIP 
(E3) and N4BP1 (inhibitor) was performed. A HOIP construct comprising 
residues 697-1072 was used which does not contain the N-terminal domains 
including the UBA domain which auto-inhibits the ligase activity of HOIP. 
There are only the catalytic RBR domain and the C-terminal LDD domain 
present in this construct (Figure 4.1.2A, Figure 4.1.3 upper panel). 1 µM 
Cy5-labelled mono-ubiquitin was added to an excess of unlabeled ubiquitin 
which allows to monitor linear ubiquitin chain formation by fluorescent 





Figure 4.1.3 The inhibitory effect of N4BP11-342 and N4BP11-392 on HOIP697-1072. 
Upper panel: Schematic presentation of the combination of HOIP and N4BP1 constructs in 
each reaction. Middle panel: The in vitro ubiquitination assay results by SDS-PAGE. The gel 
was scanned at an excitation wavelength of 633 nm and an emission wavelength of 670 nm in 
order to visualize Cy5-labelled ubiquitin. Bottom panel: Corresponding SDS-PAGE gel 
stained with Instant BlueTM to visualize the total protein content. The in vitro ubiquitination 
reaction contains: 1 µM Ube1 (E1), 10 µM UbcH5c (E2), 1 µM HOIP697-1072, 25 µM or 50 µM 
N4BP1 construct (the protein band of N4BP11-342 is indicated as “a” while N4BP11-392 is 
indicated as “b”), 50 µM mono-ubiquitin, 1 µM Cy5-labelled mono-ubiquitin. As a control, 
there was no N4BP1 added into the reaction. Assay buffer for the reaction is described in 
detail in section 3.2.4.2. Reaction was initiated by adding ATP at a final concentration of 10 
mM. Reaction temperature: 25 °C. M: standard protein ladder. * indicates the impurity band 
from purifying the N4BP1 constructs. 
 
    In the in vitro ubiquitination assay, construct N4BP11-392 comprising all 
the three N-terminal domains shows weak inhibition when compared to the 
intrinsic activity of HOIP697-1072. A similar inhibitory effect is observed in 
context of a shorter N4BP1 construct (N4BP11-342) which lacks the UBA-like 
domain (Figure 4.1.3). From this result, it is inferred that this weak inhibitory 
effect is mediated by a region of N4BP1 which contains the KH-like domain 
and the UBM-like domain. 
    To further confirm this observation, the E3 ligase activity of HOIP697-1072 
was separately monitored in the presence of all three individual N-terminal 
domains from N4BP1 (i.e. KH-like domain (N4BP11-144) or UBM-like domain 
(N4BP1144-311) or UBA-like domain (N4BP1312-392)) (Figure 4.1.4). These 
results further confirm that the N4BP1 UBA-like domain does not exhibit an 
inhibitory effect on HOIP697-1072. Furthermore, the separation of N4BP11-342 
into KH-like and UBM-like domains demonstrates that the KH-like domain 




over shorter period which covers chain synthesis over 60 minutes, it becomes 
apparent that the KH-like domain has subtle inhibitory effect on linear 
ubiquitin chain formation catalyzed by HOIP697-1072 (Figure 4.1.4C). The 
UBM-like domain is not involved in the inhibition (Figure 4.1.4B). 
 
Figure 4.1.4 The inhibitory effect of N4BP1 KH-like domain, UBM-like domain 
and UBA-like domain on HOIP697-1072. A. Schematic of the combination of HOIP and 
N4BP1 constructs in each reaction. B. The results of in vitro ubiquitination assay of N4BP1 
KH-like domain, UBM-like domain and UBA-like domain on HOIP697-1072 at the indicated 3 




HOIP697-1072 at the indicated time points from 0-60 min. Left panel in B and C: The in vitro 
ubiquitination assay results by SDS-PAGE scanned at an excitation wavelength of 633 nm 
and an emission wavelength of 670 nm in order to visualize Cy5-labelled ubiquitin. Right 
panel in B and C: Corresponding SDS-PAGE gel stained with Instant BlueTM to visualize the 
total protein content. The in vitro ubiquitination reaction contains: 1 µM Ube1 (E1), 10 µM 
UbcH5c (E2), 5 µM HOIP697-1072, 25 µM N4BP1 construct, 50 µM mono-ubiquitin, 1 µM 
Cy5-labelled mono-ubiquitin. As a control, there was no N4BP1 added into the reaction. 
Assay buffer for the reaction is described in detail in section 3.2.4.2. Reaction was initiated by 
adding ATP at a final concentration of 5 mM. Reaction temperature: 25 °C. M: standard 
protein ladder. HMW chains: high molecular weight chains. 
   
As mentioned in section 4.1.1, the identified N4BP1-binding region in 
HOIP is located in the polypeptide of residues 299-438 by the pull-down 
experiments (Figure 4.1.1E, Figure 4.1.2 B, C). This region is upstream of 
HOIP697-1072. It is also shown that the N4BP11-392 and HOIP697-1072 do not 
interact with each other when probed by ITC (Please see Appendix VI, Figure 
V6). The binding data support the notion that an allosteric effect in the active 
site of HOIP takes place upon the interaction with N4BP1. Therefore, a longer 
construct HOIP300-1072 is used in the following studies.  
 
4.1.3.2 N4BP1 UBA-like domain mediates a pronounced 
inhibitory effect on the E3 ligase activity of HOIP300-1072 
In addition to the catalytic RBR domain, HOIP300-1072 includes the 
binding region to N4BP1 which was suggested by the pull-down experiments 
(Figure 4.1.1E and Figure 4.1.2C). Compared to the full-length protein, 
HOIP300-1072 lacks the N-terminal PUB domain (Figure 4.1.2A). The construct 
requires the presence of the LUBAC subunit HOIL-1L which releases the 
auto-inhibitory effect from the HOIP UBA domain. Only when HOIL-1L binds 




To this end, all the in vitro ubiquitination assays were performed with 
the addition of HOIL-1L. From the results, N4BP11-392 displays strong 
inhibition on the E3 ligase activity of HOIP300-1072. As seen from the 60-min 
and 120-min two time points, the high molecular weight linear ubiquitin 





Figure 4.1.5 The inhibitory effect of N4BP11-392 on HOIP300-1072. Upper panel: 
Schematic of the combination of HOIP, HOIL-1L and N4BP1 constructs in the reaction. 
Middle panel: The results of in vitro inhibitory assay of N4BP11-392 on HOIP300-1072 at the 
indicated time points by SDS-PAGE. The gel was scanned at an excitation wavelength of 633 
nm and an emission wavelength of 670 nm in order to visualize Cy5-labelled ubiquitin. 
Bottom panel: Corresponding SDS-PAGE gel stained with Instant BlueTM to visualize the total 
protein content. The in vitro ubiquitination reaction contains: 1 µM Ube1 (E1), 10 µM 
UbcH5c (E2), 1 µM HOIP300-1072, 5 µM HOIL-1L (the protein band is indicated as “a”), 25 µM 
or 50 µM N4BP11-392 construct, 50 µM mono-ubiquitin, 1 µM Cy5-labelled mono-ubiquitin. As 
a control, there was no N4BP1 added into the reaction. Assay buffer for the reaction is 
described in detail in section 3.2.4.2. Reaction was initiated by adding ATP at a final 
concentration of 10 mM. Reaction temperature: 25 °C. M: standard protein ladder. * 
indicates the impurity band from purifying HOIL-1L. HMW chains: high molecular weight 
chains. 
 
In order to identify the minimal region required for inhibition, 
N4BP11-392 was divided into two parts: 1) the UBA-like domain alone 
(N4BP1312-392); 2) the construct N4BP11-311 which contains both the KH-like 
domain and the UBM-like domain. The two constructs were employed in the 
ubiquitination assay respectively.  
From the results shown in Figure 4.1.6, the UBA-like domain alone is 
efficient to inhibit the linear ubiquitin chain formation by HOIP300-1072, in 
contrast to the previous observation where the UBA-like domain does not 
inhibit HOIP697-1072 (Figure 4.1.4B). This might be due to the lack of the 
N4BP1 binding region in the HOIP697-1072 construct. The additional support 
from the binding between N4BP11-392 and HOIP300-1072 may facilitate to place 





Interestingly, the shorter construct N4BP11-311 still retains weak 
inhibitory function (Figure 4.1.6). This is in line with the previous 
observations that the KH-like domain in this construct displays a moderate 
inhibitory effect on HOIP697-1072. This weak inhibition remains to be verified 
by using the KH-like domain alone for the ubiquitination assay by 
HOIP300-1072. 
    To conclude, the strong inhibitory effect from N4BP1 UBA-like domain 
and the weak inhibitory effect from KH-like domain, as well as the key 
binding regions between N4BP1 and HOIP, work together to facilitate N4BP1 
inhibiting on the E3 ligase activity of HOIP. Further structural studies would 
help to elucidate the exact inhibitory mechanisms from the N-terminal 
N4BP1 on the ligase activity of HOIP. 
 
Figure 4.1.6 The inhibitory effect of N4BP11-311 and the UBA-like domain 
(N4BP1312-392) on HOIP300-1072. Upper panel: Schematic of the combination of HOIP, 




inhibitory assay of each N4BP1 construct on HOIP300-1072 at the indicated time points by 
SDS-PAGE. The gel was scanned at an excitation wavelength of 633 nm and an emission 
wavelength of 670 nm in order to visualize Cy5-labelled ubiquitin. Corresponding SDS-PAGE 
gel stained with Instant BlueTM was shown on the right to visualize the total protein content. 
The in vitro ubiquitination reaction contains: 1 µM Ube1 (E1), 10 µM UbcH5c (E2), 1 µM 
HOIP300-1072, 5 µM HOIL-1L (the protein band is indicated as “a”), 50 µM N4BP1 construct, 
100 µM mono-ubiquitin, 1 µM Cy5-labelled mono-ubiquitin. As a control, there was no 
N4BP1 added into the reaction. Assay buffer for the reaction is described in detail in section 
3.2.4.2. Reaction was initiated by adding ATP at a final concentration of 10 mM. Reaction 
temperature: 25 °C. M: standard protein ladder. * indicates the impurity band from purifying 
HOIL-1L.  
 
4.1.3.3 Crystallization of N4BP11-392 
After elucidating the inhibitory function of the construct N4BP11-392, it 
was decided to investigate the molecular structure by X-ray crystallography. 
The protein was successfully purified with high purity and quality via GSH 
affinity chromatography and size-exclusion chromatography (Figure 4.1.7). 
Using the LMB screen kit (Molecular Dimension), several crystal candidates 
can be obtained but unfortunately no diffraction pattern was observed when 





Figure 4.1.7 The purification of N4BP11-392 by size-exclusion chromatography 
(SEC). Protein from GSH affinity chromatography was incubated with HRV-3C protease 
overnight. The sample were then subjected to size-exclusion chromatography as shown here. 
Fraction 20 was used for crystallography.  
 
Due to the important role of the N4BP1 UBA-like domain for the 
inhibition of HOIP, a structural modeling was carried out to further provide 
some molecular insights into the 3-dimensional organization of this domain. 
Using Phyre2 for a secondary structural prediction reveals that the N4BP1 
UBA-like domain displays an ordered structure for residues 342-385 which 
features a 3-helix fold (Figure 4.1.8A). The top template for the prediction is 
the NTD domain from MCPIP1 (PDB: 2N5J). The N4BP1 UBA-like domain 
has a 53% coverage with this template at a confidence score of 96.6%. The de 
novo prediction by trRosetta also gave similar results (Figure 4.1.8B).  
 
Figure 4.1.8 The predicted secondary structure of N4BP1 UBA-like domain by 
Phyre2 (A) and trRosetta (B). The structured region is indicated in green helices or “H”. 
The MCPIP1 NTD domain (PDB: 2N5J) is the template for the prediction by Phyre2. The 
protein sequence submitted to trRosetta is N4BP1312-392. 
 
The structure model of the N4BP1 UBA-like domain by Phyre2 is based 
on the MCPIP1 NTD domain as a template, it is no surprise that the model is 
highly similar to the template (Figure 4.1.9A). The de novo modelling by 




MCPIP1 NTD domain. The only difference is that the trRosetta model has 
defined several extra residues in both the N-terminus and C-terminus of this 
domain as structured helices, resulting in longer α1 and α3 helices than the 
MCPIP1 NTD domain (Figure 4.1.9B). Both models support the conservation 
between the N4BP1 UBA-like domain and the MCPIP1 NTD domain.  
 
Figure 4.1.9 The structure models of N4BP1 UBA-like domain by Phyre2 (A) and 
trRosetta (B). The model by Phyre2 is shown in blue. Five models with low energy are 
generated by trRosetta. The top model with the lowest energy is shown as cartoon in green 
while the rest of the four models are shown as ribbons. The structure comparison between the 
N4BP1 model and the MCPIP1 NTD domain (PDB: 2N5J) is displayed on the right in each 









In this chapter, the inhibitory role of N-terminal N4BP1 (N4BP11-392) in 
LUBAC activity was studied. It was found that the N4BP1 UBA-like domain 
has a strong inhibition on the E3 ligase activity of the longer HOIP construct 
(HOIP300-1072), but does not have the inhibition on the short HOIP construct 
(HOIP697-1072), indicating that the binding region between N4BP1 and HOIP 
is important to facilitate the inhibition. Noteworthy, HOIL-1L is required to 
release the auto-inhibition of HOIP300-1072 by binding to the HOIP UBA 
domain. However, N4BP11-392 does not bind to HOIL-1L (Please see Appendix 
VI, Figure V7), which indicates that N4BP1 and HOIP do not compete to 
interact with HOIL-1L. Thus, it excludes the possibility that N4BP1 prevents 
the release of HOIP auto-inhibition via binding to HOIL-1L. Apart from the 
UBA-like domain, the KH-like domain also has a moderate inhibition on 
HOIP but does not require the binding between N4BP1 and HOIP. Taken 
together, the inhibitory effect from both domains together with the key 
binding regions between N4BP1 and HOIP maximizes the inhibition from 
N4BP1 on LUBAC.  
    Structural studies would assist to reveal the exact inhibitory mechanisms 
from N4BP1. To this end, the trials to crystallize N4BP11-392 was attempted 
but unfortunately not successful. For the future work, the crystallization 
conditions will be optimized, hopefully allowing us to obtain protein crystals 
with high quality. The trials to crystallize the N4BP1/HOIP complex is also 
important to ultimately elucidate the inhibition mechanism from the 
structural perspectives. 
    The structure modelling of the N4BP1 UBA-like domain by both Phyre2 
and trRosetta indicates that the N4BP1 UBA-like domain is structurally 
conserved with the MCPIP1 NTD domain. It is reported that the presence of 
MCPIP1 NTD domain facilitates the RNAse activity of the RNAse domain 




the two domains hinders the oligomerization of the RNAse domain and keeps 
the RNAse domain in the functional dimer states (See the short review in 
chapter 1.4.3) (Yokogawa et al., 2016). In addition, the RNAse domain within 
the C-terminal part of N4BP1 is also predicted to have a similar structure to 
the MCPIP1 RNAse domain (this will be introduced in detail in section 
4.2.2.5.1). To gain a functional insight, it would be interesting to investigate 
the possible interaction between the UBA-like domain and the RNase domain 
in N4BP1.  
It is known that MCPIP1 is involved in inflammatory signaling and plays 
as a negative regulator in NF-κB activation. These structural and functional 
similarities between N4BP1 and MCPIP1 further support the importance of 
N4BP1 involved in the TNFR signaling pathway. Since the structure of each 
domain of MCPIP1 has been solved (Yokogawa et al., 2016), it can be used as 



















Chapter 4.2  
























4.2.1 Introduction: The N4BP1 CUE domain  
The C-terminus of N4BP1 (393-892) contains two defined domains, the 
RNAse domain and the CUE domain (Figure 4.2.1). Bioinformatic analysis 
has grouped the N4BP1 CUE domain into the canonical CUE domain family, 
which is known to be associated with ubiquitin binding due to its key 
conserved motifs. 
 
Figure 4.2.1 The domain structures of the C-terminus and full length N4BP1. 
 
As introduced in section 1.4.1, N4BP1 is identified as a linear ubiquitin 
receptor. Based on binding studies by pull-down experiments, the CUE 
domain of N4BP1 shows an apparent binding preference to di-ubiquitin 
chains of different linkage types with the exception K48-diUb and 
mono-ubiquitin (Figure 4.2.2, GST-mN4BP1 (850-893)). Furthermore, if the 
construct is extended to include part of the RNAse domain (Figure 4.2.2, 
GST-mN4BP1 (706-893)), the binding specificity is restricted to M1-diUb and 
K63-diUb chains (Kliza et al., unpublished data). This may indicate that to 
some extent the RNAse domain is also involved in ubiquitin binding and may 





Figure 4.2.2 Pull-down experiments of the N4BP1 CUE domain (850-893) or 
extended CUE domain (706-893) with mono-ubiquitin and different types of 
di-ubiquitin chains (Kliza et al., unpublished data).  
 
    In this chapter, an in-depth investigation of the ubiquitin-binding 
properties of the C-terminal domain of N4BP1 will be performed. Section 
4.2.2.1 to 4.2.2.4 are centred on the interaction between the CUE domain and 
ubiquitin. The study on RNAse domain will be discussed in section 4.2.2.5.   
    Section 4.2.2.1 is focused on the quantitative characterization of the 
ubiquitin-binding properties of the CUE domain by SPR and ITC. However, 
resolving the ubiquitin-binding mode requires structural approaches. Hence, 
the structural description of the CUE domain by solution NMR is presented in 
section 4.2.2.2. This structure further allows us to study the interaction 
between the CUE domain and ubiquitin from the single-residue level by NMR 
titrations. This will be described in section 4.2.2.3. Taking all the above data 
together, a CUE/ubiquitin complex model is generated in section 4.2.2.4.     
Section 4.2.2.5 is focused on the binding specificity of N4BP1 to ubiquitin 
mediated by the RNAse domain. A model is proposed in section 4.2.3.3 to 
help explain how the CUE domain and RNAse domain work together to 













4.2.2 Results  
4.2.2.1 Quantitative analysis of the interaction between the 
N4BP1 CUE domain and ubiquitin probed by ITC and SPR 
4.2.2.1.1 The N4BP1 CUE domain specifically binds to ubiquitin 
but not NEDD8 
The canonical CUE domain was initially characterized by two major 
conserved motifs required for ubiquitin binding: an FP motif and a di-leucine 
motif (Shih et al., 2003; Figure 4.2.3). Sequence alignments of the mouse 
N4BP1 CUE domain with other CUE domain family members highlight the 
level of conservation of the FP motif. The N4BP1 CUE domain does not have 
the strictly conserved di-leucine motif, but evidence from gp78 CUE domain 
where an IL motif is present has demonstrated that this motif is involved in 
ubiquitin binding (Liu et al., 2012).  
 
Figure 4.2.3 Sequence alignments of the mouse N4BP1 CUE domain with the 
CUE domain family members. Identical residues are shaded in orange. The residues 
with >80% similarities are shaded in cyan. The FP motif and di-leucine motif are highlighted 
with red box. Sequence alignments were performed by ClustalW and visualized by bioedit. 
 
Based on an analysis by the protein fold recognition server Phyre2, the 
structure of N4BP1 CUE domain can be predicted using the CUBAN domain 
from KHNYN (PDB: 2N5M) as the top template. The N4BP1 CUE domain 
displays 93% template coverage with a confidence score of 99.6%. The 
KHNYN CUBAN domain is consisted of a three-helix bundle arrangement, 




shown that the protein has a binding preference to the ubiquitin-like protein 
NEDD8 instead of ubiquitin (See section 1.4.2; Castagnoli et al., 2019).  
In order to quantify the interaction between the N4BP1 CUE domain 
(850-893) and ubiquitin observed by pull-down experiments (Figure 4.2.2), 
ITC measurements were performed, which allow precise determination of the 
affinity between the two proteins (Figure 4.2.4).    
 
Figure 4.2.4 ITC measurements and the parameter summary of titrating the 
N4BP1 CUE domain into mono-ubiquitin and NEDD8 respectively. Each ITC plot 
contains the row data (upper) and the binding isotherm (lower) for the interactions. The data 
for CUE: monoUb were fitted to a single-site model using the MicroCal PEAQ-ITC Analysis 
Software following the method described in section 3.2.5.2. Measurement conditions: 
Syringe: 0.5 mM CUE, Cell: 50 uM monoUb or NEDD8. 18 injections, 2 µL/injection, 




The tag-free CUE domain was used for the ITC experiments. Despite the 
high sequence similarity between the KHNYN CUBAN domain and the 
N4BP1 CUE domain, the interaction between the N4BP1 CUE domain and 
NEDD8 is undetectable by ITC. However, in contrast to the pull-down 
experiments where the GST-tagged protein was used for the binding test, the 
tag-free N4BP1 CUE domain shows clear binding to mono-ubiquitin with a 
Kd value of 27.4 µM from the ITC measurements (Figure 4.2.4). The 
differences of the ubiquitin-binding properties from the GST-tagged and the 
tag-free N4BP1 CUE domain will be discussed in the following content.  
4.2.2.1.2 The interaction between the N4BP1 CUE domain and 
ubiquitin probed by SPR  
To confirm the pull-down results of the N4BP1 CUE domain and 
ubiquitin (Figure 4.2.2), SPR measurements were performed to quantitatively 
characterize the binding affinity of N4BP1 CUE domain to mono-ubiquitin 
(shorten to monoUb hereafter) and di-ubiquitin chains (shorten to 
M1/K48/K63-diUb respectively hereafter). The GST-tagged CUE domain 
(shorten to GST-CUE hereafter) was immobilized on an anti-GST antibody 
surface of a CM5 chip. MonoUb or diUb chains were in the mobile phase and 
running separately through the chip surface. 
The binding constant was calculated using the amplitude of the SPR 
signal since it was not possible to determine the very fast association and 
dissociation rates under these conditions. The response data points at the 
equilibrium stage from the sensorgrams (raw data not shown) were plotted 
against the ubiquitin concentration. The data were fitted to obtain the 
equilibrium dissociation constant (KD) as shown in Figure 4.2.5 (Please see 
section 3.2.5.3 for more data fitting details). The SPR results demonstrate the 
high affinity of M1-diUb to GST-CUE with a KD value of 6.38 µM, which is 
11-fold stronger than the monoUb, suggesting that GST-CUE specifically 




ubiquitin chains with linear linkages. K63-diUb also shows a high affinity to 
GST-CUE with a KD value of 10.31 µM, which is comparable to M1-diUb. 
K48-diUb binds to GST-CUE with a KD value of 20.42 µM, indicating a less 
affinity than M1- and K63-diUb, but still higher than monoUb. Altogether, 
these SPR results are in line with the pull-down assay from Figure 4.2.2. 
 
Figure 4.2.5 Quantitative binding measurements of GST-tagged N4BP1 CUE 
domain to monoUb and M1/K48/K63-diUb by SPR. A. The response data points at 
the equilibrium stage derived from the sensorgrams plotted against the ubiquitin 
concentration. B. Parameter table of KD summarized from the plot. Data were fitted by 







4.2.2.1.3 The interaction between the N4BP1 CUE domain and 
ubiquitin probed by ITC  
    1) GST tag artificially increases the affinity of the CUE domain 
to M1-diUb 
The above SPR measurements have shown that the GST-tagged CUE 
domain has ubiquitin linkage preference. It is also interesting to determine 
the stoichiometry of these interactions. To this end, ITC measurements are 
ideally suited to determine the number of binding sites in solution. The 
tag-free CUE domain was used for the ITC experiments (Figure 4.2.6).  
 
Figure 4.2.6 Quantitative binding measurements of the N4BP1 CUE domain to 
monoUb and M1-diUb by ITC. A. ITC titration isotherms. B. Parameter table of Kd 
summarized from A. Data were fitted to a single-site model using the MicroCal PEAQ-ITC 
Analysis Software following the method described in section 3.2.5.2. Measurement 
conditions: Syringe: 0.5 mM or 1 mM CUE (specified in each isotherm), Cell: 50 uM monoUb 
or M1-diUb. 18 injections, 2 µL/injection, duration: 2s, spacing time: 120 s, measurement 





    From the ITC results, the tag-free CUE domain shows very similar affinity 
to both monoUb and M1-diUb with a Kd value of ~ 28 µM. The CUE domain 
binds to monoUb in a 1:1 ratio and binds to M1-diUb in a 2:1 ratio. It most 
likely indicates that each ubiquitin moiety in M1-diUb interacts with one 
molecule of the CUE domain. Surprisingly, the Kd values obtained from ITC 
are different from those derived by SPR. Particularly, the affinities of the CUE 
domain to monoUb and M1-diUb are not similar to each other in the SPR 
measurements where CUE domain seems to prefer M1-diUb over monoUb 
and its binding to monoUb is very weak (Figure 4.2.5). Since GST-CUE was 
used for the SPR measurements, the GST tag might interfere with the 
interaction. To verify this hypothesis, the binding affinity of GST-CUE to 
M1-diUb was measured by ITC. As seen in Figure 4.2.6, the result from ITC 
(7.70 µM) is very similar to that from SPR (6.38 µM), both demonstrating 
that the GST-CUE shows much higher affinity to M1-diUb compared to the 
tag-free protein. 
 
Figure 4.2.7 SEC-MALLS measurements of GST-tagged CUE domain. Three 




Due to the dimerization effect from the GST, the oligomeric state of 
GST-CUE was measured by SEC-MALLS. GST-CUE monomer is ~ 32 KDa 
(3.2×104 g/mol). To our expectation, the GST-CUE species are mostly in 
dimeric states (Molar mass at ~ 5.5-8.0×104 g/mol) at three different 
concentrations (Figure 4.2.7). This result suggests that the GST dimer could 
artificially bring the two CUE domains in close proximity. Therefore, the 
affinity between the GST-CUE and M1-diUb is increased. 
 
    2) The N4BP1 CUE domain distinguishes K48-diUb from 
monoUb, M1-diUb and K63-diUb 
The binding between the tag-free CUE domain with K48- and K63-diUb 
chains was also measured by ITC respectively (Figure 4.2.8). Together with 
the above ITC results, it indicates that the CUE domain binds to monoUb, 
M1-diUb and K63-diUb at a comparable level (with a Kd value of 26~29 µM), 
while its affinity to K48-diUb is the weakest with a Kd value of 46.6 µM. 
In addition, compared to the ~2:1 ratio between the CUE domain and 
M1-diUb or K63-diUb, the binding stoichiometry between the CUE domain 
and K48-diUb is ~1:1. This indicates that one K48-diUb molecule could only 
bind to equal amount of the CUE domain.  
To conclude, among monoUb and three diUb chains used here, the 
N4BP1 CUE domain could distinguish K48-diUb from monoUb, M1-diUb and 






Figure 4.2.8 Quantitative binding measurements of the N4BP1 CUE domain to 
K48-diUb and K63-diUb by ITC. A. ITC titration isotherms. B. Parameter table of Kd 
summarized from A. Data were fitted to a single-site model using the MicroCal PEAQ-ITC 
Analysis Software following the method described in section 3.2.5.2. Measurement 
conditions: Syringe: 1 mM CUE, Cell: 50 uM K48-diUb or K63-diUb. 18 injections, 2 
µL/injection, duration: 2s, spacing time: 120 s, measurement temperature: 25℃. 
 
In the next section, the structure model of the N4BP1 CUE domain was 
solved by solution NMR. This will help characterize the ubiquitin-binding 
properties of the CUE domain by the means of NMR titrations in section 








4.2.2.2 NMR solution structure model of the N4BP1 CUE 
domain 
NMR spectroscopy was chosen as the method of choice for the 
determination of the structure of the N4BP1 CUE domain for two reasons. 
First of all, the size of the CUE domain is only ~5 KDa, ideal for solving the 
structure by NMR. Secondly, the following NMR titrations are suited to study 
the dynamics of the interaction between the CUE domain and ubiquitin.  
The CUE domain was labelled with 13C and 15N and purified to a very high 
standard required for NMR. The backbone structure was determined by 
solution NMR using the 3-dimensional experiments including HSQC, HNCA, 
NHCOCA, CBCACONH and HNCACB etc. The side chains were assigned 
using HBHA(CO)NH and HCCH-TOCSY. The structure was modelled by 
CS-ROSETTA using the experimental chemical shift data collected from the 
above spectra.  
4.2.2.2.1 Purification of the CUE domain 
The His-tagged CUE domain was expressed in E.coli which was grown in 
minimal media containing 13C-glucose and 15NH4Cl. The His-tagged protein 
can be successfully enriched via Ni-affinity chromatography. The target 
protein was subsequently cleaved by on-column cleavage by incubating with 
HRV-3C protease overnight. The tag-free CUE domain was released from the 
resin into the buffer and the protein was further purified by size-exclusion 
chromatography (SEC). Figure 4.2.9 indicates the high purity and quantity of 





Figure 4.2.9 Purification of 15N/13C-labelled N4BP1 CUE domain by 
size-exclusion chromatography (SEC). A. Purification profile by SEC. * indicates the 
target peak for CUE. B. SDS-PAGE analysis of corresponding peak fractions from A.  
Fraction 10-13 contain the final pure protein product. 
 
4.2.1.2.2 The stability test of the CUE domain at 37°C 
   To collect 2- and 3-dimensional NMR spectra with high quality and to 
minimize measurement time, all spectra were recorded at 37°C. Before 
recording the full spectra, the stability of the CUE domain at 37°C was tested. 
A freshly made protein sample was measured at 37°C at different time points 
(0h, 22h, 69h) to obtain the 1D 1H-NMR signals. The three spectra are almost 
identical by comparison, including the backbone HN, backbone Hα and 
sidechain methyl groups, indicating that the CUE domain is still stable after 





Figure 4.2.10 1D 1H-NMR spectra of the N4BP1 CUE domain measured at three 
time points at 37°C. Upper panel: Full 1D 1H-NMR spectra. Lower panel: Highlighted HN 




Furthermore, 2D 1H/15N-HSQC spectra (SOFAST) were recorded at 
different temperatures (25°C, 30°C, 34°C, 37°C). In each spectrum, almost all 
the peaks can be separated from each other. Since each peak in 1H/15N-HSQC 
represents a residue (excluding those peaks for the side chains), the results 
indicate that it is practical to assign the protein with the help from other 
advanced NMR experiments. By overlapping and comparing all the 
1H/15N-HSQC spectra together, each peak was shifting in an expected order 
which allows precisely tracking the dynamics of each residue (Figure 4.2.11).  
 
Figure 4.2.11 2D NMR 1N/15N-HSQC spectra of the N4BP1 CUE domain 
measured at a temperature range from 25°C to 37°C. Figure was generated by 
NMRviewJ software. 
 
In conclusion, the N4BP1 CUE domain displays high stability at 37°C for 
about 3 days, thus recording 3D NMR spectra with high quality and 




4.2.1.2.3 Backbone assignments of the CUE domain 
To assign the backbone Cα and carbonyl C (short as CO here) atom of the 
N4BP1 CUE domain, the tag-free 15N/13C-double labelled protein was 
subjected to different 3D NMR measurement combinations, including 
HN(CA)CO/HNCO, CBCA(CO)NH/HNCACB and HN(CO)CA/HNCA.  
The NMR assignment theory is briefly described in Chapter II. Here is an 
example of the assignments of residue R855-F862 at each corresponding 
unique NH strip (Figure 4.2.12).  
According to the signature 1N/15N-HSQC spectrum of the protein, the 
backbone amino group (NH and HN) can be identified but cannot be assigned 
yet. Each peak from 1N/15N-HSQC requires a corresponding strip in the 3D 
spectra which contain not only the chemical shifts of backbone NH and HN but 
also information about the backbone Cα and CO. The backbone assignment is 
usually conducted in this way.  
Cαs are usually at a range of 50-70 ppm where their assignments were 
identified in the first place by HNCA/HN(CO)CA and subsequently confirmed 
by CBCA(CO)NH/HNCACB. The CBCA(CO)NH/HNCACB experiments also 
detected the signals from Cβs, usually in a much lower range (18-45 ppm). 
This allows the discrimination of Cβ signals from Cα signals in the same strip 
of CBCA(CO)NH/HNCACB. Carbon atoms from the backbone CO group were 
identified by HNCO/HN(CA)CO.  
As can be seen from all the 3 spectra combinations (Figure 4.2.12), the 
peak of each atom from a certain residue links very well to the next and the 








Figure 4.2.12 An assignment example of NH strips of residue R855-F862 by 
different 3D NMR spectra combinations. Each stripe is in a certain backbone NH plane 
of the corresponding residue. The NH chemical shift value is indicated in the left corner of 
each strip. The x axis indicates the HN dimension while the y axis indicates the C dimension. 
The links between adjacent signals are indicated in dashed lines. Figures were generated by 
CCPNMR software. 
 
After creating an entire set of strips each individual residue was 
identified and assigned. Figure 4.2.13 summarizes the final 1H/15N-HSQC 
assignments of almost all the residues except S865 and K882 due to 
undetectable signals. Note that signals from prolines (P863 and P879) are 
also absent from 1H/15N-HSQC due to the lack of a hydrogen atom attached to 
the backbone amide. The first 3 residues (GPG) from the tag attached to the 
N-terminus of the protein are highly flexible and thus not assigned.    
  
Figure 4.2.13 1H/15N-HSQC assignments of the N4BP1 CUE domain. Dashed lines 
link the sidechain amide groups of Asn or Gln which are not assigned here. x axis is the HN 




4.2.1.2.4 Backbone Hα and side-chain HC/CH assignments of the 
CUE domain 
The backbone Hα and side-chain HC/CH signals of the N4BP1 CUE 
domain were primarily collected from two 3D experiments, HBHA(CO)NH 
and HCCH-TOCSY. The Hα and Hβ signals of each residue were first 
identified in certain NH planes of HBHA(CO)NH according to the backbone 
NH and HN values from 1H/15N-HSQC. Furthermore, HCCH-TOCSY helps to 
confirm the Hα and Hβ assignments in the Cα and Cβ planes respectively. In 
most cases, the signals of Hγ, Hδ etc are also visible in the same CH strip. This 
in turn helps locate the planes of Cγ, Cδ etc (Figure 4.2.14). 
 
Figure 4.2.14 The compact spectrum of all 1H-1H planes along the C axis from 
HCCH-TOCSY. x axis is the direct HN dimension while y axis is the indirect HC dimension. 
The CH trips of I861 and L890 are highlighted in red dashed boxes as assignment examples. 
Figure was generated by CCPNMR software. 




    Figure 4.2.15 shows an example to demonstrate how Hα-Hδ and Cγ-Cδ 
were assigned for residue I861. First, the Hα and Hβ signals of I861 were 
identified by HBHA(CO)NH combined with 1H/15N-HSQC. Then in the Cα 
and Cβ planes from HCCH-TOCSY, the Hα and Hβ signals are located 
respectively in the diagonal of the spectrum and correspond well to those in 
HBHA(CO)NH. The Cα and Cβ CH strip can thus be isolated. Besides, in each 
CH strip of either Cα or Cβ the signals of Hγ and Hδ can also be identified. 
Given that the direct HN and indirect HC values of a signal in the diagonal are 
the same as in HCCH-TOCSY, it is possible to find the Cγ or Cδ plane since it 
is known that the corresponding Hγ or Hδ must appear in the diagonal of that 
plane. According to this, the indirect HC value of Hγ or Hδ was obtained from 
both Cα and Cβ planes, the Cγ or Cδ plane can be finally identified by going 
through the 13C plane by matching the corresponding Hγ or Hδ signal. To 
conclude, HCCH-TOCSY has provided rich information on the chemical shift 
of sidechain H and C atoms for each residue.   
 
Figure 4.2.15 Backbone Hα and sidechain HC/CH assignments of I861 by 




In summary, almost all the backbone NH, Hα, Cα and CO atoms have 
been assigned, together with most of the HC and CH atoms from the side 
chains. The overall assignment progress is indicated in Figure 4.2.16.   
 
Figure 4.2.16 Overall assignment panel of the N4BP1 CUE domain. The assigned 
atoms are in black solid circles. The signals of the atoms in grey circle are missing in the 
spectra. The first 3 residues are from the tag. Figure was taken from CCPNMR.  
  
4.2.1.2.5 Structure modelling 
A full list including all the chemical shift information of available atoms 
from the above spectra was generated and deposited to the BMRB database 
(Entry: 50688). It was then submitted to CS-ROSETTA server for structure 
calculation. CS-ROSETTA is designed to model the de novo protein structure 
by solution NMR based on the chemical shift parameters from backbone and 
sidechain assignments. The modelling didn’t include the proton-proton NOE 
constraints due to the poor quality of the 15N- and 13C- NOESY spectra 
recorded. Only a limit numbers of constraints were obtained from the NOESY 
spectra and they were unfortunately not good enough to reconstitute an 
appropriate 3-dimentional structure combined with the backbone/sidechain 
assignment data by ARIA. Hence, the CS-ROSETTA method was employed to 
establish the structure models. 
The output of CS-ROSETTA is an ensemble of 10 best structural models 
with the lowest energy. All models are very similar to each other and 
converged into a single 3-dimensional structure, indicating high confidence of 





Figure 4.2.17 Best structure model of the N4BP1 CUE domain by solution NMR. 
A. Sequence of the CUE domain. Note that the first 3 residues “GPG” are from the tag. The 
numbers below the sequence indicate the positions of each residue in the full N4BP1 protein 
sequence. B. Structure model of the CUE domain. The best 10 structure models are indicated 
as brown ribbons. C. The best structure model with the lowest energy. Figures were generated 
by Pymol.  
 
    From the results, the N4BP1 CUE domain adopts a typical 3-helix bundle 
structure that is common among the classical CUE family members (Figure 




than the third helix. The weak NMR signals for the two loops indicate higher 
flexibility of these regions compared to the three helices. The FP motif is 
localized in the first loop, where the benzene ring of P863 is facing towards 
the third helix and in close proximity to V891 and L892. This may indicate 
that the key hydrophobic interaction within the molecule is important for 
keeping the appropriate protein structure (Figure 4.2.17C). As previously 
revealed from the study of the CUE domain from gp78, the FP motif is critical 
to keep the protein in the correct fold (Liu et al., 2012). In this study, the 
GST-tagged CUE F862G/P863A double mutant was expressed. Cleavage of 
the GST tag resulted in precipitation of the tag-free protein, indicating the 
unstable or disrupted structure of the F862G/P863A double mutant (data not 
shown). 
The structure of the CUE domain will be compared with other UBDs in the 
discussion (section 4.2.3.1). The CUE structure allows us to characterize the 
ubiquitin-binding mode of the N4BP1 CUE domain by NMR titrations. In the 
next section, both forward and reverse NMR titrations were performed 
between the CUE domain and ubiquitin (including monoUb and 
M1/K48/K63-diUb) respectively. According to the chemical shift 
perturbations (CSPs) collected from each titration pair in combination with 
previously published ubiquitin structures, together with the CUE domain 
solution NMR structure solved here, an in-depth investigation of the binding 
surfaces was achieved in section 4.2.2.3, which further helps us understand 










4.2.2.3 Quantitative analysis of the interaction between the 
N4BP1 CUE domain and ubiquitin probed by NMR titrations 
4.2.2.3.1 Identification of the perturbed surface on the N4BP1 CUE 
domain upon ubiquitin binding 
    1) Titrating monoUb to 15N-labelled CUE domain 
In order to titrate the interaction by NMR, an increasing concentration of 
label-free monoUb was added into the 15N-labelled CUE domain. The 
1H/15N-HSQC spectra of CUE were recorded. Each signal (also called a “peak”) 
in the 1H/15N-HSQC spectrum represents the backbone NH group of a certain 
residue (except those for side chains) from the 15N-labelled CUE domain. If 
the peak moves upon the addition of monoUb, it indicates that the chemical 
environments of these residues are perturbed. These affected residues might 
be involved in the binding event. The amide chemical shift perturbation (CSP, 
usually represented by Δδ) for each residue can be obtained when compared 
with the reference spectrum (the CUE domain alone, 0X spectrum in Figure 
4.2.18). A list of chemical shift perturbations of all the residues can be derived 
from the spectra, providing rich dynamic information for multiple uses, such 
as calculating the equilibrium disassociation constant (Kd), mapping the 
binding surface, establishing the binding model by molecular dynamic 





Figure 4.2.18 The serial 1H/15N-HSQC spectra of 15N-labelled CUE domain 
titrated with monoUb. The moving trend of the signal from each residue during the 
titration progress is indicated with an arrow. The legend indicates the molar ratio between 
monoUb and the CUE domain. NMR spectra were generated by NMRviewJ. 
 
From the above titration spectra, the changes for almost all the residues 
can be well-tracked during the titration progress. Most of the residues were 
affected in the binding event, though with different degrees of chemical shift 
perturbations. In general, the overall signals decreased in the first several 
titration points (molar ratio of monoUb:CUE at 0.1X-0.5X) and then 
gradually went back to the original intensity. This indicates that the 
interaction is between fast and intermediate exchange rate. The signals 
started to move very slowly at 1.0X, indicating that the binding has almost 
reached saturation at 1:1 ratio between the CUE domain and monoUb. This 




The chemical shift perturbation of each residue from a certain titration 
point was generated by the subtraction with the corresponding chemical shift 
value from 0X. Hence, the chemical shifts for all the residues at 0X are 
standardized as 0. The full chemical shift perturbation list is visualized in the 
chart in Figure 4.2.20A. The analysis for residue P862, S865, P879 and K882 
are missing due to the absence of signals in 1H/15N-HSQC. Over the titration 
progress, some residues have overlapped signals with each other. Therefore, a 
detailed peak tracking for these residues was done as shown in Figure 4.2.19. 
Note that the signal of I871 was completely broadened upon binding to 
monoUb, indicating that it undergoes strong chemical shift perturbation. In 
this case, the chemical shift deviation of I871 at each titration is all given at a 
maximum value of 0.45. 
 
Figure 4.2.19 Enlarged local titration profiles from Figure 4.2.18. The moving 
trend of the serial signals from each residue is indicated by an arrow. NMR spectra generated 





With the help from AFFINImeter-NMR from the MestReNova software, 
the chemical shift value of each signal was isolated. The Kd for each residue 
can be thus calculated (the signals from side chains are not considered) 
(Please see more details for NMR chemical shift data fitting from section 
3.2.5.4). Based on the chemical shift perturbations of all the residues, an 
average Kd for the CUE:monoUb titration pair was calculated with the value 
of 9.94 ± 1.48 µM (Table 4.2.1). It is lower than the value obtained from ITC 
(27.7 ± 6.73 µM). Due to limited data points for Kd calculation by NMR 
titration, it might not be as accurate as the ITC technique. In this case, the Kd 
values only derived from the NMR technique are compared in this section.  
From the first sight of the CSP chart (Figure 4.2.20A), it displays a 
repeated “up and down” pattern among all the 3 helices, particularly in helix 
α1 and α3. Due to the secondary structure nature of helix, it implies that 
probably only a certain side of each helix is affected in the binding event. The 
chemical shift perturbation of each individual residue at 1.0X was mapped 
onto the surface of the CUE domain (Figure 4.2.20B). The key residues with 
strong chemical shift perturbations (CSP>0.15) highlight the possible surface 
areas for the binding. From an overall view, the perturbed surface is centred 
on the groove between helix α1 and α3. Most of the residues (L884, N885, 
L887, S888, L890, V891, D893) in helix α3 (including the C-terminal tail) 
facing to this groove are affected. The C-terminal region from helix α1 is also 
significantly affected upon binding and contributes to the groove. Residue 
F862 from the conserved FP motif in the loop between α1 and α2 is involved 
to build this groove. Unfortunately, residue P863 from this FP motif cannot 
be monitored due to that proline is invisible in 1H/15N-HSQC. The last residue 
D893 of this domain is also moderately affected. All the above evidence is in 
line with the previous observation from classical CUE domains where the FP 
motif (from the α1-α2 loop) and a leucine residue (from helix α3) are involved 








Figure 4.2.20 Chemical shift perturbation (CSP) chart from the full titration 
dataset (A) and the perturbed surface of CUE domain at 1.0X (B). The chemical 
shift deviations (Δδ) for each titration point were derived by the subtraction with the 
chemical shift values from 0X. The data for residue P862, S865, P879 and K882 are missing 
due to the lack of signals in 1H/15N-HSQC. The signal of I871 was completely broadened and 
the chemical shift deviation at each titration is all given a value of 0.45. The chemical shift 
perturbation list was analyzed and generated by CCPNMR. The 1.0X chemical shift 
perturbation list was mapped onto the CUE domain surface by CHIMERA. The key residues 
with strong chemical shift perturbations (CSP>0.15) are highlighted as sticks. The cartoon 
views of the CUE domain were generated by Pymol.  
 
In addition, I871 from helix α2 is pointing towards this groove (Figure 
4.2.20B). The HSQC signal of I871 is completely broadened upon ubiquitin 
binding. It implicates that this residue also possibly takes part in the binding 
to ubiquitin. L869 from helix α2 also undergoes strong chemical shift 
perturbation though it is localized in the opposite side towards the groove. It 
may come from the indirect effect propagated from the perturbation of the 
nearby residue I871. 
 
    2) Titrating diUb chains to 15N-labelled CUE domain 
There are three titration pairs in these measurements, the label-free 
M1-diUb, K48-diUb and K63-diUb were added to the 15N-labelled CUE 
domain at increasing concentration respectively. The changes of chemical 
shifts from the residues in the CUE domain upon the diUb addition were 





Figure 4.2.21 Chemical shift perturbations (CSPs) of 15N-CUE domain upon 
addition of 3 different diUb chains respectively. A. Serial titration profiles by 
1H/15N-HSQC spectra; B. The chemical shift perturbation (CSP) charts from the 
corresponding full titration dataset. The chemical shift perturbations (Δδ) for each titration 
were derived by the subtraction with the chemical shift values from 0X. The data for residue 
P862, S865, P879 and K882 are missing due to the lack of signals in 1H/15N-HSQC. The 
signal of I871 was completely broadened and the chemical shift deviation at each titration is 
all given at 0.45. The legend indicates the molar ratio between diUb and CUE domain. The 




From the 1H/15N-HSQC profiles, almost all the signals in the CUE 
domain upon binding to diUb are affected in the same manner within all the 3 
titration pairs (Figure 4.2.21A). They are also comparable to the profile of 
monoUb:CUE. Quantitative analysis from the chemical shift perturbations 
also indicates a similar CSP pattern to each other as well as to that of 
monoUb:CUE, but the degrees of perturbations are different (Figure 4.2.21B, 
Figure 4.2.22A).  
Mapping the CSPs onto the surface of the CUE domain at maximum 
saturation helps us visualize and compare the perturbed surface upon binding 
to monoUb or diUbs (Figure 4.2.22B). In general, the perturbed surfaces are 
almost identical. This implicates that CUE domain employs a general binding 
mode to interact with monoUb or diUb chains.  
The CUE domain has the most affected surface when interacting with 
monoUb or M1-diUb. The perturbed surfaces of the CUE domain upon 
binding to K48-diUb and K63-diUb are slightly less affected. The average Kd 
values calculated for each titration pair also indicate that the CUE domain has 
a relatively lower affinity to K48-diUb and K63-diUb compared to monoUb 
and M1-diUb (Table 4.2.1).  
 
Table 4.2.1 The averaged dissociation constant (Kd) of CUE domain upon 
binding to ubiquitin or chains calculated by NMR chemical shift deviations 
Titration pair monoUb M1-diUb K48-diUb K63-diUb 
CUE 9.94 ± 1.48 µM 10.69 ± 4.03 µM 19.22 ± 0.75 µM 17.73 ± 3.14 µM 
The Kd value calculated for each individual residue was averaged to get the overall Kd. 
Data were fitted by the advanced tool AFFINImeter-NMR from the MestReNova software 






Figure 4.2.22 The chemical shift perturbation (CSP) chart for the 4 titration 
pairs (A) and the perturbed surface of CUE domain (B) at maximum saturation 




indicates the molar ratio between monoUb (or diUbs) and the CUE domain. The maximum 
titration ratio for each pair is used here. The chemical shift perturbation (Δδ) for each 
titration were derived by subtracting the chemical shift values from 0X. The data for residue 
P862, S865, P879 and K882 are missing due to the lack of signals in 1H/15N-HSQC. The 
signal of I871 was completely broadened and the chemical shift deviation at each titration is 
all given at 0.45. The chemical shift perturbation list at maximum saturation was analyzed 
and generated by CCPNMR and mapped onto the CUE domain surface by CHIMERA. The 
key residues with strong chemical shift perturbations are highlighted.  
 
4.2.2.3.2 Identification of the perturbed surface on ubiquitin upon 
binding to the N4BP1 CUE domain 
There are four titration pairs to identify the perturbed surface on the 
ubiquitin side. The label-free CUE domain was added to the 15N-labelled 
monoUb, M1-diUb, K48-diUb and K63-diUb at an increasing concentration 
respectively. The chemical shifts of the residues from ubiquitin can be 
detected by recording the 1H/15N-HSQC spectra. The chemical shift 
perturbation of ubiquitin was thus obtained by compared with the reference 
spectrum. 
    1) Titrating the CUE domain into 15N-labelled monoUb 
The 1H/15N-HSQC profile of 15N-labelled monoUb titrated with the CUE 
domain was the first set of measurements recorded by NMR. The full 
assignments of free-bound monoUb was previously introduced in Chapter II 
(Figure 2.6). It was used here as the reference (i.e. 0X). According to the data 
from ITC, the CUE domain binds to monoUb at 1:1 ratio. It is confirmed by 
the observation here where the peak moving became very slow or almost 
stopped in the 1H/15N-HSQC spectra from 1.0X to 4.0X (Figure 4.2.23).  
From the titration profiles, some of the peaks were moving in a certain 
direction to a new position during the titration process while other peaks 




signals during titration is slightly decreased but staying visible. Thus, the 
moving trend can be distinguished. The decreasing signal might come from 
the serial dilutions introduced by keeping adding the CUE domain. This 
suggests that the interaction between the CUE domain and monoUb is most 
likely undergoing a “fast exchange”, or to a less extend, between fast and 
intermediate exchange. 
An overall Kd value of 6.44 µM was calculated for CUE:monoUb, based 
on those residues with significant chemical shift perturbations (as indicated 
in Figure 4.2.23 and Table 4.2.2).  
 
Figure 4.2.23 The serial 1H/15N-HSQC spectra of 15N-labelled monoUb titrated 
with the CUE domain. The moving trend of the residues with significant chemical shift 
perturbations over the titration progress is indicated with arrows. The legend indicates the 
molar ratio between the CUE domain and monoUb. The structure of monoUb is inserted in 
the right corner. NMR spectra generated by NMRviewJ. 
 
Residues with strong CSPs might be directly or indirectly involved in the 




selected from Figure 4.2.23 and enlarged in Figure 4.2.24 and Figure 4.2.25. 
In Area A, it is easy to recognize the moving tracks of all the residues as 
indicated by the arrows. The Kd value of each residue can be thus calculated 
based on their corresponding chemical shift perturbations (Table 4.2.2). 
There are also several residues (T14, Q31, R42, Q49, R72, L73 etc.) in Area B 
which need more careful efforts to distinguish (Figure 4.2.24). For example, 
the signals for T14 and Q49 started to merge at 0.3X and completely overlap 
at 0.5-0.75X. The two peaks separated again at 1X, which allows extracting 
the exact chemical shift pattern. 
 
Figure 4.2.24 Enlarged local titration profiles (Area A and B) from Figure 
4.2.23. The moving trend of the residues with significant chemical shift perturbations is 
indicated with arrows. NMR spectra generated by NMRviewJ. 
 
It is particularly interesting to find that residue K48 was undergoing 
significant chemical shift perturbation during the titration (Figure 4.2.23 
Area C; Figure 4.2.25). It moved across residue N25 and K29 and finally to a 
very distancing position, indicating that K48 is strongly affected in the 
binding event. The moving path of K48 is isolated while the exact peak 
position at 0.3-0.5X is hard to separate as indicated in Figure 4.2.25. A rough 




Apart from the above-mentioned residues, the signal of residue L71 was 
completely broadened upon binding to the CUE domain, suggesting an 
important role in the interaction.  
 
Table 4.2.2 Dissociation constant (Kd) of representative residues of monoUb 
calculated from NMR chemical shifts 
Residue Kd (µM) Residue Kd (µM) Residue Kd (µM) 
V5 4.05 Q31 4.30 L50 5.93 
K6 12.33 D32 5.81 E51 10.75 
T7 6.03 K33 6.28 K63 7.18 
L8 5.92 E34 5.75 L67 4.80 
K11 5.65 I36 4.97 H68 3.42 
T12 5.13 R42 5.85 L69 8.59 
I13 5.34 I44 7.53 V70 6.44 
T14 7.22 F45 3.38 R72 3.62 
L15 7.50 A46 4.98 L73 4.47 
N25 6.57 G47 5.62 R74 31.24 
K29 8.62 K48 6.66 
Average 6.44 ± 0.51 
I30 7.66 Q49 5.53 
    Data were fitted by the advanced tool AFFINImeter-NMR from the MestReNova 
software according to the method described in section 3.2.5.4. Due to large errors in the Kd 
calculation for each residue, an average Kd was calculated based on all the residues listed in 









Figure 4.2.25 Resolving the signals of residue K48 during the titration progress. A dashed trendline is indicated to show the moving trend. NMR 




    2) Titrating the CUE domain into 15N-labelled M1-diUb 
M1-diUb consists of two mono-ubiquitin molecules linked via the normal 
peptide bond in a “head to tail” manner, thus this ubiquitin linkage is “linear”. 
Due to the overall similar chemical environment of the two ubiquitin moieties 
in one M1-diUb molecule, it is no surprise that most of the 1H/15N-HSQC 
spectrum of free-bound M1-diUb is similar to that of monoUb (Figure 4.2.26; 
See Figure A1 from Appendix II for the full assignments of M1-diUb). Because 
of this, on the other hand, it is difficult to separate the signals of the 
equivalent residues from both moieties. Therefore, in most cases, the 
overlapped peaks in the HSQC spectrum of M1-diUb are annotated with both 
pairwise residues, for example, V5/81, K48/124 etc.  
 
Figure 4.2.26 The overlapped 1H/15N-HSQC spectra of monoUb and M1-diUb at 
free-bound states (0X). The signals are color-coded according to the corresponding 
spectrum. Residues with difference chemical shifts between the two spectra are highlighted. 





Even so, there are still some differences between monoUb and M1-diUb. 
Some of the residues have deviated chemical shift values between the two 
spectra. Some of the peaks in M1-diUb split into two signals including E18/94, 
G35/111, R74/150, G75/151 etc, indicating the slightly different chemical 
environments between the two equivalent residues. Noteworthy, G76 and 
G152 can be well separated in M1-diUb, among which the G152 signal is 
overlapped with G76 from monoUb. The signal of Q2 is visible in monoUb but 
absent in M1-diUb, while M1/77 are visible in M1-diUb but absent in monoUb 
(Figure 4.2.26). 
Figure 4.2.27 The 1H/15N-HSQC spectra of M1-diUb titrated with the CUE 
domain. The moving trend of the residues with significant chemical shift perturbations 
during the titration progress is indicated with arrows. The legend indicates the molar ratio 
between the CUE domain and M1-diUb. The structure of M1-diUb is inserted in the right 
corner. UbP: proximal Ub; UbD: distal Ub. NMR spectra generated by NMRviewJ. 
 
The 1H/15N-HSQC spectral profile of titrating CUE into 15N-labelled 




Most of the peaks moved in the same way as in CUE:monoUb and stopped 
moving from 2X. The spectra at 2.5X and 3X are almost identical to 2X. This 
observation is in line with the 2:1 binding ratio of CUE:M1-diUb from the ITC 
measurements. 
By addition of an increasing amount of the CUE domain into 15N-labelled 
M1-diUb, some of the residues were undergoing significant chemical shift 
perturbations. The Kd values of these residues are summarized in Table 4.2.3. 
The average Kd based on these residues is 14.77 µM to reflect the overall 
binding affinity between the CUE domain and M1-diUb.  
 
Table 4.2.3 Dissociation constant (Kd) of representative residues of M1-diUb 
calculated from NMR chemical shifts 
Residue Kd (µM) Residue Kd (µM) Residue Kd (µM) 
M1/77 9.99 Q31/107 11.48 I61/137 18.95 
V5/81 9.70 D32/108 23.16 S65/141 23.61 
K6/82 11.81 K33/109 15.64 L67/143 8.85 
T7/83 24.12 E34/110 18.50 H68 or H144* 5.76 
L8/84 13.20 I36/112 12.09 H144 or H68* 15.05 
G10/86 12.95 R42/118 19.47 L69 or L145* 4.83 
K11/87 14.13 I44/120 11.53 L145 or L69* 13.91 
T12/88 13.31 A46/122 21.25 V70/146 13.89 
I13/89 19.70 G47/123 39.06 R72/148 27.79 
T14/90 24.32 K48/124 5.16 L73/149 33.05 
L15/91 20.60 Q49/125 5.12 R74 or R150* 14.20 
N25/101 30.36 L50/126 20.78 R150 or R74* 64.63 
K29/105 20.73 E51/127 34.96 Average 14.77 ± 0.27 
Data were fitted by the advanced tool AFFINImeter-NMR from the MestReNova 
software according to the method described in section 3.2.5.4. *Note that the Kd of H68 and 
H144, L69 and L145, R74 and R150 can be all resolved but cannot be distinguished with each 
other in each pair, thus cannot be assigned to a certain residue. Due to large errors in the Kd 
calculation for each residue, an average Kd was calculated based on all the residues listed in 





    Several local areas were selected from the titration profiles (Area A-C and 
some discrete peaks from Figure 4.2.27) for a careful investigation. 
As enlarged in Figure 4.2.28, nine residue pairs are displayed in Area A. 
Signals from H68 and H144 were overlapped when the CUE domain was 
absent. However, when it came to the full saturation state (at 3.0X), the two 
residues can be very well separated. This indicates that the two equivalent 
histidine residues from the two ubiquitin moieties are affected in different 
degrees upon binding to the CUE domain. This “one peak to two peaks” 
pattern also happens to I3/79, I61/137 and S65/141.   
There are also examples where both equivalent residues from the two 
ubiquitin moieties can be resolved. In the case of M1 and M77, the two 
residues can be separated from each other no matter the CUE domain was 
present or not, indicating the difference chemical environments around them. 
This can be explained by the fact that the M77 from the proximal ubiquitin 
has been occupied to form the linear linkage with G76 from the distal 
ubiquitin while M1 is free and exposed to the solvent in M1-diUb. Throughout 
titrations, it is observed that only one of the signals from M1 and M77 was 
slightly moving while another one stayed almost still, indicating that only one 
methionine residue in this pair is affected in the binding event. 
For the rest of the residue pairs in Area A, the two equivalent residues in 
each pair were completely overlapped and followed a certain trend together 
during the titrations but cannot be separated from each other at all time. It 
indicates that the two equivalent residues from the two ubiquitin moieties are 
affected in the same fashion upon binding to the CUE domain.  
In Area B, each residue in pair L69/145 and R74/150 was well separated 
from another during the titration progress respectively. However, they were 
perturbed in different degrees as reflected from the Kd values. Residue pair 
L15/91 and I30/106 tend to diverge from each other respectively throughout 





Figure 4.2.28 Enlarged local titration profiles (Area A and B) from Figure 4.2.27. 
The moving trends of residues from 0X to 3X with significant chemical shift perturbations 




In Area C, three residues N25/101, K29/105 and K48/124 are very near 
to each other (Figure 4.2.29A). The chemical shift perturbation pattern is 
highly similar to that of CUE:monoUb. The signals of the equivalent residues 
from each pair remain overlapped throughout the titration progress. K48/124 
again was undergoing strong chemical shift perturbation. While the CUE 
domain was increased, the signal of K48/124 evolved fast and crossed the 
N25/101 signal from 0.1X to 0.5X and then passed the K29/105 signal from 
0.5X to 1.0X. At 1.0X, three individual peaks reappeared again, displaying a 
clear moving trend. K48/124 seems to start splitting into two signals from 
1.0X, but unfortunately the resolution is not enough to separate them apart. 
From a rough calculation, the Kd for K48/124 (5.16 µM) from CUE:M1-diUb 
is comparable to K48 from CUE:monoUb (6.66 µM). This result further 
supports the importance of residue K48 from ubiquitin for the interaction 
with the CUE domain.   
There are two residue pairs I61/137 and S65/141, following the “one 
peaks to two peaks” pattern as mentioned before but behave a little differently 
(Figure 4.2.29B). When CUE:M1-diUb reached to 1:1 ratio (i.e. 1X), it is clear 
to see two separated peaks from the original one. However, only one of the 
peaks kept moving while another kept staying still. This indicates that one of 
the equivalent residues from the two ubiquitin moieties was undergoing 
remarkable chemical shift perturbation while another was hardly affected in 
the binding event.  
Despite the differences between the two ubiquitin moieties from 
M1-diUb described above, the chemical shift perturbation pattern for each 
ubiquitin moiety is still highly similar to that of monoUb titrated with the 
CUE domain (It will be compared in Figure 4.2.39). A detailed CSP 








Figure 4.2.29 Resolving the signals of K48/124 (A), I61/137 and S65/141 (B) during the titration progress. Figure A is the enlarged image of 




    3) Titrating the CUE domain into 15N-labelled K48-diUb 
Due to that the two ubiquitin moieties are linked via K48 linkage in 
K48-diUb, each ubiquitin is considered as an individual chain from the 
structural view. Thus, the same numbering rule from monoUb (From M1 to 
G76) was used for each chain in K48-diUb. Unlike the similar chemical 
environment for both ubiquitin moieties in M1-diUb, more equivalent 
residues from the two ubiquitin moieties in K48-diUb can be distinguished 
(See Figure A2 from Appendix II for the full assignments of K48-diUb). 
Figure 4.2.30 shows the serial 1H/15N-HSQC spectral profile of titrating the 
CUE domain into 15N-labelled K48-diUb. Although at first sight, the spectra 
look similar to those of CUE:monoUb or CUE:M1-diUb, however, more 
details for some key residues during the titrations reveal much different 
behaviour.  
 
Figure 4.2.30 The serial 1H/15N-HSQC spectra of K48-diUb titrated with the CUE 
domain. The moving trends of the residues with significant chemical shift perturbations 
during the titration progress are indicated with arrows. The legend indicates the ratio 
between the CUE domain and K48-diUb. The structure of K48-diUb is inserted in the right 
corner. UbP: proximal Ub; UbD: distal Ub. NMR spectra generated by NMRviewJ. 
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To begin with, residue G47 and A46 highlight this remarkable difference. 
The chemical shift changes of G47 throughout the titrations exhibited a 
slow to intermediate exchange pattern observed in all the titration pairs 
including CUE:monoUb, CUE:M1-diUb and CUE:K48-diUb. However, 
compared to G47/123 from M1-diUb, G47 signal from each ubiquitin chain in 
K48-diUb can be separated. Upon binding to the CUE domain, the signals 
were very weak or invisible in early stages, and then both G47 reappeared 
again and followed their own way to a new position respectively. Besides, one 
of the G47 signals moves faster than the other one. It is known that K48 in the 
proximal ubiquitin is occupied to form the isopeptide bond with G76 from the 
distal ubiquitin while K48 in the distal ubiquitin is free from forming the 
linkage. This different nature of the surrounding area for each G47 in 
K48-diUb could well explain their different perturbation degrees in the 
interaction. In comparison, G47 and its equivalent G123 from M1-diUb are 
overlapped and moved in the same way throughout the whole titration 
progress, similar to the behaviour of G47 in monoUb (Figure 4.2.31A).  
Residue A46 is even more interesting. Apart from the well-separated 
signals of A46 from both ubiquitin chains in K48-diUb during the titrations, 
the moving direction is different from that of either monoUb or M1-diUb 




Figure 4.2.31 A comparison of chemical shift perturbation patterns for G47 (A) 
and A46 (B) between three different titration pairs. The moving trends of the 
residues over the titration progress are indicated with red dashed arrows. The signals of G47 
from a full set of titration gradient (0X to maximum saturation) are shown in A. The signals 
of A46 at 0X, 0.75X and 2.0X are shown in B. The legend indicates the molar ratio between 
the CUE domain and monoUb (or M1-diUb or K48-diUb). NMR spectra generated by 
NMRviewJ. 
 
Three key areas (Area A-C) from the whole spectra (Figure 4.2.30) were 
isolated for a more careful analysis.  
Most of the residues in Area A followed the “one peak to two peaks” 
pattern, where the equivalent residues from the two ubiquitin chains split 
into two separated signals during the titrations and affected differently upon 
binding to the CUE domain (Figure 4.2.32).  
It’s worth noticing that the signals of I13 from the two ubiquitin chains 
can be separated very well before fully saturated by the CUE domain (for 
example, 0.75X as shown here). But the two signals tended to merge again at 
saturation (5.0X as shown here). The similar pattern also happens to residue 
V70 and K6, among which the two signals of K6 were completely merged at 
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saturation. It indicates that the CUE domain might prefer to interact with 
residues from a certain chain at the beginning of the binding event. Until 
saturation, the binding from both equivalent residues tends to reach the 
similar or even the same intensity.     
 
Figure 4.2.32 Enlarged local titration profile of Area A from Figure 4.2.30. 
Upper left corner: an overview of Area A from Figure 4.3.18. The rest of the 3 figures: the 
enlarged pictures of single key residues from Area A. The moving trend of each residue is 
indicated with black arrow or red dashed arrow. The signals are color-coded by the 
corresponding titration ratio as indicated in the corner. The legend indicates the molar ratio 





The residues in Area B can be grouped into four classes: 
Most of the residues have the “one peak to one peak” pattern, including 
T12, T14, I23, I30, E51, R72, L73 and R74, suggesting that the equivalent 
residues from both ubiquitin chains was undergoing the same perturbations 
via binding to the CUE domain. It’s clear to see R42 and L50 followed the 
“one peak to two peaks” pattern, while to the opposite, the signals of Q31 and 
L69 from both chains started to merge respectively during the titrations (“two 
peaks to one peak”). F45 and Q49 displayed the “two peaks to two peaks” 
pattern where they had well-separated signals from both chains no matter the 
CUE domain was present or not (Figure 4.2.33).  
 
Figure 4.2.33 Enlarged local titration profile of Area B from Figure 4.2.30. The 
spectra from 0x and 5.0x are shown here. The moving trend of each residue is indicated with 
red dashed arrows. The signals are color-coded by the corresponding titration ratio as 
indicated in the left corner. The legend indicates the molar ratio between the CUE domain 




Residue K48 from Area C is one of the major concerns in this study. In 
the case of CUE:K48-diUb, the K48 signals from the two ubiquitin chains 
cannot be separated. It moved significantly slower than that in CUE:monoUb 
or CUE:M1-diUb (Figure 4.2.34). At maximum saturation (5.0X), the signal 
of K48 still could not pass through residue N25. This can be also 
well-reflected from its higher Kd value (141.1 µM) (Table 4.2.4). N25 and K29 
also behaved differently from those in CUE:monoUb or CUE:M1-diUb (Figure 
4.2.34). During the titration progress, the signals of N25 from both chains in 
K48-diUb converged to one signal while K29 diverged to two signals.  
 
Figure 4.2.34 A comparison of residue N25, K29 and K48 among the three 
titration pairs. Only signals from 0X and 4X are shown here. The moving trend of each 
residue is indicated with red dashed arrows. The signals are color-coded by the 
corresponding titration ratio as indicated in the left corner of each figure. The legend 
indicates the ratio between the CUE domain and ubiquitin. NMR spectra generated by 
NMRviewJ. 
 
The Kd values of the key residues analyzed here are summarized in Table 
4.2.4. The average Kd based on these residues is 27.25 µM to reflect the 
overall binding affinity between the CUE domain and K48-diUb. 
To summarize, there are more variations between the two ubiquitin 
chains in K48-diUb upon binding to the CUE domain. The average Kd for 
CUE:K48-diUb suggests a less tight affinity than CUE:monoUb or 
CUE:M1-diUb. The complete CSP list for K48-diUb also indicates a less 
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perturbed degree in comparison to monoUb or M1-diUb upon binding to the 
CUE domain (It will be compared in Figure 4.2.39).  
However, from an overall view, the CSP patterns for both ubiquitin 
chains in K48-diUb are still largely in common with that of monoUb from 
monoUb:CUE (Figure 4.2.39), indicating a conserved binding mode among 
monoUb, M1-diUb and K48-diUb. This will be discussed in more detail 
together with the other titration pairs in part 5 of this section.  
 
Table 4.2.4 Dissociation constant (Kd) of representative residues of K48-diUb 
calculated from NMR chemical shifts 
Residue Kd (µM) Residue Kd (µM) Residue Kd (µM) 
V5 119.84 Q31-B 305.22 L50-A 41.11 
K6 49.45 D32 118.30 L50-B 106.37 
T7 357.94 K33 112.50 E51 13.96 
L8-A 14.84 E34 76.33 K63 13.01 
L8-B 108.10 I36 8.66 L67 92.66 
G10 599.15 R42-A 9.59 H68-A 88.48 
K11-A 165.67 R42-B 92.78 H68-B 277.40 
K11-B 416.27 I44-A 55.19 L69-A 32.59 
T12 67.27 I44-B 74.26 L69-B 63.15 
I13-A 84.31 F45-A 8.83 V70-A 18.64 
I13-B 228.64 F45-B 73.13 V70-B 27.32 
T14 105.42 A46-A 17.81 R72 37.24 
L15 49.82 A46-B 102.72 L73 214.30 
N25-A 18.10 G47-A 138.47 R74 52.84 
N25-B 29.62 G47-B 148.68 G76 47.17 
K29-A 20.70 K48 141.10 
Average 27.25 ± 0.47 K29-B 103.40 Q49-A 84.80 
Q31-A 79.75 Q49-B 156.73 
Data were fitted by the advanced tool AFFINImeter-NMR from the MestReNova 
software according to the method described in section 3.2.5.4. A and B indicate the residues 
from ubiquitin chain A or chain B in K48-diUb. Due to large errors in the Kd calculation for 
each residue, an average Kd was calculated based on all the residues listed in the table to 
represent the overall affinity. 
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    4) Titrating the CUE domain into 15N-labelled K63-diUb 
The titrations between K63-diUb and the CUE domain are the last set of 
experiments. In general, the overall 1H/15N-HSQC spectrum of K63-diUb at 
free-bound state is highly similar to that of M1-diUb. This can be 
well-explained by the similar flexible and stretching structure of both 
K63-diUb and M1-diUb. The overlapped spectra suggest that the two 
ubiquitin moieties from both diUb molecules have very similar chemical 
environments. The differences between the two diUbs are limited, for 
example, the signals of Q2, V17 and E18 are visible in K63-diUb but absent in 
M1-diUb. The signal of E64/140 cannot be separated in M1-diUb, but well 
split in K63-diUb (Figure 4.2.35). 
 
Figure 4.2.35 The overlapped 1H/15N-HSQC spectra of K63-diUb and M1-diUb at 
free-bound states (0X). The signals are color-coded according to the corresponding 
spectrum. Residues with difference chemical shifts between the two spectra are highlighted. 
NMR spectra generated by NMRviewJ. 
 
When it comes to the NMR titrations, CUE:K63-diUb is also very similar 
to CUE:M1-diUb in terms of not only the moving trend but also the degrees of 
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chemical shift perturbations (Figure 4.2.36). The major differences between 
CUE:K63-diUb and CUE:M1-diUb will be discussed below.  
Figure 4.2.36 The serial 1H/15N-HSQC spectra of K63-diUb titrated with the CUE 
domain. The moving trends of the residues with significant chemical shift perturbations 
during the titration progress are indicated with arrows. The titration ratio in the legend 
indicates the molar ratio between the CUE domain and K63-diUb. The structure of K63-diUb 
is inserted in the right corner. UbP: proximal Ub; UbD: distal Ub. NMR spectra generated by 
NMRviewJ. 
 
Several key residues in K63-diUb that behave differently from M1-Ub are 
displayed in Figure 4.2.37. Residue Q2 is visible in K63-diUb but absent in 
M1-diUb. The two equivalent Q2 from both ubiquitin chains in K63-diUb can 
be separated at 0X, but fully converged from 0.4X until saturation (3.0X). 
The signal of E64/140 cannot be separated in M1-diUb while the two 
equivalent E64 from both chains in K63-diUb moved similarly and stayed 
separated at all time during the titrations. Unlike M1-diUb, two H68 signals 
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from both chains in K63-diUb kept being overlapped no matter the CUE 
domain was present or not. This happens the same to residue L69. 
 
Figure 4.2.37 Resolving key residues in K63-diUb that are different from 
M1-diUb during the titrations. The moving trend of each signal is indicated with a red 
dashed arrow. The signals are color-coded by the corresponding titration ratio as indicated in 
the corner of each figure. The legend indicates the molar ratio between the CUE domain and 
K63-diUb. NMR spectra generated by NMRviewJ. 
 
Residue K48 evolved in the same way with strong chemical shift 
perturbation as that in both monoUb and M1-diUb upon binding to the CUE 
domain. The Kd values for K48 in CUE:monoUb, CUE:M1-diUb and CUE: 
K68-diUb are comparable within a range of 5-8 µM, which again confirms the 
importance of K48 in the binding event. The signals of K29 from both 
ubiquitin chains in K63-diUb can be isolated at 0X. During the titration 
progress, K29 from one of the chains stayed unchanged while the other one 




Figure 4.2.38 Resolving residue N25, K29 and K48 from K68-diUb upon 
binding to the CUE domain. Upper panel: the isolated spectra at 0X and 3X. Bottom 
panel: the overlapped spectra of both 0X and 3X. The moving trend of each signal is indicated 
with a red dashed arrow. The signals are color-coded by the corresponding titration ratio as 
indicated in the bottom right corner of each figure. The legend indicates the ratio between the 
CUE domain and K63-diUb. NMR spectra generated by NMRviewJ. 
 
The Kd values of the key residues with significant chemical shift 
perturbations are summarized in Table 4.2.5. The average Kd based on these 
residues is 9.56 µM to reflect the overall binding affinity between the CUE 
domain and K63-diUb. This overall Kd is close to that of CUE:monoUb (6.44 
µM) and CUE:M1-diUb (14.77 µM). A comparison of the CSP lists between 
K63-diUb and monoUb or M1-diUb also indicates the similar perturbed 
patterns upon binding to the CUE domain (It will be compared in Figure 
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4.2.39). Despite several subtle differences, it still suggests that K63-diUb 
employs the same binding mode for the interaction with the CUE domain.  
 
Table 4.2.5 Dissociation constant (Kd) of representative residues of K63-diUb 
calculated from NMR chemical shifts 
Residue Kd (µM) Residue Kd (µM) Residue Kd (µM) 
V5 8.82 K29* 15.12 K48 7.97 
K6 10.34 Q31 1.942 Q49 33.85 
T7 10.06 D32 11.86 L50 3.08 
L8 13.52 K33 6.88 E51 12.21 
G10 10.66 E34 12.55 L67 3.34 
K11 9.47 I36 11.65 H68 14.55 
T12 10.81 R42 10.24 L69 9.81 
I13 7.81 I44 8.88 V70 8.29 
T14 15.40 A46 10.25 R72 12.72 
L15 11.38 G47 24.14 Average 9.56 ± 0.24 
Data were fitted by the advanced tool AFFINImeter-NMR from the MestReNova 
software according to the method described in section 3.2.5.4. Note that all the residues 
(except K29) cannot be distinguished between chain A and B in K63-diUb. *K29 from one of 
the ubiquitin chains stays unchanged upon binding, hence only the one with significant CSP 
is shown here. Due to large errors in the Kd calculation for each residue, an average Kd was 













    5) Correlating chemical shift perturbations with the structure 
of ubiquitin 
A general comparison for the perturbed surfaces of monoUb or diUb 
chains at saturation states from all the four titration pairs was carefully 
performed according to the CSPs collected from the NMR titrations. 
Figure 4.2.39 summarizes the corresponding CSPs for the four titration 
pairs at saturation states. Residues with undetectable signals in the spectrum 
were left blank in the chart. Residue L71 is broadened in all the four 
ubiquitins. Thus, a maximum value was given. To make it easier for the 
comparison between monoUb and diUb chains, M1-diUb is separated into 
two chains. To specify, chain A is the distal ubiquitin and chain B is the 
proximal ubiquitin for all the three diUb chains.  
From an overall view, the CSP patterns are all similar within the four 
ubiquitins. Most of the perturbed areas are within β2 and β4, as well as a 
short loop area next to the β3 C-terminus. The less affected areas include β1, 
α1 and α2. The above areas contain some hotspots for the binding, including 
the canonical I44 hydrophobic patch. Apart from the I44 patch, residue G47 
and K48 which are located next to β3 also have strong CSPs in monoUb, 
M1-diUb and K63-diUb, but much less pronounced in K48-diUb.  
Due to the overlapped signals for most of the equivalent residues in 
M1-diUb and K63-diUb, both proximal and distal ubiquitin moieties are 
affected almost in the same degree with only minor differences. The CSP 
intensity is also comparable to that of monoUb. However, K48-diUb has a 
lower level of CSPs for both ubiquitin chains compared to monoUb or M1- or 
K63-diUb. This is also supported by the lower affinity obtained from ITC. 
Due to more different chemical environments between the two ubiquitin 
chains in K48-diUb, the distal ubiquitin was perturbed a little stronger than 
the proximal one.  
In brief, based on the four CSP charts, monoUb, M1-diUb and K63-diUb 
chains employ the same binding mode to interact with the CUE domain, 
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while although K48-diUb also uses a similar binding mode, there are more 
differences between the two ubiquitin moieties and its interaction with the 
CUE domain is weaker.   
 Figure 4.2.39 Chemical shift perturbations (CSPs) charts of monoUb and three 
diUb chains upon binding to the CUE domain at saturation states. The chemical 
shift perturbations (Δδ) for each titration were derived by the subtraction with the chemical 
shift values from 0X. Residues with missing assignments in 1H/15N-HSQC are left blank. The 
titration ratio in the legend indicates the molar ratio between the CUE domain and ubiquitins. 
The chemical shift perturbation lists were analyzed and generated by CCPNMR. 
 
The above CSPs were then mapped to the surface of monoUb and diUb 
chains respectively. To start with, monoUb was first analyzed (Figure 4.2.40). 
Residue G10, I13, G47, K48, V70 and L71 all have a CSP value above 0.2, 




Figure 4.2.40 The perturbed surface of monoUb at maximum saturation (2X) 
upon binding to the CUE domain. A. The “front” view of the perturbed surface to show 
the ubiquitin I44 patch. B. The 90º degree view of the perturbed surface. The molar ratio 
between monoUb and the CUE domain used here is 2:1 (2X). The CSP list at 2X was 
generated by the subtraction with the chemical shift values from 0X and then mapped to the 
monoUb surface by CHIMERA. On the right panel of each figure, the key residues with 
CSP>0.1 are shown as sticks while residues with CSP>0.2 are highlighted in red in the 
cartoon view by Pymol.  
 
The most perturbed area is the classical I44 hydrophobic patch with 
some extension including G47 and K48 as shown in Figure 4.2.40A. Despite 
residue L8 and I44 were only slightly perturbed in the binding event 
(CSP<0.15), some other residues from this I44 patch including Q49, H68, 
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V70 and L71 all have higher CSPs upon binding to the CUE domain. Another 
less perturbed area is next to the I44 patch (Figure 4.2.40B), including 
residue T7, G10, K11, I13, T14, Q31 and D32.  
 
Figure 4.2.41 ITC measurements and the parameter summary of the interaction 
between the N4BP1 CUE domain and monoUb K48 mutants. A. ITC titration 
isotherms. B. Parameter table of Kd summarized from A. Data were fitted to a single-site 
model using the MicroCal PEAQ-ITC Analysis Software following the method described in 
section 3.2.5.2. Measurement conditions: Syringe: 0.5 mM CUE domain, Cell: 50 µM 
monoUb or mutants. 18 injections, 2 µL/injection, duration: 2s, spacing time: 120 s, 
measurement temperature: 25℃. 
 
The importance of ubiquitin K48 for the binding is confirmed by ITC 
measurements. Ubiquitin mutant K48A completely abolishes the interaction 
with the CUE domain (Figure 4.2.41). Intriguingly, similar to the WT 
ubiquitin, the binding affinity between ubiquitin K48R mutant and the CUE 
domain is unchanged, indicating that the positively charged side chain from 




Figure 4.2.42 A comparison of the perturbed surfaces from monoUb (A), 
M1-diUb (B) and K63-diUb (C) at maximum saturation upon binding to the CUE 
domain. The molar ratio between monoUb and the CUE domain used here is 2:1 (2X). The 
molar ratio between diUb (M1- or K63-diUb) and the CUE domain used here is 3:1 (3X). The 
CSP list for each molecule was mapped to the monoUb surface (PDB: 1UBQ), M1-diUb 
surface (PDB: 2W9N) and K63-diUb surface (PDB: 3H7P) by CHIMERA respectively. UbP: 
proximal Ub; UbD: distal Ub. 
 
    The CSPs from M1- and K63-diUb were also mapped to the 
corresponding surfaces. As seen from Figure 4.2.42, it is clear to find a similar 
perturbed surface from both ubiquitin moieties. The perturbed surface is also 
comparable to that of monoUb. Although the two ubiquitin moieties in 
M1-diUb and K63-diUb have relatively different spatial arrangements, they 
both adopt an open conformation. This allows the I44 patch from each 
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ubiquitin moiety well exposed to the solvent. Thus, two molecules of the CUE 
domain could bind to both ubiquitin moieties from one diUb molecule with 
an equal chance. This is further supported by the ITC measurements where 
the stoichiometry between the CUE domain and M1-diUb (or K63-diUb) is 2:1. 
The affinities of the CUE domain to monoUb or M1- 0r K63-diUb are also 
comparable with each other from ITC, supporting that the same binding 
mode is shared between the three binding pairs. 
The above results indicate that the CUE domain does not discriminate 
among monoUb, M1-diUb and K63-diUb.  
    In contrast to M1-diUb and K63-diUb, K48-diUb adopts a closed 
conformation. The crystal structure of K48-diUb reveals that the two I44 
patches interact with each other (PDB: 1AAR) (Figure 1.3 in Chapter I), which 
restricts the I44 patch to interact with binding partners containing UBDs. 
However, there are several NMR solution structures of K48-diUb in complex 
with UBDs, which displays a less compacted conformation, allowing the I44 
patch more available to the solvent. Here the K48-diUb solution structure 
taken from the K48-diUb/HHR23AUBA complex (PDB: 1ZO6) was chosen for 
mapping the CSPs from CUE:K48-diUb to its surface.  
As shown in Figure 4.2.43, part of the I44 patch from both proximal and 
distal ubiquitins was affected upon binding to the CUE domain, but in a less 
degree of perturbation. The K48 residue in the proximal ubiquitin is occupied 
to form the K48 linkage, thus the K48 extended surface is blocked. 
Surprisingly, the K48 extended surface from the distal ubiquitin was also 
much less involved. This is also supported by the Kd comparison from NMR 
where the Kd value of K48 in K48-diUb (141.10 µM) is a lot less than the other 
three ubiquitins (5-8 µM). All the above factors make K48-diUb less 




Figure 4.2.43 The perturbed surface of K48-diUb from K48-diUb/N4BP1CUE. The 
CSPs of K48-diUb upon binding to the N4BP1 CUE domain were mapped to the K48-diUb 
structure (PDB:1ZO6) by CHIMERA. The molar ratio between K48-diUb and the CUE 
domain used here is 3:1 (3X). UbP: proximal Ub; UbD: distal Ub.  
 
From the NMR titration study in this section, it is clear to conclude that 
the N4BP1 CUE domain is not in favour of binding to K48-diUb compared to 
monoUb, M1-diUb or K63-diUb as reflected from the average Kd values  
summarized in Table 4.2.6 (data taken from Table 4.2.2-4.2.5). Hence, it is 
further confirmed from the NMR titration studies here that the CUE domain 
could distinguish K48-diUb from monoUb, M1- and K63-diUb, which is in 
agreement with the ITC data. 
 
Table 4.2.6 The average dissociation constant (Kd) of ubiquitin upon binding to 
the CUE domain calculated from NMR chemical shift perturbations 
Titration pair monoUb M1-diUb K48-diUb K63-diUb 
CUE 6.44 ± 0.51 µM 14.77 ± 0.27 µM 27.25 ± 0.47 µM 9.56 ± 0.24 µM 




The perturbed surface of ubiquitin from each titration pair will be 
compared with other UBD/ubiquitin complex in the discussion (section 
4.2.3.2.3). The CSP data from both ubiquitin and the CUE domain will be 
used to establish a docking model in the next section, which will help locate 



























4.2.2.4 Molecular docking of the N4BP1 CUE domain to 
monoUb 
Based on the binding studies in section 4.2.2.3, the CUE domain shares 
the same binding mode to both monoUb and di-ubiquitin chains. To this end, 
a docking model of the CUE domain in complex with monoUb was generated 
according to the CSP data collected from NMR titrations (Figure 4.2.44). 
In this model, two major features are highlighted: First of all, the FP 
motif of the CUE domain interacts with residue V70 and L71 from ubiquitin 
via their hydrophobic side chains. V70 and L71 are part of the ubiquitin I44 
hydrophobic patch, although residue I44 from ubiquitin is not involved in the 
interaction in this model. This is in agreement with the observation from the 
NMR titrations where I44 was much less perturbed upon binding to the CUE 
domain.   
Another key feature is the polar interaction between residue D893 from 
the CUE domain and residue K48 from ubiquitin. The negatively charged 
carboxyl group from the D893 side chain is only 3.8 Å away from the 
positively charged amino group from the K48 side chain. In section 4.2.2.3.2, 
the importance of K48 in the interaction has been demonstrated by ITC using 
the K48A and K48R mutants (Figure 4.2.41). The K48A mutant completely 
abolishes the interaction between ubiquitin and the CUE domain. On the 
other hand, the key role of the K48 positively charged side chain is also 
confirmed by using the K48R mutant. Different from K48A, the K48R mutant 
retains the same binding affinity as the WT ubiquitin. The side chain of 
arginine has a similar length to that of lysine. Most important of all, both side 
chains are positively charged, which very well explains the ability of K48R to 
interact with the CUE domain.  
The N4BP1CUE/monoUb complex will be compared with other 




Figure 4.2.44 The docking model of the N4BP1 CUE domain in complex with 
monoUb. A. Cartoon representation of the model. The hydrogens of residue D893 from 
CUE and residue K48 from ubiquitin are displayed to help indicate the distance between the 
two residues. Key residues involved in the interaction are colored in red (for Ub) and yellow 
(for CUE). B. The ubiquitin is shown in a surface presentation to indicate the binding 
interface. The N4BP1 CUE domain is coloured in green while the ubiquitin is coloured in cyan. 





4.2.2.5 Functional analysis of the N4BP1 RNAse domain 
As mentioned in the introduction of this chapter, the pull-down 
experiments have shown that the N4BP1 RNAse domain contributes to the 
binding specificity of the CUE domain to M1-diUb and K63-diUb (Figure 
4.2.2). This suggests that apart from the RNAse activity, the RNAse domain 
may have other functions related to ubiquitin binding. This section will be 
focused on this topic.   
4.2.2.5.1 Sequence analysis and structure modelling 
In the first instance, a sequence/structural homology searching for the 
N4BP1 RNAse domain was performed.  
Based on the structure prediction of N4BP1 RNAse domain by Phyre2, 
the top template (c3v33A) is the RNAse domain from the human MCPIP1 
(Uniprot: Q5D1E8; reviewed in section 1.4.3). As shown in the sequence 
alignments, the N4BP1 RNAse domain and the MCPIP1 RNAse domain (both 
from mouse) are very similar with a 51.5% identity and 72.4% similarity 
(Figure 4.2.45). This result is also in line with that N4BP1 is evolutionarily 
close to the MCPIP family from the phylogenetic study (Anantharaman and 
Aravind, 2006; Figure 1.27).  
 
Figure 4.2.45 Sequence alignment of the RNAse domain from mN4BP1 and 
mMCPIP1. The asterisks (*) indicate the conserved Asp and Cys residues from both 
domains. The corresponding Asp box and Cys box are indicated. Identical residues are 
shaded in the same color in pairs while the residues with >80% similarities are also shaded 




The structure of the RNAse domain from human MCPIP1 has been solved. 
The negatively-charged pocket which includes the key catalytic residue D141 
has been identified to be responsible for the RNAse activity (Figure 4.2.46A) 
(Xu et al., 2012). D141 is conserved in N4BP1 (The corresponding residue is 
D623 in human N4BP1 and D621 in mouse N4BP1). In a study using human 
N4BP1, theD623N mutant lost the RNAse activity (Yamasoba et al., 2019). 
Here, the de novo structure model of mouse N4BP1 RNAse domain (613-774) 
was predicted by trRosetta. It is quite similar to the MCPIP1 RNAse domain 
when superimposed together (RMSD=1.748). The negatively-charged pocket 
is also conserved in both domains (Figure 4.2.46B). It may suggest that both 
proteins employ the same mechanism to catalyze RNA.   
Interestingly, the RNAse domain of MCPIP1 also has the 
deubiquitinating (DUB) activity towards K48- and K63-linked ubiquitin 
chains. Residue C157 has been identified as the active Cys site for the DUB 
activity (Liang et al., 2010). It is no surprise that C157 is also conserved in the 
N4BP1 RNAse domain (C637 in mouse N4BP1). The DUB signature Asp box 
and Cys box are also conserved (Figure 4.2.45). This indicates that the N4BP1 
RNAse domain might be also involved in ubiquitin-related process.  
In the following content, the RNAse construct or the construct containing 
both the RNAse domain and the CUE domain from N4BP1 will be purified 
and applied to the biophysical measurements to characterize their binding 




Figure 4.2.46 Structure modelling of the mouse N4BP1 RNAse domain. A. Crystal 
structure of the human MCPIP1 RNAse domain (PDB: 3V33). B. Structure model of mouse 
N4BP1 RNAse domain (613-774) by trRosetta. The key residues in the RNAse catalytic 
center (the negatively-charged pocket) are indicated. The charge distribution on the 
surface is shown on the right. Positively-charged residues are indicated in blue while 








4.2.2.5.2 Protein design and purification 
In this section, the short form “RNAse” will be used to represent the 
RNAse domain (613-774) and “RNAseCUE” to represent the N4BP1 
C-terminal construct (613-893) containing both the RNAse domain and the 
CUE domain. The protein constructs used is summarized in Figure 4.2.47. 
 
Figure 4.2.47 Domain structures of the RNAse and RNAseCUE constructs. TF: 
trigger-factor chaperone. His: 6×His tag. 
 
Initial expression tests showed that the expression of RNAse or 
RNAseCUE was almost all in the inclusion body either using pET47b or 
pCold-I vector in the E.coli bacterial system, indicating the difficulties to 
make the RNAse domain properly folded and soluble. The pGEX-6P1 vector 
was also used. Unfortunately, only GST is expressed rather than the fusion 
protein GST-RNAse or GST-RNAseCUE. The N-terminal boundary of 




    To get sufficient soluble protein for biophysical analysis with 
mono-ubiquitin or di-ubiquitin chains, the below two methods were applied 
in this study. 
    1) Construction of the TF-tagged RNAse/RNAseCUE 
RNAse and RNAseCUE were cloned into the pCold-TF vector for protein 
expression. The target protein is fused with a prokaryotic chaperone protein 
trigger factor (TF, ~50 kDa) in the N-terminus to help increase protein 
solubility (Figure 4.2.47). The expression of the fusion protein was very 
strong and a high yield of expressed protein can be obtained with a simple 
TALON affinity chromatography step (Figure 4.2.48). The tagged protein was 
further polished by size exclusion chromatography (SEC).  
 
Figure 4.2.48 Purification of TF-tagged RNAse and RNAseCUE by TALON 
affinity chromatography. 
 
Unfortunately, both RNAse and RNAseCUE precipitated when the 
trigger factor fusion was cleaved. Therefore, the fusion proteins were applied 






    2) Construction of the chimeric RNAse/RNAseCUE 
    As discussed in 4.2.2.5.1, the N4BP1 RNAse domain shares high 
homology to that from MCPIP1. Due to the successful purification and 
crystallization of the human MCPIP1 RNAse domain in prokaryotic E.coli 
expression system (Xu et al., 2012), a sequence optimization of the mouse 
N4BP1 RNAse domain was performed.  
Again, a careful full-length sequence alignment between mouse N4BP1 
and human MCPIP1 was conducted, highlighting both similarities and 
differences (Figure 4.2.49). It has been reported that the human MCPIP1 
RNAse domain (112-334) can be crystalized though residues 112-133 are 
missing in the structural model due to the absence of interpretable electron 
density (Xu et al., 2012). hMCPIP1112-132 is a short sequence adjacent to the 
N-terminal of the NCPIP1 RNAse domain which is absent in N4BP1 and 
might aid solubility for MCPIP1. Therefore, hMCPIP1112-132 was fused to the 
N-terminus of N4BP1 RNAseCUE (613-893) to create a chimera of the 
RNAseCUE domain with the aim to increase solubility. The same chimeric 
protein was also created for the isolated RNAse domain (Figure 4.2.47). 
 
Figure 4.2.49 Full-length sequence alignment between hMCPIP1 and mN4BP1. 
Note that only part of the alignment is shown here. Dashed box highlights the RNAse 
domains. Sequence in small black boxes is the adaptor sequence from hMCPIP1112-132. 
Sequence was aligned by MEGA and visualized by bioedit. 
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The expression and solubility of both chimeric RNAse and RNAseCUE 
constructs was strongly improved compared to the corresponding WT 
construct and can be purified despite large amount of protein are found in 
inclusion bodies. The purification procedures were optimized into 3 steps. 
The soluble fraction was first purified by TALON affinity chromatography. 
Then an anion exchange step using a Mono Q column was performed (Figure 
4.2.50). The pure chimeric RNAse or RNAseCUE was eluted at a salt 
concentration of ~100 mM NaCl. The peak fractions were then applied to 
analytical size-exclusion chromatography (See details in Figure 4.2.54). 
  
Figure 4.2.50 Purification of chimeric RNAse (A) and RNAseCUE (B) by anion 
exchange. In each figure, the purification profile is shown on the left while the SDS-PAGE 
gel of peak fractions is shown on the right. Chimeric RNAse is 23.0 KDa, chimeric RNAseCUE 
is 36.1 KDa. 
 
4.2.2.5.3 Binding studies  
    1) SPR measurements reveal the binding preference of 
RNAseCUE to M1-diUb chains 
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To characterize the ubiquitin binding properties in a quantitative manner, 
an affinity screening of RNAse or RNAseCUE was conducted by Surface 
Plasmon Resonance (SPR). TF-tagged RNAse or RNAseCUE protein was 
immobilized on a CM5 sensor chip by amine coupling. The analytes (i.e. 
monoUb or M1/K48/K63-diUb chains in this study) were in the mobile phase 
and running separately through the chip surface for the interaction.  
 
Figure 4.2.51 Quantitative analysis of TF-tagged RNAse or RNAseCUE 
interacting with monoUb and M1/K48/K63-diUb by SPR. A. Plots of response at the 
equilibrium stage from the sensorgrams against the ubiquitin concentration. B. Calculated 
dissociation constants (KD) table. Data were fitted by Matlab following the method described 




The binding constant was calculated using the amplitude of the SPR 
signal since it was not possible to determine the very fast association and 
dissociation rates under this condition. The response data points at the 
equilibrium stage from the sensorgrams (raw data not shown) were plotted 
against the ubiquitin concentration. The data were fitted to a single-site 
model to obtain the equilibrium dissociation constant (KD) as shown in Figure 
4.2.51. TF-RNAseCUE displays the highest affinity to M1-diUb with a KD 
value of 0.2 µM, then followed by K63-diUb at 5.4 µM. TF-RNAseCUE also 
binds to K48-diUb, but less effectively (KD = 19.0 µM) and has the least 
affinity to monoUb (KD = 92.2 µM). These results are in line with the 
observations from the pull-down assays where GST-RNAseCUE prefers 
binding to M1- and K63-diUb (Figure 4.2.2).  
On the contrary, TF-RNAse does not show interactions with any of the 
four analytes, which indicates the indirect involvement of the RNAse domain 
in promoting the ubiquitin-binding specificity. To conclude, the C-terminal 
CUE domain is the sole ubiquitin-binding element in the RNAseCUE 
construct.   
    2) ITC measurements confirm the high affinity between 
RNAseCUE and M1-diUb 
    To confirm that RNAseCUE binds to M1-diUb with high affinity, ITC 
measurements were performed. As shown in Figure 4.2.52A, the averaged Kd 
from three replicates of titrating M1-diUb into TF-RNAseCUE is 2.12 µM. The 
N value is ~ 0.2, indicating that the ratio between M1-diUb and 
TF-RNAseCUE is only about 1: 5. If assuming that RNAseCUE still binds to 
monoUb in the same way as the CUE domain to monoUb at 1:1 ratio, only 20% 
of the TF-RNAseCUE was involved in the binding event here. This might 
come from the folding problems from RNAseCUE when the protein is 
expressed in prokaryotic system as previously mentioned in section 4.2.2.5.2. 
Nevertheless, the Kd value still indicates a high affinity interaction. As a 
control, M1-diUb does not interact with TF. 
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The interaction between TF-RNAseCUE and monoUb was undetectable 
by ITC (Figure 4.2.52). Based on the Kd value (92.2 µM) measured from SPR, 
it might be beyond the sensitivity of ITC to detect such weak binding.   
 
Figure 4.2.52 Quantitative binding measurements of TF-RNAseCUE with 
M1-diUb and monoUb by ITC. A. The isotherm of titrating 0.5 mM M1-diUb into 0.1 mM 
TF-RNAseCUE (left), and 0.5 mM monoUb into 50 µM TF-RNAseCUE (right) respectively. B. 
Parameter table of Kd and stoichiometry summarized from A and B. Data were fitted to a 
single-site model using the MicroCal PEAQ-ITC Analysis Software following the method 
described in section 3.2.5.2. Measurement conditions: 18 injections for monoUb into 
TF-RNAseCUE, 2 µL/injection; 29 injections for M1-diUb into TF-RNAseCUE, 1 µL/injection. 







    3) ITC measurements confirm that the RNAse domain is not 
the direct ubiquitin-interacting module  
Although the addition of the RNAse domain to the CUE domain 
significantly increases the specificity to M1-diUb, SPR measurements could 
not detect any binding between the RNAse domain and ubiquitin (Figure 
4.2.51). To further confirm this observation, the ITC measurements were also 
performed to detect the affinity of TF-tagged RNAse to monoUb or M1-diUb.  
As expected, there is no interaction from TF-RNAse with either monoUb 
or M1-diUb under the sample concentrations as specified in Figure 4.2.53. 
The intramolecular interaction between the RNAse domain and the CUE 
domain is also undetectable (Figure 4.2.53C). This further supports that the 
CUE domain is the sole ubiquitin-interacting module in the C-terminus of 
N4BP1. 
 
Figure 4.2.53 ITC measurements of TF-RNAse to monoUb, M1-diUb and the 
CUE domain respectively. A. The isotherm of titrating 0.25 mM TF-RNAse into 25 µM 
M1-diUb. B. The isotherm of titrating 0.2 mM TF-RNAse into 50 µM monoUb. C. The 
isotherm of titrating 0.5 mM CUE domain into 50 µM TF-RNAse. Measurement conditions: 





4.2.2.5.4 Chimeric RNAse and RNAseCUE display oligomeric 
states 
Structural and cell biological studies have revealed that the dimerization 
of the MCPIP1 RNAse is required to perform its RNAse activity. As introduced 
in section 1.4.3, the MCPIP1 RNAse domain forms oligomers. The MCPIP1 
NTD domain could also interact with the RNAse domain. The interface of 
NTD-RNAse is partially overlapped with the RNAse dimer interface. Thus, it 
is proposed that this effect maintains the RNAse domain as dimer instead of 
oligomers (Yokogawa et al., 2016). Due to the high sequence similarity 
between the RNAse domains from both MCPIP1 and N4BP1, we hypothesized 
that the N4BP1 RNAse domain could also form oligomers.  
To test this hypothesis, chimeric RNAseCUE was chosen for the analysis. 
Chimeric RNAseCUE is His-tagged with an additional 20aa-adptor from 
MCPIP1 attached to the N-terminus, making it a less artificial construct 
compared to the TF-tagged version. The peak fractions of the corresponding 
chimeric protein from the anion exchange (as described in Figure 4.2.50) 
were applied to the analytical size-exclusion chromatography. Several 
standard proteins with known molecular weight were also analyzed 
respectively using the same condition as references. As seen from the gel 
filtration profiles in Figure 4.2.54A, the peak position of both chimeric RNAse 
(23 KDa) and chimeric RNAseCUE (36.1 KDa) is approximately located in 
between the Alcohol dehydrogenase peak (150 KDa) and Carbonic 











Figure 4.2.54 Analytical size-exclusion chromatography reveals oligomeric 
states of chimeric RNAse and chimeric RNAseCUE. A. The analytical size-exclusion 
profiles of the chimeric proteins as well as the standard proteins. The Mw of the standard 
protein is indicated. The method followed what’s described in section 3.2.5.1. B. The 
calibration curve of the gel filtration column. The column used here is SuperoseTM 12 
10/300L (GE Healthcare). Ve is the elution volume of the corresponding protein peak. Vo is 
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the void volume of the column (7.2 mL). The curve was linearly fitted to the equation 
y=-1.7788x+5.0463 where x is the Ve/Vo ratio and y is the Log10 value of the protein 
molecular weight. The gel filtration profiles of the two chimeric proteins are shown in the left 
corner. The Ve/Vo of each peak was applied to the fitted equation correspondingly to 
estimate the molecular weight as indicated by the red circles in the calibration curve. 
 
The molecular weight of the two chimeric proteins was calculated 
according to the calibration curve derived from the gel filtration profiles of 
the standard proteins (Figure 4.2.54B). The elution volume/void volume ratio 
(Ve/Vo) of the 3 peaks of interests (i.e. Peak 1 from chimeric RNAse; Peak 2 
and 3 from chimeric RNAseCUE) was calculated respectively from the 
corresponding gel filtration profile. Then the molecular weight of the protein 
from each peak was estimated by applying its Ve/Vo ratio to the calibration 
curve (Figure 4.2.54B). The estimated molecular weight is summarized in 
Table 4.2.7.  
From the results, the single peak of the chimeric RNAse corresponds to a 
molecular weight of a tetramer. There are two peaks close to each other in the 
chimeric RNAseCUE profile where Peak 2 corresponds to a tetramer and 
Peak 3 indicates a dimeric state. This shows that chimeric RNAseCUE exists 
in an equilibrium of the dimeric and tetrameric species, which cannot be 
separated by gel filtration.  
 
Table 4.2.7 The molecular weight estimation of the protein peaks from the 
analytical SEC profiles of chimeric RNAse and chimeric RNAseCUE 
Protein Monomer Mw. Peak Calculated Mw. Oligomeric states 
Chimeric RNAse 23 KDa Peak 1 102.91 KDa tetramer 
Chimeric RNAseCUE 36.1 KDa 
Peak 2 121.37 KDa tetramer 




    In summary, the gel filtration profiles of both chimeric RNAse and 
chimeric RNAseCUE indicate the oligomeric state of the N4BP1 RNAse 
domain present in the solution. 
Based on the above experimental evidence, a hypothesis was proposed: 
the oligomerization of the RNAse domain brings the C-terminal CUE domains 
together in close proximity, which increases the chance for linear ubiquitin 
chains to recognize more CUE molecules at a time. The high affinity of the 
interaction between the RNAseCUE construct and the linear ubiquitin chains 
is achieved not only by the direct binding of the CUE domain but also from 
the appropriate structural arrangements of the RNAse domains.  
 Here, to verify this hypothesis, the interaction of TF-RNAseCUE with 
M1-diUb or M1-tetraUb was compared by ITC measurements (Figure 4.2.55). 
M1-tetraUb was titrated into TF-RNAseCUE, resulting in a Kd value of 0.59 
µM, which is about 4 times tighter than the affinity between TF-RNAseCUE 
and M1-diUb (2.12 µM) from the study in section 4.2.2.5.3. The increased 
affinity further supports that the oligomeric RNAse domain contributes to the 
increased local concentration of the N4BP1 C-terminus, which makes the 
whole RNAseCUE construct prefer to interact with longer linear ubiquitin 
chains. 
A structural model of dimer-induced specificity of N4BP1 for linear 






Figure 4.2.55 Quantitative binding measurements of TF-RNAseCUE to M1-diUb 
and M1-tetraUb by ITC. A. The isotherm of titrating 0.5 mM M1-diUb into 0.1 mM 
TF-RNAseCUE. The data was taken from Figure 4.2.51. B. The isotherm of titrating 0.25 mM 
M1-tetraUb into 0.1 mM TF-RNAseCUE. C. Parameter table of Kd and stoichiometry 
summarized from A and B. Data were fitted to a single-site model using the MicroCal 
PEAQ-ITC Analysis Software following the method described in section 3.2.5.2. 
Measurement conditions: 29 injections, 1 µL/injection, duration: 2s, spacing time: 120 s, 










4.2.3 Discussion  
4.2.3.1 Structure comparison of the CUE domain with other 
UBDs 
In section 4.2.2.2, the structure model of the N4BP1 CUE domain was 
generated based on the backbone and sidechain assignments by solution 
NMR. The N4BP1 CUE domain adopts a 3-helix bundle structure which is 
similar to the canonical CUE family. The structure is also in agreement with 
the de novo structure prediction by trRosetta. The CS-ROSETTA model and 
the trRosetta model can be very well aligned (RMSD=0.895) (Figure 4.2.56). 
Thus, the CS-ROSETTA model allows the further characterization of the 
ubiquitin-binding properties of the N4BP1 CUE domain. 
 
Figure 4.2.56 Structure superimposition of the CS-ROSETTA model and 
trRosetta model. A. Structure model of CUE by CS-ROSETTA. B. Structure model by 
trRosetta. C. Structure superimposition of the two models. Figures were generated by Pymol.  
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A protein structure comparison via the DALI server was performed using 
this CS-ROSETTA model as an entry. Among the several top results, the CTD 
domain of MCPIP1 was found (PDB: 2N5L). Most of the other top structures 
only share similar 3-helix fold with the N4BP1 CUE domain, but lack the 
conserved FP motif or have no related ubiquitin-binding properties. Thus, 
they will not be discussed here.  
The structure of N4BP1 CUE domain and MCPIP1 CTD domain can be 
aligned as shown in Figure 4.2.57 (RMSD=3.308). The main difference 
between the two domain is that the helix α3 from MCPIP1CTD is longer than 
N4BP1CUE. Nevertheless, the FP motifs from both domains are conserved and 
located in the loop between helix α1 and α2. Although the structure of 
MCPIP1CTD is available, the classification of this domain is yet unclear. The 
function of MCPIP1CTD also remains further investigation. However, 
considering that the full length MCPIP1 has three domains that are similar to 
N4BP1 (See the discussion in section 4.2.3.4; see Appendix III for the full 
sequence alignments), the reported function of MCPIP1 in immune responses 





Figure 4.2.57 Structure superimposition of N4BP1CUE and MCPIP1CTD. A. 
Structure model of N4BP1CUE. B. Solution NMR structure of MCPIP1CTD (PDB: 2N5L). C. 
Structure superimposition of the two structures. Figures were generated by Pymol.  
 
Apart from the CTD domain from MCPIP1, several other UBDs can be 
also found, including the CUE domain from gp78 (also called AMFR or 
RNF45) (PDB: 2EJS) and CUE2 (PDB: 1OTR), the UBA domain from p47 
(PDB: 1V92) etc (Figure 4.2.58). Interestingly, although sharing high 
sequence similarity with the N4BP1 CUE domain, the CUBAN domain from 
KHNYN (PDB: 2N5M) cannot be found via DALI search. A careful structural 
comparison between the N4BP1 CUE domain and these UBDs will be 




Figure 4.2.58 Structures of the N4BP1 CUE domain and representative CUE 
domain, UBA domain and CUBAN domain. All the α1 helices are colored from dark 
blue to light blue. All the α2 helices are colored from green to yellow. All the α3 helices are 
colored from orange to red. Figures were generated by Pymol using the structure model of 
N4BP1CUE (from this thesis), gp78CUE (PDB: 2EJS), CUE2-1 (PDB: 1OTR), p47UBA (PDB: 
1V92), KHNYNCUBAN (PDB: 2N5M).  
 
    Due to poor sequence similarity, the N4BP1 CUE domain could not be 
aligned with either the gp78CUE or CUE2-1 domain by a simple Pymol 
sequence alignment. Then a pairwise alignment was performed manually as 
shown in Figure 4.2.59. The alignment of the first helix (α1) from both pairs 
allows matching the three helical bundles in good agreement. According to 
the sequence alignments from Figure 4.2.3, the FP motifs are conserved. The 
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structural comparison here further confirmed the conserved position of the 
FP motifs among the three domains. 
 
Figure 4.2.59 The structure comparison of the N4BP1 CUE domain with gp78CUE 
(A) and the CUE2-1 domain (B). The first helix (α1) from both structure pairs are 
manually aligned together. FP motifs are highlighted in both structures. Figures were 
generated by Pymol using the structure model of N4BP1CUE (from this thesis), gp78CUE (PDB: 
2EJS) and CUE2-1 (PDB: 1OTR). 
 
    For the comparison between N4BP1CUE and p47UBA, surprisingly, helix α3 
from p47UBA is aligned with helix α1 from N4BP1CUE by Pymol according to 
sequence similarity (Figure 4.2.60A). Manual superimposing the first helix 
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(α1) from both domains results in a complete misalignment of the second 
helix (α2) as shown in Figure 4.2.60B. The comparison highlights the 
difference in both sequence and helix fold between the two domains.
 
Figure 4.2.60 The structure comparison of the N4BP1 CUE domain with the p47 
UBA domain. A. Structure superimposition by sequence alignment by Pymol. B. Structure 
superimposition by manually aligning α1 from both domains together. Figures were 
generated by Pymol using the structure model of N4BP1CUE (from this thesis) and p47UBA 
(PDB: 1V92). 
 
As mentioned previously in this chapter, the top template for the 
sequence-based structural prediction of the N4BP1 CUE domain by Phyre2 is 
the KHNYN CUBAN domain (PDB: 2N5M). A simple sequence alignment 
indicates that they share ~ 33% identity and ~ 46% similarity (Figure 4.2.61A). 
However, as seen from Figure 4.2.58, it is obvious that the structures differ 
substantially. The relative locations of helix α2 and α3 from both proteins 
display a different spatial arrangement. A superimposition of the two 
domains demonstrates that the structures have separate folds which cannot 
be aligned (Figure 4.2.61B). This observation is in line with the different 




Figure 4.2.61 Sequence and structure comparisons of N4BP1CUE with 
KHNYNCUBAN. A. Sequence alignments between the two domains. Identical residues are 
shaded in orange. The residues with >80% similarities are shaded in cyan. Sequence 
alignments were done by EMBOSS Needle and visualized by bioedit. B. The superimposition 
of the two domains. Figures were generated by Pymol using the structure model of N4BP1CUE 
(from this thesis) and KHNYNCUBAN (PDB: 2N5M). 
 
From the above structural comparisons, despite the high sequence 
similarity between the N4BP1 CUE domain and the KHNYN CUBAN domain, 
the N4BP1 CUE domain is structurally conserved with the members from the 
canonical CUE family. It is particularly highlighted from the conservation of 
the FP motif. Hence, this domain is grouped into the CUE domain family.  
At the middle stage of this project, the research group who solved the 
KHNYN CUBAN domain also published the human N4BP1 CUE structure by 
solution NMR and named it CoCUN (Nepravishta et al., 2019). However, 
despite the 3-helix arrangement, Nepravishta and colleagues claimed that 
CoCUN has a large part of random coils and shares similar protein fold with 
KHNYNCUBAN, which is not in agreement with the finding in this thesis. By 
carefully looking at the NMR procedure, we found that all the assignments of 
the carbon atoms (from both backbone and sidechains) from CoCUN were 
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absent in the chemical shift list. Thus, it is questionable that the CoCUN 
structure provided by this group is accurate. Since the CoCUN structure is not 
deposited in the PDB database, it is difficult to compare the results of this 
work with their structure in more detail. The CoCUN/ubiquitin complex 



























4.2.3.2 The ubiquitin-binding specificity of the N4BP1 CUE 
domain 
In addition to the structural study of the N4BP1 CUE domain, 
investigating the interaction between the N4BP1 CUE domain and ubiquitin 
is another key topic. Thus, the binding studies were performed by multiple 
biophysical approaches including SPR, ITC and NMR titrations in section 
4.2.2.1 and 4.2.2.3.  
Quantitative analysis by SPR shows that the GST-tagged CUE domain 
has high affinity to M1-diUb compared to other types of ubiquitin. However, 
it was later demonstrated that the dimeric GST has an artificial effect on the 
affinity. Thus, the ITC technique was chosen to be an ideal approach which 
allows using the tag-free CUE domain for the characterization. The ITC 
results demonstrate that the N4BP1 CUE domain has lower binding affinity to 
K48-diUb compared to monoUb, M1-diUb and K63-diUb. The affinity of CUE 
to the latter three ubiquitins is comparable to each other. 
To further characterize the ubiquitin-binding mode, NMR titrations were 
performed to locate the perturbed surfaces from both the CUE domain and 
ubiquitin, which allows the below analysis for surface comparison. 
4.2.3.2.1 Perturbed surface comparison – from the CUE domain 
side  
As demonstrated in section 4.2.2.3.1, by mapping the CSPs from NMR 
titrations to the CUE surface, the main perturbed area is within the groove 
between helix α1 and α3. The key residues from this perturbed area was 
compared with those involved in ubiquitin binding from the 





Figure 4.2.62 The comparison between the key perturbed residues of N4BP1 
CUE domain, CUE2-1 domain and gp78 CUE domain. Key residues with strong CSPs 
(>0.15) from N4BP1 CUE domain and residues involved in ubiquitin-binding in CUE2-1 
domain and gp78 CUE domain are highlight as red sticks. The CUE2-1 structure is generated 
by Pymol using PDB: 1OTR. The gp78 CUE domain structure is generated by Pymol using 
PDB: 2LVO. 
 
    From this perspective, it appears that all three CUE domains share a 
similar binding surface for the interaction (Figure 4.2.62). In particular, the 
FP motif is well located in the groove between helix α1 and α3 in each CUE 
domain. For the N4BP1 CUE domain, residues from the N-terminus of helix 
α3 (eg. L884, N885, S888 etc) are likely to be involved in the binding. 
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However, from the N4BP1CUE/ubiquitin docking model from section 4.2.2.4, 
the binding interface of N4BP1CUE is restricted to the FP motif and the last 
residue D893. The other residues with high CSPs are probably affected 
indirectly by secondary effects upon ubiquitin binding.   
4.2.3.2.2 Perturbed surface comparison – from the ubiquitin side 
The CSPs from NMR titrations are also mapped to the surface of 
monoUb and diUb chains respectively. They were also compared with other 
UBD/ubiquitin complexes.  
    1) Comparison of the monoUb surfaces 
For the perturbed surface of monoUb in the CUE:monoUb pair, the most 
perturbed area is the I44 hydrophobic patch with the extended surface 
centred on K48. The importance of K48 for the binding is confirmed by ITC 
measurements in Figure 4.2.41. There is also another less perturbed area next 
to the I44 patch which is not directly involved in the interaction from the 
N4BP1CUE/ubiquitin docking model as shown in section 4.2.2.4. 
The perturbed surface centred on the I44 patch and the K48 extension in 
this study is reminiscent of the binding surface from CUE2-1/ubiquitin 
complex (PDB:1OTR) (Kang et al., 2003). The key residues involved in the 
interaction with CUE2-1 are also highlighted on the ubiquitin surface (Figure 
4.2.63 right). A surface comparison confirmed that the key residues (V70, L71 
etc) from the I44 patch and the K48 extension (G47, K48) are all perturbed 
upon binding in both cases (Figure 4.2.63). However, despite the similarities, 
I44 is not involved in the N4BP1CUE/ubiquitin complex, which results in the 





Figure 4.2.63 The comparison of the perturbed surface of monoUb in 
monoUb/N4BP1CUE and monoUb/CUE2-1. The surface look of monoUb/N4BP1CUE is 
the same as Figure 4.2.20. For monoUb from monoUb/CUE2-1 complex (PDB: 1OTR), the 
key residues involved in the binding were coloured in red by CHIMERA according to Kang et 
al., 2003.  
 
    2) Comparison of the M1-diUb and K63-diUb surfaces  
Mapping the CSPs to the corresponding surfaces of M1- and K63-diUb 
indicates that the same binding mode is shared between CUE/M1-diUb, 
CUE/K63-diUb and CUE/monoUb. Due to the open conformation of both 
M1- and K63-diUb, one molecule of M1- or K63-diUb could adopt two CUE 
molecules at the same time. It is also supported by the ITC results from 
section 4.2.2.1. Thus, the CUE domain does not discriminate between 
monoUb, M1-diUb and K63-diUb.  
The perturbed surfaces of M1- and K63-diUb are further compared with 
several UBDs which display distinct ubiquitin linkage specificity respectively. 
The NEMO CoZi domain has been characterized to specifically bind to 
linear ubiquitin chains. It has a coiled-coil structure and forms a parallel 
dimer to interact with M1-diUb (Rahighi et al., 2009). The two ubiquitin 
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moieties in M1-diUb have divergent binding modes. As shown in Figure4.2.64, 
the distal ubiquitin contacts the CoZi domain via the canonical I44 patch and 
the C-terminal tail. The C-terminal tail is part of the M1-linkage region, 
demonstrating the ability from the CoZi domain to recognize this linkage. In 
contrast to the distal ubiquitin, the I44 patch from the proximal ubiquitin is 
not involved in the interaction. Instead, residues that are located next to this 
I44 patch are employed for the binding. From an overall view, the structure of 
M1-diUb from this complex appears twisted along the linkage region 
compared to the crystal structure of the apo M1-diUb, indicating a high 
degree of rotational flexibility for the ubiquitin chains with M1-linkage. 
In comparison, the perturbed surface of M1-diUb upon binding to the 
N4BP1 CUE domain is different (Figure 4.2.64). First of all, the perturbed 
surfaces from the two ubiquitin moieties are almost identical in 
M1-diUb/N4BP1CUE. Key residues from the I44 patch involved in the 
interactions for both cases are different. Residue L8, I44 and L73 are not 
strongly perturbed in M1-diUb/N4BP1CUE but crucial to M1-diUb/NEMOCoZi. 
Besides, the ubiquitin K48 extended surface is employed by 
M1-diUb/N4BP1CUE, but not in M1-diUb/NEMOCoZi. Although the rotational 
flexibility of M1-diUb is not considered in the binding study with the N4BP1 
CUE domain here, the binding modes between M1-diUb/N4BP1CUE and 




Figure 4.2.64 The comparison between the perturbed surface of M1-diUb from 
M1-diUb/N4BP1CUE and the binding surface of M1-diUb from M1-diUb/NEMOCoZi. 
A. The cartoon view of respective M1-diUb chains. B. The surface view of respective M1-diUb 
chains. The distal ubiquitins from the two structures are placed in the same position for a 
better comparison. The key perturbed residues (CSP>0.15) on the M1-diUb surface (PDB: 
2W9N) upon binding to the N4BP1 CUE domain were highlighted in salmon by Pymol 
according to the 3X CSP list. The M1-diUb surface from M1-diUb/NEMOCoZi (PDB: 2ZVO) 
was generated by Pymol and the key residues involved in the binding were highlighted in 
salmon. UbP: proximal Ub; UbD: distal Ub. 
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As exemplified in section 1.1.3.2, the UIM domains from RAP80 and the 
NZF domain from TAB2 both show specificity to K63-diUb chains. When it 
comes to the comparison with K63-diUb/N4BP1CUE, from a general view, the 
I44 patches from the two ubiquitin moieties in all the three complexes are 
both involved in the binding (Figure 4.2.65). K63-diUb displays various 
conformations in complex with different UBDs due to that K63-diUb has a 
more flexible lysine-linked isopeptide bond, thus, the rotational flexibility of 
K63-diUb is higher than the M1 linkage. 
In the case of the interaction between RAP80UIM and K63-diUb, the 
proximal ubiquitin interacts with UIM1 while the distal ubiquitin interacts 
with UIM2. This “one UIM to one Ub” mode seems similar to “one CUE to one 
Ub”. However, UIM1 and UIM2 are tandemly linked via the inter UIM 
domain in RAP80 to form a continuous α-helix whereas each N4BP1 molecule 
only contains one CUE domain. Thus, the binding stoichiometry is different. 
On the other hand, the K48 extended surface is not involved in 
K63-diUb/RAP80UIM. Most important of all, the binding specificity of RAP80 
comes from the certain length of the inter UIM domain which places the two 
UIM domains in the most ideal positions to bind to both ubiquitin moieties 
simultaneously. While on the contrary, the N4BP1 CUE domain does not 
show binding specificity to K63-diUb.   
As for the K63-diUb/TABNZF complex, one NZF domain binds to both I44 
patches in K63-diUb. This specificity highlights the main difference from 





Figure 4.2.65 The comparison between the perturbed surface of K63-diUb from 
K63-diUb/N4BP1CUE and the binding surface of K63-diUb from 
K63-diUb/RAP80UIM and K63-diUb/TABNZF respectively. A. The cartoon view of 
respective K63-diUb chains. B. The surface view of respective K63-diUb chains. The distal 
ubiquitins from the three structures are placed in the same position for a better comparison. 
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The key perturbed residues (CSP>0.15) on the K63-diUb surface (PDB: 3H7P) upon binding 
to the N4BP1 CUE domain were highlighted in limegreen by Pymol according to the 3X CSP 
list. The K63-diUb surfaces from K63-diUb/RAP80UIM (PDB: 3A1Q) and K63-diUb/TABNZF 
(PDB: 2WWZ) were generated by Pymol respectively. The key residues involved in the 
binding were highlighted in limegreen. UbP: proximal Ub; UbD: distal Ub. 
 
    3) Comparison of the K48-diUb surfaces 
In section 4.2.2.3.2, the CSP patterns of K48-diUb binding to the CUE 
domain is similar to the other titration pairs, but with lower intensity. 
Considering the compact conformation of K48-diUb, it has been 
demonstrated that K48-diUb has less accessibility to interact with the N4BP1 
CUE domain via the canonical monoUb surface.  
The binding surface of K48-diUb in the K48-diUb/HHR23AUBA complex 
is shown in Figure 4.2.66B for the comparison with K48-diUb/N4BP1CUE. In 
the K48-diUb/HHR23AUBA complex, the I44 patch in the proximal ubiquitin 
is employed for the binding, which centred on the residue I44. In contrast, the 
CSPs of I44 in both ubiquitin moieties of K48-diUb are at a much lower level 
upon binding to the N4BP1 CUE domain. Residue K48 and L73 from the 
distal ubiquitin are crucial for the binding to HHR23AUBA, however they are 
less involved in the interaction with the CUE domain.  
Although the binding stoichiometries of K48-diUb/HHR23AUBA and 
K48-diUb/N4BP1CUE both indicate a 1:1 ratio, HHR23AUBA shows the high 
specificity to recognize K48-diUb, while the N4BP1 CUE domain is not in 
favour of binding to K48-diUb compared to monoUb, M1-diUb or K63-diUb 





Figure 4.2.66 The comparison between the perturbed surface of K48-diUb from 
K48-diUb/N4BP1CUE (A) and the binding surface of K48-diUb from 
K48-diUb/HHR23AUBA2 (B). The CSPs of K48-diUb upon binding to the N4BP1 CUE 
domain were mapped to the K48-diUb structure (PDB:1ZO6) by CHIMERA. The molar ratio 
between K48-diUb and the CUE domain used here is 3:1 (3X). The K48-diUb surface from 
K48-diUb/HHR23AUBA2 (PDB: 1ZO6) was generated by CHIMERA where the key residues 
involved in the binding were highlighted in red. Both structures are positioned to the best 





4.2.3.2.3 Comparison of the N4BP1CUE/ubiquitin complex with 
other complexes 
In section 4.2.2.4, based on the CSPs from NMR titration, the complex 
model between the N4BP1 CUE domain and monoUb was generated. The 
complex model highlights the hydrophobic interaction between the CUE FP 
motif and ubiquitin I44 patch, as well as the polar interaction between CUE 
D893 and ubiquitin K48.  
This complex model is also compared with another two CUE/ubiquitin 
complexes (Figure 4.2.67). From an overall view, the orientation of the N4BP1 
CUE domain is rotated ~ 90° compared to the CUE domains positioned in the 
other two complexes. Although the ubiquitin I44 hydrophobic patch is 
involved in the interface in all the three complexes, the CUE domains from 
both CUE2-1 and gp78 directly contact residue I44 from ubiquitin while the 
different CUE orientation in the N4BP1CUE/ubiquitin complex does not 
employ I44 for the interaction.  
It is worth noticing that ubiquitin K48 binds to both CUE domains via 
polar interaction in the N4BP1CUE/ubiquitin complex and the 
CUE2-1/ubiquitin complex. Structural study reveals that residue D51 from 
CUE2-1 interacts with ubiquitin K48 in the complex. It was proposed that 
CUE2-1 may play an inhibitory role in the formation of K48-linked ubiquitin 
chains (Kang et al., 2003). On the contrary, ubiquitin K48 is not involved in 






Figure 4.2.67 Comparison of three CUE domains in complex with monoUb. 
Ubiquitin from each complex is placed in the same position for a better comparison. Key 
residues involved in the interaction are coloured in red. The CUE domain is coloured in green 
while ubiquitin is coloured in cyan. Figures were generated by Pymol using the docking 
model for the N4BP1CUE/ubiquitin complex, PDB: 1OTR (CUE2-1/ubiquitin complex) and 
PDB: 2LVO (gp78CUE/ubiquitin complex). 
 
The model of the N4BP1 CUE domain in complex with monoUb is also 
superimposed onto the structures of M1-diUb, K63-diUb and K48-diUb 
respectively. As shown in Figure 4.2.68, two molecules of CUE could 
simultaneously bind to the two ubiquitin moieties from either M1-diUb or 
K63-diUb. This is also in accordance with the 2:1 ratio of CUE:M1-diUb or 
CUE:K63-diUb observed from the ITC studies. However, in the case of 
K48-diUb, the steric obstruction allows only one CUE molecule to be adopted. 
As suggested in Figure 4.2.68, if the N4BP1CUE/ubiquitin model was 
superimposed onto the proximal ubiquitin of K48-diUb, the key residues K48, 
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V70 and L71 from the distal ubiquitin are facing to the CUE domain. 
Therefore, there is not enough space to adopt another CUE molecule. This 
model also supports the 1:1 ratio of CUE:K48-diUb measured by ITC.   
 
Figure 4.2.68 Structure models of the N4BP1 CUE domain interacting with 
different types of di-ubiquitin chains. Key residues involved in the interaction are 
indicated in red. The N4BP1 CUE domain is coloured in green while di-ubiquitin chains are 
coloured in cyan. UbP: proximal Ub; UbD: distal Ub. Figures were generated by 
superimposing the N4BP1CUE/ubiquitin complex model to M1-diUb (PDB: 2W9N), K63-diUb 
(PDB: 3H7P) and K48-diUb (PDB:1ZO6) respectively.  
 
As mentioned in section 4.2.3.1, the structure of human N4BP1 CUE 
domain (the CoCUN domain) has been solved by solution NMR by another 
research group. The CoCUN/ubiquitin complex structure is also present from 
the same study (Nepravishta et al., 2019), but again absent in the PDB 
database. According to their descriptions, several conflicts were found in 




First of all, ubiquitin I44 lacks a measurable CSP from the 
CoCUN/ubiquitin complex, which is in line with the observation from this 
work. However, this complex still shows that ubiquitin I44 is involved in the 
interaction with CoCUN based on the observation where ubiquitin I44A 
mutant abolished the interaction.  
In contrast to the structural findings of this work, the valine and leucine 
residues at the end of helix α3 in CoCUN did not show any CSPs. The 
C-terminal tail of CoCUN is not involved in the interaction according to the 
CoCUN/ubiquitin complex, while in the N4BP1CUE/ubiquitin complex 
presented in this thesis, the C-terminal tail of N4BP1CUE forms polar 
interaction with residue K48 from ubiquitin. Strong CSPs of the key residues 
were observed from both N4BP1CUE and ubiquitin. This is also supported by 
the ITC data using the K48 mutants.  
In addition, ubiquitin K48 also has strong perturbation according to the 
CSP data for the interaction between CoCUN and ubiquitin. However, 
Nepravishta and colleagues did not consider or include it in their 
CoCUN/ubiquitin complex. Due to that the structure of CoCUN/ubiquitin is 
not deposited in the PDB database, superimposing this complex to different 
diUbs cannot be achieved. Nevertheless, the CoCUN/ubiquitin complex could 
not explain the ability that N4BP1CUE distinguishes K48-diUb from other 
types of ubiquitin. 
In all, considering the inaccuracy of the CoCUN structure, it is also 










4.2.3.3 Structural model of dimer-induced specificity of 
N4BP1 for linear ubiquitin chains 
In section 4.2.2.1 and 4.2.2.3, the ubiquitin-binding properties of the 
N4BP1 CUE domain were investigated while in section 4.2.2.5, the 
ubiquitin-binding properties of the N4BP1 construct containing both the 
RNAse domain and the CUE domain were studied. A summary of the Kd 
values collected from this while chapter is shown in Figure 4.2.69.  
 
Figure 4.2.69 The summary of the Kd values from this study. The Kd value is 
indicated above each bar. The data are colour-coded according to the protein used for the 
interaction (The data of GST-CUE are coloured in orange while CUE in sky blue and 





The N4BP1 CUE domain could only distinguish K48-diUb from monoUb, 
M1-diUb and K63-diUb. The affinity of the CUE domain to monoUb, M1-diUb 
and K63-diUb are comparable. The RNAseCUE construct (including both the 
RNAse domain and the CUE domain) displays higher affinity to M1-diUb 
compared to monoUb, K48-diUb and K63-diUb. The tight binding between 
RNAseCUE and M1-diUb is further confirmed by ITC. However, the N4BP1 
RNAse domain does not interact with ubiquitin under the experimental 
condition used here, which makes the CUE domain as the sole 
ubiquitin-binding module in the N4BP1 C-terminus. This suggests that the 
RNAse domain has an indirect role in mediating ubiquitin binding via the 
CUE domain. Further investigation by analytical sec-exclusion 
chromatography demonstrated that the RNAse domain forms oligomers 
(including dimer and tetramer). 
Based on the above experimental evidence, a structural model of 
dimer-induced specificity of N4BP1 for linear ubiquitin chains is proposed in 
this section. 
The structure prediction of the whole C-terminal N4BP1 construct 
RNAseCUE was performed by trRosetta. The secondary structure of the linker 
region (775-849) between the RNAse domain and the CUE domain was 
predicted by Phyre2. As seen from Figure 4.2.70, the trRosetta prediction 
provided five top models and the straight-line length of this linker is within a 
range of 40-60 Å. The linker between the RNAse domain and the CUE 
domain is only partially structured and indicates high flexibility. Phyre2 could 
not find the structure template with confidence > 5% for this linker. 
Superimposing the RNAse domains from all the 5 models together indicates 
that the movement of the CUE domain is very flexible within a large range of 




Figure 4.2.70 Superimposition of the five top models of the N4BP1 C-terminus 
(RNAseCUE) (A) and secondary structure prediction of the linker region (B). 
The models were predicted by trRosetta. The RNAse domains from the five models were 
superimposed and coloured in green. The five CUE domains are coloured in yellow. The 
RNAse domain and the CUE domain are shown in the surface mode, while the five flexible 
linkers are shown in cartoon. The grey dashed lines indicate the straight-line distance 
(ranging from 40 to 60 Å) between the RNAse domain and the CUE domain. The secondary 
structure prediction of the linker region (775-849) was performed by Phyre2. Figure 




The predicted CUE domain is highly similar to the CUE structure model 
described in section 4.2.1.2.5 (RMSD=0.895, see the discussion in section 
4.2.3.1), which allows the superimposition of the N4BP1CUE/ubiquitin docking 
model to the predicted RNAseCUE structure (The top model 1 of RNAseCUE 
was used here, Figure 4.2.71A). Furthermore, as mentioned in section 
4.2.2.5.4, the oligomerization of the RNAse domain was proposed to be able 
to bring several CUE domains in close distance. Since the crystal structure of 
the MCPIP1 RNAse head-to-tail dimer is available (PDB: 5H9V), an N4BP1 
RNAseCUE head-to-tail dimer model was generated based on this crystal 
structure (Figure 4.2.71B). Then the M1-diUb/N4BP1CUE model from Figure 
4.2.68 was superimposed onto the CUE domain of this dimer model. The top 
model 1 of RNAseCUE was used as one of the protomers. For another 
protomer, the distance between the CUE N-terminus and the RNAse 
C-terminus was estimated at ~ 60 Å by Pymol. This could be possibly 
achieved by one of the models as presented in Figure 4.2.70. 
The above model only considers the RNAse dimer for the binding. 
However, the RNAse or the RNAseCUE also displays tetrameric states as 
demonstrated in section 4.2.2.5.4. In theory, this effect could increase the 
chance for the N4BP1 CUE domain binding to longer linear ubiquitin chains. 





Figure 4.2.71 Working models of the N4BP1 C-terminal construct (RNAseCUE) 
interacting with ubiquitin. A. Superimposition of the top model 1 of the N4BP1 
C-terminus with the N4BP1CUE/ubiquitin docking model. B. The RNAseCUE dimer model. 
The top model 1 of the N4BP1 C-terminus was used as one of the protomers on the left. The 
grey dashed lines indicate the straight-line distance between the RNAse domain and the CUE 
domain in another RNAseCUE protomer. MonoUb and M1-diUb are shown in the surface 
mode. The schematic representation of the structure model is shown on the right of each 
figure. The top model 1 of the N4BP1 C-terminus was predicted by trRosetta. Figure 
generated by Pymol.  
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In this section, a working model of the interaction between the dimeric 
C-terminal N4BP1 and linear ubiquitin chains was discussed. This model 
describes a novel ubiquitin-binding mode which helps explain the high 
affinity of the interaction from two aspects (Figure 4.2.72): 
1) As a general UBD, the CUE domain binds to ubiquitin in a moderate 
affinity. It could only discriminate K48-linked ubiquitin chains from monoUb, 
M1- and K63-linked chains; 
2) The RNAse domains could form head-to-tail oligomers to increase the 
local concentration of the C-terminal CUE domains and possibly re-organise 
the CUE domains in an ideal spatial arrangement, hence increasing the 
affinity to interact with the longer linear ubiquitin chains.  
 
Figure 4.2.72 Schematic representation of the monomeric, dimeric and 










4.2.3.4 N4BP1/MCPIP1/KHNYN comparison  
As introduced in Chapter I, the RNAse domains of N4BP1, KHNYN and 
MCPIP family member MCPIP3 are grouped close together based on a 
phylogenetic study (Anantharaman and Aravind, 2006; Figure 1.27).  
In Chapter 4.1, it has been shown that the top template of the predicted 
N4BP1 UBA-like domain by Phyre2 was the NTD domain from MCPIP1 
(Figure 4.1.8 and 4.1.9). From the study in Chapter 4.2, the structure 
comparison by DALI server found that the N4BP1 CUE domain is similar to 
the NCPIP1 CTD domain (Figure 4.2.57). In addition, although the N4BP1 
CUE domain and the KHNYN CUBAN domain share high sequence similarity 
by a Phyre2 search, the structures of the two domains are proved to be 
different (Figure 4.2.61). In addition, N4BP1 RNAse domain shares high 
sequence similarity to the MCPIP1 RNAse domain (Figure 4.2.45). The 
RNAse activity from both domains has been experimentally confirmed 
(Matsushita et al., 2009; Xu et al., 2012; Yamasoba et al., 2019; Yokogawa et 
al., 2016).  
Therefore, a careful domain comparison between the 3 proteins was 
conducted and displayed in Figure 4.2.73. The full-length sequence 
alignments are summarized in Appendix III. Interestingly, apart from the 
high similarity between N4BP1 and MCPIP1 from the above findings, the 
sequence alignments also indicate that N4BP1 and KHNYN are very similar to 
each other except that the UBA-like domain is absent in KHNYN. The RNAse 




Figure 4.2.73 Domain comparison between MCPIP1, N4BP1 and KHNYN. CTD: 
C-terminal domain. CUBAN: Cullin-binding domain associating with NEDD8. KH: K 
Homology domain. NTD: N-terminal domain. Pro: Proline-rich domain. UBA: Ubiquitin 
association domain. UBM: Ubiquitin binding motif. ZF: CCCH-type zinc-finger motif.  
 
There are several functional studies of MCPIP1 as summarized in section 
1.4.3, which revealed the negative roles of MCPIP1 in regulating NFκB 
activation. The study of KHNYN is limited. The interaction between KHNYN 
CUBAN and NEDD8 suggests a role of KHNYN in regulating the E3 ligase 
activity of CRLs. The functional study of N4BP1 is mainly centred on its 
RNAse activity in degrading virus RNA. Until recently, N4BP1 is identified as 
a novel linear ubiquitin receptor and negatively regulates the TNFR signaling 
pathway from the cell biological studies by the research group of Koraljka 
Husnjak.  
These sequence and structure similarities between the three proteins 
could possibly offer some new perspectives to study the function of each 
protein. For example, the structure of each domain from MCPIP1 is available, 
which is helpful for the structure investigation of N4BP1 and KHNYN. The 
function of MCPIP1 and N4BP1 in negatively regulating inflammatory 
signaling could also possibly provide some new directions to study the 




























In this thesis, two functions of N4BP1, inhibition of LUBAC and ubiquitin 
binding have been investigated. 
In Chapter 4.1, the N-terminus of N4BP1 was identified as the inhibitory 
module. Based on the observation from in vitro ubiquitin assays, the 
UBA-like domain strongly inhibits the E3 ligase activity of HOIP, while the 
KH-like domain displays a much weaker inhibitory effect. Pull-down assays 
have demonstrated that the HOIP binding region from N4BP1 covers the 
UBM-like domain and it is important to modulate the inhibition. In all, the 
three domains from the N4BP1 N-terminus cooperate as a single functional 
module to achieve optimal inhibition of HOIP.  
Chapter 4.2 are focused on the linear ubiquitin-binding specificity of 
N4BP1. The NMR structure of the CUE domain was solved in section 4.2.2.2. 
Although sequence analysis implies that the N4BP1 CUE domain shares high 
sequence similarity with the CUBAN domain from KHNYN, however, the 
CUE domain adopts a conserved protein fold shared with other canonical 
CUE domains. The FP motif from the N4BP1 CUE domain is also conserved 
among the CUE domain family and plays a key role in the interaction with 
ubiquitin.  
In section 4.2.2.1, the ubiquitin-binding properties of the CUE domain 
were quantitively characterized by SPR and ITC. SPR measurements have 
shown that the GST-tagged CUE domain prefers binding to M1-diUb 
compared to monoUb, K63- and K48-diUb. However, the ITC measurements 
using the tag-free CUE domain demonstrated that the CUE domain only has a 
lower affinity to K48-diUb, while its affinity to monoUb, M1-diUb and 
K63-diUb is similar. Additional SEC-MALLS analysis indicated that the 
GST-tagged CUE domain is in the dimer form due to the dimerization of the 
GST tag. The GST dimer brings the two CUE molecules in close proximity, 
thus artificially increasing the affinity to M1-diUb.  
To identify the perturbed surfaces from both the CUE domain and 
ubiquitin in the interaction, a series of NMR titrations were performed in 
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section 4.2.2.3. The main perturbed surface of the CUE domain consists of a 
groove between helix α1 and α3, where the conserved FP motif is located. 
From an overall view, the CSP patterns of the CUE domain in different 
CUE:ubiquitin pairs are similar, indicating that the CUE domain deploys a 
conserved binding mode to interact with monoUb or diUb chains. The CSP 
patterns of different ubiquitin chains are also correlated with the 
corresponding surfaces. The perturbed surface of monoUb upon binding to 
the CUE domain highlights the key involvement of the I44 hydrophobic patch 
and the K48 extended surface in the interaction. The distal and proximal 
ubiquitin moieties from M1- and K63-diUb also have similar CSP patterns to 
monoUb. As M1- and K63-diUb both adopt an open conformation, it allows 
the I44 patch as well as the K48 extension from both proximal and distal 
ubiquitin moieties well exposed to the solvent. Therefore, two CUE domain 
molecules form the same independent interface with the two ubiquitin 
moieties as observed for the monoUb. In the case of K48-diUb, the I44 patch 
and the K48 extended surface from both proximal and distal ubiquitin were 
much less perturbed, which is in line with the lower affinity observed between 
CUE and K48-diUb by ITC. Notably, one of the K48 residues from the two 
ubiquitin moieties in K48-diUb is occupied to form the K48 linkage, thus the 
K48 extended surface in the proximal ubiquitin is not accessible to the CUE 
domain, suggesting that only one CUE molecule could interact with one 
K48-diUb molecule. This is in agreement with the 1:1 stoichiometry between 
the CUE domain and K48-diUb observed from ITC. In all, the study in section 
4.2.2.3 demonstrates that the CUE domain discriminates against K48-diUb 
interaction, while binding to M1-, K63- and monoUb is in a nonselective 
fashion.  
In section 4.2.2.4, a docking model for the interaction between the CUE 
domain and monoUb was presented. The FP motif of the CUE domain 
interacts with part of the ubiquitin I44 patch (V70 and L71) while I44 is not 
involved. Residue D893 in the C-terminal tail of the CUE domain forms polar 
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interaction with residue K48 from ubiquitin. These two binding properties 
place the CUE molecule onto the ubiquitin surface in a different orientation 
compared to the other canonical CUE/ubiquitin complexes. Superimposing 
this model to the structure of M1- or K63-diUb indicates that two CUE 
molecules could well bind to the two ubiquitin moieties at the same time. 
While on the contrary, K48-diUb could only adopt one CUE molecule 
following this model. Again, this is in agreement with the stoichiometry from 
the experimental evidence by ITC.  
In section 4.2.2.5, the involvement of the RNAse domain in the ubiquitin 
binding was investigated. The N4BP1 C-terminal construct RNAseCUE 
(containing both the RNAse domain and the CUE domain) displays high 
affinity to M1-diUb by both SPR and ITC studies. Interestingly, the RNAse 
domain doesn’t interact with ubiquitin, suggesting its indirect role in 
mediating ubiquitin binding while the CUE domain is the sole 
ubiquitin-binding domain in the N4BP1 C-terminus. Similar to its 
homologous RNAse domain in MCPIP1, the analytical size-exclusion 
chromatography demonstrated that the N4BP1 RNAse domain also forms 
oligomers (including dimers and tetramers). Based on the evidence, a 
structural model was proposed in section 4.2.3.3 to illustrate the 
dimer-induced specificity of N4BP1 for linear ubiquitin chains. In this model, 
the dimerization of the RNAse domain brings two CUE molecules in close 
vicinity, thus the local concentration of the N4BP1 C-terminus is increased, 
which facilitates the binding to linear diUb chains. This suggests that 
oligomerization of the RNAse domain could induce appropriate structural 
arrangements of N4BP1 to facilitate recognition for linear ubiquitin chains. 
This is further supported by the ITC study where the RNAseCUE construct 
displays higher affinity to M1-tetraUb than M1-diUb. 
Taken together, the two modules from N4BP1 facilitate its negative 
regulation of LUBAC activity in TNFR signaling. On one hand, the N-terminal 
N4BP1 inhibits the E3 ligase activity of LUBAC, which results in the reduced 
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synthesis of linear ubiquitin chains (Figure 5.1 ①). On the other hand, the 
C-terminal N4BP1 might competitively bind to linear ubiquitin chains, 
thereby prevents the linear ubiquitination to the substrates catalyzed by 
LUBAC (Figure 5.1 ②). In addition, the N4BP1 C-terminus could also 
compete with other key modulators (eg. NEMO) in the TNFR signaling for 
binding to linear ubiquitin chains, thus disrupting the downstream substrate 
recruitments in this signaling pathway (Figure 5.1 ③). All these effects impair 
the TNFR signaling mediated by linear ubiquitin chains.   
The study in this thesis provides a wider understanding of the negative 
regulatory roles of N4BP1 in TNFR signaling from a biochemical and 
structural perspectives. It will be interesting to investigate how the three 
domains from N4BP1 N-terminus cooperate to inhibit HOIP. Structural 
approaches which elucidate the complex of N4BP1 with HOIP will ultimately 
shed light on the molecular basis for the function of N4BP1.  
Furthermore, it will be important to solve the structure of the dimeric or 
oligomeric form of N4BP1 in complex with linear ubiquitin chains to confirm 
the model proposed in this thesis. The N4BP1 RNAse domain is homologous 
to the RNAse domain in MCPIP1. Although the crystal structure of the 
dimeric MCPIP1 RNAse domain has been solved, it is challenging to express 
the N4BP1 RNAse domain for structural studies using the 
prokaryotic expression system. Therefore, the expression of this domain 
requires appropriate optimization in the future. Eukaryotic expression 
systems using mammalian or insect cells might be helpful to produce the 










Figure 5.1 Schematic representation of the modulation by N4BP1 in the TNFR 
signaling. Key components regulated by N4BP1 are highlighted while others are shaded. ①: 
The inhibition of the E3 ligase activity of LUBAC by the N4BP1 N-terminus. ②: The N4BP1 
C-terminus prevents the linear ubiquitination to the substrates catalyzed by LUBAC. ③: The 
N4BP1 C-terminus competes with key modulators such as NEMO in the TNFR signaling for 
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Appendix I  
Full chemical shift assignment list of 
the N4BP1 CUE domain 
 
Residue  Atom Chemical  
SD 
No. Name Name Shift 
850 Glu H 8.09629 0.00549 
850 Glu N 120.31422 0.06579 
850 Glu Cβ 30.23615 0.02078 
850 Glu Cα 57.04142 0.10474 
850 Glu C 177.39061 0.02378 
850 Glu Hα 4.44084 0.00267 
850 Glu Hβa 2.11863 0.00113 
850 Glu Hβb 2.18288 0.00278 
850 Glu Cγ 36.82023 0 
850 Glu Hγa 2.33323 0.00146 
850 Glu Hγb 2.33323 0.00146 
851 Thr H 8.26442 0.00583 
851 Thr N 115.12059 0.02795 
851 Thr C 174.99923 0.02699 
851 Thr Cα 63.3913 0.0411 
851 Thr Cβ 69.32607 0.07823 
851 Thr Hα 4.31951 5.53E-04 
851 Thr Hβ 4.29038 4.67E-04 
852 Ser N 117.20887 0.04914 
852 Ser H 8.33714 0.00703 
852 Ser Cα 59.93276 0.04293 
852 Ser Cβ 63.21361 0.08294 
852 Ser C 175.59769 0 
852 Ser Hα 4.42433 0.00515 
852 Ser Hβb 4.05257 0.01025 
852 Ser Hβa 3.97813 0.00438 
853 Glu H 8.37014 0.00542 
853 Glu N 123.128 0.07468 
853 Glu Cα 58.83371 0.07559 
853 Glu Cβ 29.83386 0.06249 
853 Glu C 178.74942 0.01861 
853 Glu Hα 4.21881 0.00378 
853 Glu Hβa 2.13675 0.00277 
853 Glu Hβb 2.13687 0.00292 
853 Glu Hγb 2.40338 0.0015 
     
Residue  Atom Chemical  
SD 
No. Name Name Shift 
853 Glu Hγa 2.33514 0.00515 
853 Glu Cγ 36.64704 0 
854 Leu H 7.98784 0.00392 
854 Leu N 121.61625 0.0461 
854 Leu Cα 57.4809 0.03315 
854 Leu Cβ 42.21615 0.02716 
854 Leu C 177.94657 0.06515 
854 Leu Hα 4.18322 0.00376 
854 Leu Hβb 1.80022 0.00497 
854 Leu Hβa 1.51728 0.01133 
854 Leu Cδb 24.89424 3.37E-07 
854 Leu Cδa 24.15242 0 
854 Leu Cγ 26.85965 4.77E-07 
854 Leu Hγ 1.68187 0.00727 
854 Leu Hδa* 0.87789 0.00223 
854 Leu Hδb* 0.92233 0.00277 
855 Arg H 8.12983 0.00553 
855 Arg N 119.05411 0.05761 
855 Arg Cβ 30.14622 0.00891 
855 Arg Cα 60.23006 0.10028 
855 Arg C 177.61017 0.01239 
855 Arg Hα 3.80196 0.00313 
855 Arg Hβb 1.95359 0.00227 
855 Arg Hβa 1.81888 0.00183 
855 Arg Cγ 27.95641 3.37E-07 
855 Arg Hγb 1.59034 0.00228 
855 Arg Hγa 1.48044 0.00175 
855 Arg Cδ 43.54572 4.77E-07 
855 Arg Hδb 3.29597 0.00135 
855 Arg Hδa 3.16435 0.00234 
856 Glu H 7.97112 0.00464 
856 Glu N 116.21697 0.06065 
856 Glu Cα 59.14594 0.05624 
856 Glu Cβ 29.50653 0.09037 
856 Glu C 178.79195 0.0246 
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Residue  Atom Chemical  
SD 
No. Name Name Shift 
856 Glu Hα 3.99803 0.00169 
856 Glu Hβb 2.10851 0.00185 
856 Glu Hβa 2.1084 0.00177 
856 Glu Cγ 36.2916 4.77E-07 
856 Glu Hγb 2.41173 0.00155 
856 Glu Hγa 2.38281 8.50E-04 
857 Ala H 7.80064 0.00184 
857 Ala N 121.094 0.05281 
857 Ala Cα 54.9543 0.02988 
857 Ala Cβ 18.7895 0.05326 
857 Ala C 180.704 0.03011 
857 Ala Hα 4.16664 0.00158 
857 Ala Hβ* 1.57795 0.0027 
858 Leu H 8.20107 0.00522 
858 Leu N 118.795 0.01867 
858 Leu Cα 57.7554 0.05957 
858 Leu Cβ 42.6221 0.01129 
858 Leu C 178.644 0.01153 
858 Leu Hα 4.18868 0.0045 
858 Leu Hβb 2.0874 0.00503 
858 Leu Hβa 1.53785 0.00242 
858 Leu Cγ 26.8942 0 
858 Leu Hγ 1.90272 0.00766 
858 Leu Cδb 24.0427 0 
858 Leu Hδb* 0.98716 0.00208 
858 Leu Cδa 26.6646 0 
858 Leu Hδa* 0.92698 0.00306 
859 Leu H 8.26439 0.00851 
859 Leu N 119.22 0.05008 
859 Leu Cβ 41.8063 0.03857 
859 Leu Cα 56.7925 0.1639 
859 Leu C 178.638 0.00234 
859 Leu Hα 4.15521 0.00241 
859 Leu Hβb 1.88375 0.0071 
859 Leu Hβa 1.52466 0.00641 
859 Leu Cδb 23.1468 0 
859 Leu Hδb* 0.94597 9.55E-04 
859 Leu Cδa 25.6006 0 
859 Leu Hδa* 0.91052 0.00201 
860 Lys H 7.29934 0.00352 
860 Lys N 116.238 0.05614 
860 Lys Cα 57.9332 0.08189 
Residue  Atom Chemical  
SD 
No. Name Name Shift 
860 Lys Cβ 32.7757 6.74E-07 
860 Lys C 177.84 0.00576 
860 Lys Hα 4.12328 0.00356 
860 Lys Hβb 1.91612 0.00388 
860 Lys Hβa 1.91539 0.00356 
860 Lys Cγ 25.2764 3.37E-07 
860 Lys Hγb 1.64656 0.00149 
860 Lys Hγa 1.47579 0.00481 
860 Lys Cδ 28.8931 4.77E-07 
860 Lys Hδa 1.72046 0.00353 
860 Lys Hδb 1.72046 0.00353 
860 Lys Cε 42.2128 0.00824 
860 Lys Hεa 3.03621 0.00285 
860 Lys Hεb 3.03621 0.00285 
861 Ile H 7.20144 0.00294 
861 Ile N 117.623 0.02096 
861 Ile Cα 62.9815 0.05552 
861 Ile Cβ 39.0492 0.02049 
861 Ile C 175.432 0.00203 
861 Ile Hα 3.8023 0.00587 
861 Ile Hβ 1.59729 0.00222 
861 Ile Hγ1b 1.49252 0.00208 
861 Ile Cγ1 27.5811 0.00346 
861 Ile Hγ1a 1.00397 0.00327 
861 Ile Cγ2 17.2953 0.01505 
861 Ile Hγ2* 0.27291 0.00235 
861 Ile Cδ1 13.5253 0.02146 
861 Ile Hδ1* 0.76578 0.00239 
862 Phe H 7.86912 0.00712 
862 Phe N 119.783 0.0612 
862 Phe Cα 55.2044 0.01902 
862 Phe Cβ 39.1369 0 
862 Phe C 172.737 0 
862 Phe Hα 5.05266 0.00132 
862 Phe Hβb 3.01858 0 
862 Phe Hβa 2.98603 0.00418 
863 Pro Hα 4.68758 0.00428 
863 Pro Hβb 2.27898 0.00357 
863 Pro Hβa 2.08149 0.00395 
863 Pro C 177.901 0 
863 Pro Cα 63.676 0.10253 
863 Pro Cβ 32.9096 4.77E-07 
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Residue  Atom Chemical  
SD 
No. Name Name Shift 
863 Pro Cγ 26.3509 3.37E-07 
863 Pro Hγa 1.98092 0.00175 
863 Pro Hγb 1.98097 0.00158 
863 Pro Cδ 50.1881 0.01452 
863 Pro Hδb 3.75909 0.0025 
863 Pro Hδa 3.49974 0.00103 
864 Asp H 8.16817 0.00364 
864 Asp N 120.531 0.06676 
864 Asp Cβ 42.1296 0.06683 
864 Asp Cα 54.7433 0.03448 
864 Asp C 177.907 0 
864 Asp Hα 4.73769 0.00132 
864 Asp Hβb 2.87327 0.00346 
864 Asp Hβa 2.78036 0.00461 
865 Ser Hα 4.2059 0.00501 
865 Ser Hβa 4.02295 0.00472 
865 Ser Hβb 4.02295 0.00472 
865 Ser C 176.299 0 
865 Ser Cα 61.8636 0 
865 Ser Cβ 63.4852 0 
866 Glu H 8.86338 0.01399 
866 Glu N 121.114 0.0386 
866 Glu Cβ 29.2864 0.18082 
866 Glu C 178.499 0.01258 
866 Glu Cα 58.9041 0.05924 
866 Glu Hα 4.20821 0 
866 Glu Hβa 2.11296 0 
866 Glu Hβb 2.11296 0 
867 Gln H 7.76158 0.00409 
867 Gln N 117.75 0.05862 
867 Gln Cα 57.4756 0.15808 
867 Gln Cβ 28.4956 0.06969 
867 Gln C 176.949 0.02566 
867 Gln Hα 4.21834 0.00147 
867 Gln Hβb 2.24256 0.0032 
867 Gln Hβa 1.94189 0.0031 
867 Gln Cγ 34.4686 4.77E-07 
867 Gln Hγb 2.41192 0.00198 
867 Gln Hγa 2.33079 0.00239 
868 Lys H 7.7575 0.00587 
868 Lys N 120.152 0.02388 
868 Lys Cα 59.9546 0.09999 
Residue  Atom Chemical  
SD 
No. Name Name Shift 
868 Lys Cβ 32.4403 0.0472 
868 Lys C 177.807 0.042 
868 Lys Hα 3.94321 0.00247 
868 Lys Hβa 1.91229 0.00222 
868 Lys Hβb 1.9535 0.0025 
868 Lys Cγ 25.2764 3.37E-07 
868 Lys Hγa 1.46519 0.00542 
868 Lys Hγb 1.55405 0.0064 
868 Lys Cδ 29.6743 5.84E-07 
868 Lys Hδb 1.73357 0.00339 
868 Lys Hδa 1.73315 0.00319 
868 Lys Cε 42.2244 4.77E-07 
868 Lys Hεa 3.03437 0.00297 
868 Lys Hεb 3.03477 0.00282 
869 Leu H 7.5776 0.00398 
869 Leu N 117.685 0.0783 
869 Leu Cα 57.4517 0.15305 
869 Leu Cβ 41.7007 0.03246 
869 Leu C 179.013 0.00721 
869 Leu Hα 4.23806 0.00195 
869 Leu Hβb 1.78746 0.00239 
869 Leu Hβa 1.6478 0.0048 
869 Leu Cγ 27.0504 0 
869 Leu Hγ 1.73922 0.0025 
869 Leu Cδb 24.3551 0 
869 Leu Hδb* 0.98976 0.00126 
869 Leu Cδa 24.0086 0 
869 Leu Hδa* 0.93839 0.00129 
870 Lys H 7.43241 0.00492 
870 Lys N 119.745 0.05829 
870 Lys Cα 58.1664 0.13547 
870 Lys Cβ 32.5915 0.0583 
870 Lys C 178.294 0.00871 
870 Lys Hα 4.18154 0.00429 
870 Lys Hβa 1.93246 0.0047 
870 Lys Hβb 1.93246 0.0047 
870 Lys Cγ 24.964 0 
870 Lys Hγa 1.53745 0.00147 
870 Lys Hγb 1.53765 0.00147 
870 Lys Cδ 29.0493 4.77E-07 
870 Lys Hδa 1.78621 0.0048 
870 Lys Hδb 1.78621 0.0048 
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Residue  Atom Chemical  
SD 
No. Name Name Shift 
870 Lys Hεa 3.03879 7.64E-04 
870 Lys Hεb 3.03879 7.64E-04 
871 Ile H 8.15904 0.00582 
871 Ile N 119.766 0.05856 
871 Ile Cβ 38.0721 0.05619 
871 Ile Cα 65.5724 0.14795 
871 Ile C 176.878 0.00696 
871 Ile Hα 3.52254 0.00366 
871 Ile Hβ 2.02602 0.00364 
871 Ile Cγ2 17.487 0.03299 
871 Ile Hγ2* 0.92966 0.00353 
871 Ile Cδ1 14.1374 0.02193 
871 Ile Hδ1* 0.92632 0.00563 
871 Ile Cγ1 30.542 0.01963 
871 Ile Hγ1a 0.97757 0.00441 
871 Ile Hγ1b 1.70294 0.0013 
872 Asp H 7.87591 0.0083 
872 Asp N 118.717 0.06038 
872 Asp Cα 57.6551 0.0633 
872 Asp Cβ 40.1209 0.01395 
872 Asp C 179.439 0.02414 
872 Asp Hα 4.49454 0.00222 
872 Asp Hβb 2.75854 4.10E-04 
872 Asp Hβa 2.67651 0.00599 
873 Gln H 7.90065 0.00764 
873 Gln N 119.765 0.05288 
873 Gln Cα 58.7929 0.07978 
873 Gln Cβ 28.6422 0.08718 
873 Gln C 178.979 0.0039 
873 Gln Hα 4.13587 0.00412 
873 Gln Hβb 2.32871 0.00452 
873 Gln Hβa 2.18527 0.00211 
873 Gln Cγ 33.8436 0 
873 Gln Hγb 2.59886 0.00108 
873 Gln Hγa 2.4155 0.00129 
874 Ile H 8.41827 0.01871 
874 Ile N 121.613 0.03438 
874 Ile Cα 64.3688 0.03043 
874 Ile Cβ 37.4898 0.00936 
874 Ile C 178.391 0.03093 
874 Ile Hα 3.95593 0.00216 
874 Ile Hβ 2.03401 0.00355 
Residue  Atom Chemical  
SD 
No. Name Name Shift 
874 Ile Cγ1 28.6746 4.77E-07 
874 Ile Hγ1b 1.63895 0.00101 
874 Ile Hγ1a 1.35955 7.10E-04 
874 Ile Cγ2 18.2461 0 
874 Ile Hγ2* 0.92857 8.97E-04 
874 Ile Cδ1 13.8474 0 
874 Ile Hδ1* 0.79977 8.25E-04 
875 Leu H 8.36051 0.00678 
875 Leu N 119.913 0.03797 
875 Leu Cβ 41.0843 0.07007 
875 Leu Cα 57.541 0.05608 
875 Leu C 179.28 0.04123 
875 Leu Hα 4.06523 0.00506 
875 Leu Hβb 1.86484 0.0068 
875 Leu Hβa 1.47942 0.00543 
875 Leu Cδb 22.949 0 
875 Leu Hδb* 0.87416 0.00241 
875 Leu Cδa 25.8834 0 
875 Leu Hδa* 0.87396 0.00196 
875 Leu Cγ 26.5817 0 
875 Leu Hγ 1.87544 0.00334 
876 Ala H 7.51682 0.00778 
876 Ala N 119.165 0.0597 
876 Ala Cα 53.9187 0.08417 
876 Ala Cβ 18.2907 0.16455 
876 Ala C 178.916 0.03093 
876 Ala Hα 4.15281 0.00218 
876 Ala Hβ* 1.47892 0.00192 
877 Ala H 7.54681 0.00774 
877 Ala N 118.421 0.07757 
877 Ala Cα 52.8415 0.06334 
877 Ala Cβ 19.2129 0.01321 
877 Ala C 177.305 0.01031 
877 Ala Hα 4.22297 0.00479 
877 Ala Hβ* 1.31484 0.00119 
878 His H 7.62823 0.00282 
878 His N 115.8 0.1143 
878 His Cα 53.7042 0.07041 
878 His Cβ 29.6642 0.04828 
878 His C 173.164 0 
878 His Hα 4.92971 0.00121 
878 His Hβb 3.0162 0.0017 
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Residue  Atom Chemical  
SD 
No. Name Name Shift 
878 His Hβa 2.89972 0.0013 
879 Pro C 176.573 0 
879 Pro Cβ 31.4713 5.84E-07 
879 Pro Cα 64.5846 0.06347 
879 Pro Hα 4.44034 0.00192 
879 Pro Hβb 2.22887 0.00332 
879 Pro Hβa 1.70084 0.00223 
879 Pro Cγ 27.2529 6.74E-07 
879 Pro Hγb 1.94806 0.00237 
879 Pro Hγa 1.69754 0.00291 
879 Pro Cδ 50.0597 6.74E-07 
879 Pro Hδb 3.45294 0.01065 
879 Pro Hδa 3.43333 0.00733 
880 Tyr N 115.455 0.10386 
880 Tyr C 175.727 0.03301 
880 Tyr H 7.72745 0.01725 
880 Tyr Cβ 37.8631 0.05164 
880 Tyr Cα 56.3868 0.03244 
880 Tyr Hα 4.69267 0.00526 
880 Tyr Hβb 3.25107 0.00353 
880 Tyr Hβa 3.08055 0.00518 
881 Met H 7.3873 0.01575 
881 Met N 122.519 0.01209 
881 Met C 175.16 0 
881 Met Cβ 33.7922 0.00104 
881 Met Cα 56.1775 0 
881 Met Hα 4.3915 0.00193 
881 Met Hβb 2.10066 0.00143 
881 Met Hβa 2.00082 0.00175 
881 Met Cγ 32.3857 0 
881 Met Hγb 2.49945 0.00147 
881 Met Hγa 2.37641 0.00313 
882 Lys Hα 4.47614 0.00318 
882 Lys Hβb 1.99422 0.00254 
882 Lys Hβa 1.76864 0.00278 
882 Lys C 175.105 0 
882 Lys Cβ 33.2495 0.0184 
882 Lys Cα 55.3267 0.06015 
882 Lys Cγ 24.0265 5.84E-07 
882 Lys Hγb 1.47847 0.00179 
882 Lys Hγa 1.41202 0.00184 
882 Lys Cδ 28.5806 3.37E-07 
Residue  Atom Chemical  
SD 
No. Name Name Shift 
882 Lys Hδa 1.71363 0.00219 
882 Lys Hδb 1.71363 0.00219 
882 Lys Cε 42.8494 0 
882 Lys Hεa 3.05549 0.00218 
882 Lys Hεb 3.05569 0.00224 
883 Asp H 7.17861 0.01917 
883 Asp N 118.628 0.10886 
883 Asp Cα 53.4716 0.11584 
883 Asp Cβ 42.274 0.06952 
883 Asp Hα 4.71019 8.11E-04 
883 Asp Hβb 2.87945 0.00528 
883 Asp Hβa 2.70758 0.00543 
883 Asp C 176.091 0.00416 
884 Leu H 8.67368 0.01377 
884 Leu N 126.55 0.08685 
884 Leu Hα 4.06978 0.00669 
884 Leu Hβa 1.6475 0.00455 
884 Leu Hβb 1.71405 0.00167 
884 Leu C 178.926 0.01058 
884 Leu Cα 57.5991 6.74E-07 
884 Leu Cβ 42.1532 6.74E-07 
884 Leu Cγ 26.8942 4.77E-07 
884 Leu Hγ 1.71305 0.00267 
884 Leu Cδa 24.1989 0 
884 Leu Hδa* 0.91592 0.00332 
884 Leu Cδb 25.1022 0 
884 Leu Hδb* 0.95163 0.00179 
885 Asn H 8.43173 0.00931 
885 Asn N 118.696 0.04015 
885 Asn Cα 56.1423 0.11868 
885 Asn Cβ 38.0127 0.01407 
885 Asn C 177.243 0 
885 Asn Hα 4.50167 0.00722 
885 Asn Hβb 2.99602 8.50E-04 
885 Asn Hβa 2.84701 0.00267 
885 Asn Nd2 113.666 0.02465 
885 Asn Hδ2b 7.79014 0.00525 
885 Asn Hδ2a 6.91251 0.00272 
886 Ala H 7.86152 0.002 
886 Ala N 124.32 0.04563 
886 Ala Cα 54.3886 0.05908 
886 Ala Cβ 18.7821 2.38E-07 
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Residue  Atom Chemical  
SD 
No. Name Name Shift 
886 Ala C 179.992 1.91E-06 
886 Ala Hα 4.21537 0.00604 
886 Ala Hβ* 1.51465 0.00185 
887 Leu H 8.05634 0.00893 
887 Leu N 118.261 0.05979 
887 Leu Cα 57.4633 0.09047 
887 Leu Cβ 43.216 0.05622 
887 Leu C 178.648 0.01234 
887 Leu Hα 4.0626 0.01148 
887 Leu Hβb 1.8814 0.00517 
887 Leu Hβa 1.43823 0.00803 
887 Leu Cγ 27.8491 0 
887 Leu Hγ 1.64082 0.00144 
887 Leu Cδa 23.7302 0 
887 Leu Hδb* 0.86229 0.00165 
887 Leu Cδb 26.3521 0 
887 Leu Hδa* 0.86001 8.50E-04 
888 Ser H 8.23167 0.01184 
888 Ser N 113.876 0.07414 
888 Ser Cβ 63.2108 0.07844 
888 Ser Cα 61.9158 0.11383 
888 Ser Hα 4.19304 0 
888 Ser Hβa 4.00923 0 
888 Ser Hβb 4.00923 0 
888 Ser C 175.32 0 
889 Ala H 7.45268 0.00845 
889 Ala N 122.257 0.07279 
889 Ala Cα 54.2191 0.11425 
889 Ala Cβ 18.3724 0.00342 
889 Ala C 179.035 0.01231 
889 Ala Hα 4.22546 0.00249 
889 Ala Hβ* 1.4988 0.00516 
890 Leu H 7.38504 0.00737 
890 Leu N 117.066 0.10314 
890 Leu Cα 56.1446 0.11266 
890 Leu Cβ 42.3105 0.03678 
890 Leu C 178.295 0 
890 Leu Hα 4.24396 0.00552 
890 Leu Hβb 1.95295 0.00181 
890 Leu Hβa 1.45344 0.00284 
890 Leu Cγ 26.2868 3.37E-07 
890 Leu Hγ 1.75265 0.00421 
Residue  Atom Chemical  
SD 
No. Name Name Shift 
890 Leu Cδa 25.7272 3.37E-07 
890 Leu Hδa* 0.62804 0.00212 
890 Leu Cδb 22.7928 3.37E-07 
890 Leu Hδb* 0.82602 0.00179 
891 Val H 7.58846 0.00583 
891 Val N 119.438 0.04858 
891 Val Hα 3.56229 0.02212 
891 Val Hβ 1.8538 0.00776 
891 Val C 176.468 0 
891 Val Cβ 31.7106 0.07969 
891 Val Cα 64.866 0.0286 
891 Val Cγa 22.0939 2.38E-07 
891 Val Cγb 22.0939 2.38E-07 
891 Val Hγa* 0.81864 0.00297 
891 Val Hγb* 0.81918 0.00297 
892 Leu H 7.51931 0.01412 
892 Leu N 121.079 0.15188 
892 Leu Cα 55.157 0.12877 
892 Leu Hα 4.26399 0.0058 
892 Leu Hβa 1.67129 0.00382 
892 Leu C 176.219 0.01051 
892 Leu Cγ 26.7555 4.77E-07 
892 Leu Hγ 1.73772 5.24E-04 
892 Leu Cδb 25.2925 0 
892 Leu Hδb* 1.01228 7.00E-04 
892 Leu Cδa 23.2274 0 
892 Leu Hδa* 0.95517 8.86E-04 
892 Leu Cβ 42.9379 0.21664 
892 Leu Hβb 1.73791 7.10E-04 
893 Asp H 7.47737 0.00388 
893 Asp N 125.456 0.06679 
893 Asp Cα 56.273 0.0295 
893 Asp Cβ 42.4644 4.77E-07 
893 Asp Hα 4.4153 0.0011 
893 Asp Hβb 2.68709 0.00118 
893 Asp Hβa 2.59496 0.00474 
* indicates the atoms that are equivalent to each other 







Appendix II  
Full 1H/15N-HSQC assignments of diUb 
chain 
 
Figure A1 Full 1H/15N-HSQC assignments of M1-diUb. The spectrum was acquired 
from this thesis. The signals were assigned according to the previously reported chemical 
shifts of M1-diUb (BMRB entry: 26790). Signals of the sidechains are linked via dashed lines 
















Figure A2 Full 1H/15N-HSQC assignments of K48-diUb. The spectrum was acquired 
from this thesis. The signals were assigned according to the previously reported chemical 
shifts of ubiquitin (BMRB entry: 17769) and M1-diUb (BMRB entry: 26790). Signals of the 
sidechains are linked via dashed lines and not assigned. NMR signals were assigned by 















Figure A3 Full 1H/15N-HSQC assignments of K63-diUb. The spectrum was acquired 
from this thesis. The signals were assigned according to the previously reported chemical 
shifts of ubiquitin (BMRB entry: 17769) and M1-diUb (BMRB entry: 26790). Signals of the 
sidechains are linked via dashed lines and not assigned. NMR signals were assigned by 











Appendix III  
Sequence alignments of N4BP1 with 
MCPIP1 and KHNYN 
 
Figure A4 Sequence comparison between mN4BP1 (Uniprot: Q6A037) and 
hMCPIP1 (Uniprot: Q5D1E8). Domains sharing high sequence similarity were 
highlighted in dashed boxes. A. Schematic representation of the domain structures from the 
two proteins. B. Full-length sequence alignments between the two proteins. Identical 
residues are shaded in red. The residues with >80% similarities are shaded in grey. 




Figure A5 Sequence comparison between mN4BP1 (Uniprot: Q6A037) and 
mKHNYN (Uniprot: Q80U38). N4BP1 shares overall high sequence similarity with 
KHNYN except that KHNYN does not contain the UBA-like domain. Domains sharing high 
sequence similarity were highlighted in dashed boxes. A. Schematic representation of the 
domain structures from the two proteins. B. Full-length sequence alignments between the 
two proteins. Identical residues are shaded in red. The residues with >80% similarities are 









Appendix IV  
Protein constructs and primers used in 
this thesis 
 










mN4BP1 (1-392) KH+UBM+UBA pGEX-6P1 N4BP1-F N4BP1-392R 
mN4BP1 (1-342) KH+UBM pGEX-6P1 N4BP1-F N4BP1-342R 
mN4BP1 (1-311) KH+UBM pGEX-6P1 N4BP1-F N4BP1-311R 
mN4BP1 (1-144) KH-like domain pET47b 47b-N4BP1-F 47b-N4BP1-144-R  
mN4BP1 (144-311) UBM-like domain pET47b 47b-N4BP1-144-F 47b-N4BP1-311-R  
mN4BP1 (312-392) UBA-like pET47b 47b-N4BP1-312-F  47b-N4BP1-392-R 
mN4BP1 (613-774) RNAse pCold-TF pCold-RNAse-F pCold-RNAse-R  
hMCPIP1 (112-132) + 
mN4BP1 (613-774) 




mN4BP1 (613-893) RNAseCUE pCold-TF pCold-RNAse-F pCold-CUE-R 
hMCPIP1 (112-132) + 
mN4BP1 (613-893) 
Chimeric RNAseCUE pCold-I 
pCold-NM; NM-1; 
NM-2 pCold-CUE-R 
mN4BP1 (850-893)  CUE pET47b 47b-CUE-F 47b-CUE-R 
mN4BP1 (850-893)  CUE pGEX-6P1 6P1-CUE-F 6P1-CUE-R 













Table A2 Other protein constructs used in this thesis 
Construct Name Domain description Vector Note 
hHOIP (697-1072) RBR+LDD pET49b Lab stock 
hHOIP (300-1072) ZF+NZF1+NZF2+UBA+RBR+LDD pET49b Lab stock 
hHOIL-1L (1-478) FL protein lacking the last 32 residues pET49b Lab stock 
CDC34    pET15 Lab stock 
M1-diUb   pET47b Lab stock 
M1-tetraUb   pGEX-4T1 Lab stock 
M-Cys-Ub  pGEX-6P1 Lab stock 
NEDD8   pGEX-2TK Lab stock 
Ub WT   pGEX-6P1 Lab stock 
Ub K48A    pGEX-6P1 Lab stock 
Ub K48R   pGEX-6P1 Lab stock 
UbcH5c   pGEX-6P1 Lab stock 
UBC13    pET15b  Lab stock 
Ube1  pET28 Lab stock 



















Table A3 Primers used for making the N4BP1 protein constructs 
Primer Name Sequence (5’-3’) 
47b-N4BP1-F CTTTCAGGGACCCGGGATGGCGGCCCGGGTG 
47b-N4BP1-144-F CTTTCAGGGACCCGGGAACGAGAACCTCCCCAGTAATCAG 
47b-N4BP1-312-F  CTTTCAGGGACCCGGGGGTAAGGGGTCAGCTGGAAATG 
47b-N4BP1-144-R  TTAATTAAGCCTCGAGTCAGTTGCTCTCAAAGAGCTTCACAAAC 
47b-N4BP1-311-R  TTAATTAAGCCTCGAGTCAATCTGGCAAAAGCTCCCCTTC 
47b-N4BP1-392-R TTAATTAAGCCTCGAGTCATTCTTGGAGCCTTTTATTTTCTTTTTC 
47b-CUE-F CTTTCAGGGACCCGGGGAGACCAGCGAGCTGAGGG 


































Appendix V  
Structure statistics for N4BP1 CUE 
CS-Rosetta model 
Table A4: Summary of structure statistics for N4BP1 CUE CS-Rosetta model 
Experimental restraints input for CS-Rosetta  
13Cα shifts                     44 
13Cβ shifts                     44 
13C’ shifts                     43 
15N shifts                      40 
1HN shifts                      40 
13Hα shifts                     44 
Total restraints             255 
Average pairwise RMSD* (Å)  
Cα                               0.49 
Backbone atoms        0.48 
Heavy atoms              0.80 
All atoms                   1.01 
Measures of structure quality** 
Ramachandran favored regions (%)                     100 
Ramachandran Outliers (%)                                 0 
Ramachandran distribution Z-score                      
          whole -1.43 ± 0.90 
          helix -0.69 ±0.60 
          sheet none 
          loop -1.64 ± 1.39 
Favored rotamers (%)                                        100
Poor rotamers (%)                                           0 
Cβ deviations >0.25 Å                                         0
Bad bonds (%)                                                 0
Bad angles (%)                                                   0 
All-atom clashscore***                                     1.4
* Pairwise RMSD was calculated using the structure ensemble containing 10 best refined 
models.       
**Quality data for model 5 from the Structure ensemble. Model 5 is the overall representative, 
medoid model (most similar to other models in the ensemble). 





Appendix VI  
Supplementary binding data 
 
 
Figure A6 ITC measurement reveals that N4BP11-392 doesn’t bind to HOIP697-1072. 
A: The isotherm of titrating N4BP11-392 into HOIP697-1072. B: The isotherm of titrating 
N4BP11-392 into buffer as control. Data were analyzed by the MicroCal PEAQ-ITC Analysis 
Software. Measurement conditions: Syringe: 0.5 mM N4BP11-392, Cell: 50 µM HOIP697-1072, 18 







Figure A7 Analytical size-exclusion chromatography reveals that N4BP11-392 
doesn’t bind to HOIL-1L. The SEC column used here is Superose 10/300 GL (24 mL, GE 
Healthcare). The buffer used here is SEC buffer (150 mM NaCl, 50 mM HEPES, pH 7.6, 1 mM 
DTT). Flow rate: 0.5 mL/min. Each protein in the sample is 100 µM. Loading volume is 200 
µL for all the measurements. “HOIL-1L/N4BP1 1-392” indicates the UV trace of the mixture 
of N4BP11-1392 and HOIL-1L (each at 100 µM) together loaded onto the column. No peak shift 
was observed for the protein mixture indicating that there was no larger protein complex 
formed. “SUM” is the sum of the two separate UV traces of N4BP11-1392 and HOIL-1L. 












Appendix VII  
Investigating the role of an arginine 
residue near the Fe-S cluster N2 in 
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    Mitochondria are among the most important and complicated organelles 
in eukaryotes. Originated from endosymbiosis, mitochondria are 
semiautonomous and involved in various processes, including energy 
metabolism, signal transduction, redox homeostasis etc. The main function 
of mitochondria is supplying energy to the cells. During aerobic respiration, 
products from glycolysis, β-oxidation of fatty acid as well as amino acid 
oxidation are transferred to the tricarboxylic acid cycle (TCA), and the energy 
is reserved in the form of two reductive substrates—NADH and FADH2. In 
mitochondria, electrons from the reductive substrates are transferred 
through the electron transport chain (ETC) and then reduce O2 to finally 
generate H2O. At the same time, the protons are pumped from the 
mitochondria matrix to the intermembrane space, generating the so-called 
“proton-motive force (Δp)”. Protons then follow the electrochemical gradient 
to return to the matrix via ATP synthase. ATP is thus generated. 
The electron transport chain consists of a series of redox carriers, 
including NAD+/NADH, flavoprotein, cytochrome, iron-sulfur protein and 
ubiquinone. These basic units are further assembled into four complexes 
(complex I-IV) (Table B1; Figure B1).  
 
Table B1 The composition of mammalian electron transport chain 




980 KDa FMN, two [2Fe-2S], six [4Fe-4S] 
II succinate dehydrogenase 120 KDa 
FAD, [2Fe-2S], [4Fe-4S], [3Fe-4S], 
cyt b560 
III cytochrome bc1 complex 480 KDa cyt b562, cyt b566, Rieske FeS, cyt c1 




Figure B1. The mitochondrial respiratory chain showing all four complexes and 
ATP synthase (© 2015 Sazanov, by permission, Licence No: 4872620687820). 
 
Complex I (NADH: ubiquinone oxidoreductase) is the largest protein 
complex in the respiratory chain, including one flavin mononucleotide and 
eight iron-sulfur clusters. Complex II (succinate dehydrogenase) has four 
subunits and six cofactors. The electrons are transferred through the 
iron-sulfur clusters from both Complex I and Complex II, and finally reach to 
the ubiquinone binding site to reduce ubiquinones (UQ or CoQ). Complex III 
(cytochrome bc1 complex) catalyzes the electron transfer from reduced 
ubiquinone (UQH2) to cytochrome c. Complex IV (cytochrome c oxidase) is 
the last enzyme in the respiratory chain. The electrons are transferred from 
cytochrome c to reduce O2 into H2O. 
    For each pair of electrons transferred to O2 through the respiratory chain, 
four protons are pumped out through the inner mitochondrial membrane by 
Complex I, four by Complex III and two by Complex IV. The proton gradient 
thus forms the proton-motive force to generate ATP through ATP synthase 
(Figure B1). The overall equation for this process is: 





1.1.1 Complex I 
    Complex I (NADH: ubiquinone oxidoreductase), also known as NADH 
dehydrogenase, at a molecular weight of ~980 KDa in mammalian species, is 
one of the largest membrane protein assemblies and one of the most 
important components in the mitochondria respiration chain.  
 
Figure B2 A brief structure of the core subunits of mammalian Complex I 
showing the peripheral arm and the membrane arm (© 2016  Zhu et al., by 
permission, Licence No: 4872630418512). 
 
    Electron microscopic reconstructions have established the overall 
L-shaped structure of Complex I from all reported organisms (Baradaran et 
al., 2013; Djafarzadeh et al., 2000; Grigorieff, 1998). The peripheral arm 
protrudes into the mitochondrial matrix and the membrane arm is embedded 
in the inner membrane. Mammalian Complex I consists of 45 subunits, of 
which 14 make up the catalytic core (Figure B2). The core subunits are highly 
conserved from bacteria to human, dominating the catalytic machinery (Zhu 
et al., 2016). Because the main research object in this chapter is the Complex I 
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from Yarrowia lipolytica (a yeast species), the corresponding names of the 
core subunits from Bos taurus and Yarrowia lipolytica are compared in 
Table B2.  
 
Table B2 The nomenclature of 14 core subunits of Complex I 







75 KDa NUAM one [2Fe-2S], two [4Fe-4S] 
51 KDa NUBM flavin, one [4Fe-4S] 
49 KDa NUCM  
30 KDa NUGM  
24 KDa NUHM  
PSST NUKM one [2Fe-2S] 




ND1 NU1M  
ND2 NU2M  
ND3 NU3M  
ND4 NU4M  
ND5 NU5M  
ND6 NU6M  
ND4L NULM  
 
    Complex I first oxidizes one molecule of NADH, then delivers two 
electrons through a long chain of iron-sulfur clusters and finally reduces one 
molecule of ubiquinone. Concomitantly, four protons are pumped into the 
mitochondrial matrix, thus contributing ~ 40% of the proton-motive force to 
the ATP synthesis. These processes are described as proton-coupled electron 
transfer (PCET) reactions. The overall equation of this catalysis is: 
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NADH+H++UQ+4H+in → NAD++UQH2+4H+out 
    As a major contributor of reactive oxygen species (ROS), Complex I 
dysfunction has been implicated in various diseases such as Leigh disease, 
Leber’s hereditary optic neuropathy etc. Moreover, Complex I is the most 
common site for mitochondrial anomalies, accounting for as many as 
one-third of respiratory chain deficiencies. Genetic engineering by mouse 
model has revealed several important roles of different Complex I subunits. 
Understanding how Complex I functions at the molecular level will ultimately 
assist to develop powerful medical treatments to the mitochondria-related 
diseases. 
    In Complex I, NADH oxidation and electron transfer have been now 
relatively well understood. In contrast, the mechanism of how electron 
transfer and ubiquinone reduction are involved in proton translocation is still 
ambiguous (Hirst & Roessler, 2016).   
1.1.2 Iron-sulfur clusters 
    Iron-sulfur clusters are found in metalloproteins including ferredoxins, 
hydrogenases, and mitochondrial Complex I, acting as key cofactors in the 
redox reaction to transfer electrons. For over 40 years, electron paramagnetic 
resonance spectroscopy (EPR) has been employed as a powerful way to 
characterize Fe-S clusters. There are 8 iron-sulfur clusters in mammalian 
Complex I, seven of which participate in the process of electron transfer. 
Among them, cluster N1a and N1b are binuclear [2Fe-2S] clusters, while 
cluster N2, N3, N4, N5, N6a and N6b are tetranuclear [4Fe-4S] clusters. 
Bacteria Complex I contains an additional [4Fe-4S] cluster, named N7, but 
not conserved. When Complex I is reduced with NADH, some of the clusters 
are paramagnetic thus can be detected by EPR spectroscopy (for example, 




Figure B3 Fe-S clusters and the electron transfer relay in Complex I. The X-band 
and W-band EPR spectra showing the overall signals of Fe-S clusters in Complex I from B. 
taurus. Spectra coloured in black are the original data while spectra coloured in red are the 
simulated data. The subspectra of four Fe-S clusters are isolated by simulation and indicated 
respectively below the X-band and W-band EPR spectra. The electron transfer relay is shown 
next to the spectra. Clusters coloured in grey don’t contribute to EPR signals (© 2016 Hirst 
and Roessler, by permission).  
 
Fe-S clusters in Complex I are arranged in a specific relay to transfer 
electrons, thus defining the main electron pathway (Hirst & Roessler, 2016). 
Figure B3 shows the typical EPR spectra of NADH reduced Complex I from B. 
taurus, of which four Fe-S clusters can be identified. N1 signal from Y. 
lipolytica has been shown to correspond to the N1b signal from B. taurus 
(Zickermann et al., 2007). Note that only at a temperature below 10 K and 
higher microwave power, can cluster N5 be detectable due to its fastest spin 
relaxation rate (Kerscher et al., 2002). In the order of increasing spin 




1.1.3 Cluster N2 
    Cluster N2 is in the terminal of the electron transfer pathway in Complex 
I and localized in the interface between the PSST and 49 KDa subunit in Bos 
taurus. While all the other EPR-detectable clusters in this pathway show a 
relatively lower redox midpoint potential, N2 exhibits the highest midpoint 
potential (the Em,7 of N2 is ~-140 mV). It receives electrons from upstream 
Fe-S clusters and then transfers to ubiquinone (Ohnishi, 1998).  
1.1.3.1 The study of cluster N2 by EPR spectroscopy in Y. 
lipolytica 
The pH dependence of cluster N2 and its close distance to the 
ubiquinone binding site has made it attractive to investigate the role of N2 in 
proton translocation (Zwicker et al., 2006). Most of the research on N2 is 
conducted by EPR spectroscopy. Thanks to the genetic tools using Y. 
lipolytica, site-directed mutagenesis of the nuclear genome encoded subunit 
can be easily achieved. Thus, several critical residues that are close to the N2 
cluster have been mutated to study the coupled mechanism. Table B4 shows 
the reported changes of the N2 EPR signal from corresponding point 
mutation. 
From the EPR spectra, several key residues that display significant 
changes of EPR signals have been identified. Shifted EPR signal may indicate 
a possible change of the microenvironment around N2. The decreased or 
increased intensity of N2 signals may imply the changes of the N2 potential. 
Most of the reported EPR spectra of N2 cluster are in relatively low 
resolution or limited by the sample preparation (some mutations were 
detected using the membrane prep). It still could not give a whole picture of 
how electron transfer in cluster N2 is coupled with proton translocation. To 




Table B3 Reported N2 EPR signals of mutations in NUCM subunit (Bovine: 49 
KDa) from Y. lipolytica 







Complex I reduced 




et al., 2001 
R141A undetectable 
D143E decreased 
























Y144W gxy shifted to lower field 
Y144I undetectable 
Y144H 







1.1.3.2 Possible participation of cluster N2 in proton 
translocation 
    Some evidence has partially supported that cluster N2 is involved in 
coupling redox energy to proton translocation. The highly conserved residue 
Tyr87, located in the Nqo4 subunit of Complex I in Thermus thermophilus, 
close to cluster N2 and facing the quinone-binding site, has been suggested to 
participate in both electron and proton transfer (Berrisford & Sazanov, 2009). 
Cluster N2 has an unusual coordination by ‘tandem cysteines’, Cys54 and 
Cys55 (Figure B4), which has been proposed to initiate conformational 
changes and/or protonation of bound quinone (Berrisford & Sazanov, 2009). 
    The reduction potential of cluster N2 is pH-dependent at a value of -60 
mV/ pH within physiological pH range and it has been demonstrated that a 
-60 mV/ pH is needed for a strong proton-coupled electron transfer reaction 
(Ingledew & Ohnishi, 1980), giving cluster N2 much possibility to act as an 
energy-coupling site. However, the reported pH dependence value of cluster 
N2 is -36 mV/ pH in Y. lipolytica (Zwicker et al., 2006). Through 
site-directed mutagenesis in Y. lipolytica, the conserved residue His226 has 
been identified as the major redox-Bohr group that modulates the N2 redox 
potential. At pH 7, the midpoint potential of cluster N2 in H226M shifted 
from -140 mV to -220 mV and the pH dependence of cluster N2 was 
completely abolished (Grgic et al., 2004; Zwicker et al., 2006). Recently, Le 
Breton and co-workers re-measured the pH dependence of cluster N2 and 
concluded that cluster N2 from bovine Complex I possessed a pH 
dependence of -40 mV per pH unit which is in agreement with the 
observation from Y. lipolytica. Advanced EPR study of the 
micro-environment of cluster N2 has demonstrated that two weak-coupled 
exchangeable protons are present near cluster N2 but not strong enough to 
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be coupled with the energy transduction, thus excluding the direct role of 
cluster N2 as the energy-coupling site in Complex I (Le Breton et al., 2017).   
    Even so, the possible indirect role of cluster N2 in Complex I catalysis 
cannot be excluded and its clear function requires further investigation. 
 
Figure B4 Conserved key residues around cluster N2 with bovine complex I 
numbering (© 2018 J. Wright, by permission, private correspondence).  
 
1.1.4 Quinone reduction  
    In Complex I, ubiquinone is reduced by its direct electron donor cluster 
N2. Ubiquinone accepts one electron to become semiquinone radicals, which 
further receive one electron to form ubiquinol (QH2). It is quite free for 
ubiquinone to diffuse in the inner mitochondrial membrane because of its 
hydrophobic property, making itself a perfect carrier to transfer electrons to 
Complex III in the respiratory chain. Notably, ubiquinone is competent to 
carry both electrons and protons, thus playing a critical role in coupling 
redox energy to proton translocation. 
    The 3.3 Å crystal structure of the entire Complex I from T. thermophilus 
has provided several important clues to the mechanism of quinone binding 
and proton translocation. Co-crystallization of this bacterial Complex I with 
decylubiquinone reveals that the quinone headgroup is located about 12 Å 
from cluster N2 to guarantee the electron transfer, and forms hydrogen bond 
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with H38 and Y87 of the subunit Nqo4 (corresponding to the 49KDa in 
bovine), thus a quinone-binding channel was proposed (Baradaran et al., 
2013). By hybrid quantum mechanics and molecular mechanics simulations 
in T. thermophilus, a hypothesis was proposed that the quinone reduction is 
coupled to its local protonation by three residues from Nqo4. Tyr87 and 
His38 rapidly transfer one proton respectively to quinone to generate QH2. 
The local deprotonation of Asp139 by His38 further stabilized the QH2 
species. The His-Asp forms the ion pair that undergoes a large 
conformational change during this process. When quinone receives an 
electron from the cluster N2, the His-Asp pair remains intact. But after the 
protonation of quinone, the two residues from this ion pair dissociate from 
each other. Meanwhile, the hydrogen bond between Y87 and the headgroup 
of QH2 is destroyed (Sharma et al., 2015). From the structure of mammalian 
Complex I with a 4.2 Å resolution, a similar quinone-binding channel is 
identified, indicating the high conservation between prokaryotes and 
eukaryotes (Zhu et al., 2016). The conserved critical residues that form the 
hydrogen bond with quinone can be identified as well (Figure B5 left). 
Interestingly, a “bottleneck” composed by several charged and polar residues 
was described in this channel, suggesting that conformational changes may 





Figure B5 The proposed quinone-binding channel in mammalian Complex I 
from bovine (© 2016  Zhu et al., by permission, Licence No: 4872630418512). The 
bottleneck is indicated by the two red arrows on the right.  
 
1.1.5 Protein arginine methylation  
Protein arginine methylation is one of the most prevalent and conserved 
post-translational modifications. It is widely spread in eukaryotes and 
catalyzed by a group of protein family called protein arginine 
methyltransferases (PRMTs). PRMTs could transfer the methyl group from 
S-adenosylmethionine (AdoMet) to the guanidine group of the arginine 
residue in the target protein.  
Figure A6 shows the methylation pathway catalyzed by PRMTs (Esse et 
al., 2012). In general, PRMTs can be classified into two main subfamilies, 
both of which could catalyze mono-methylation process to produce 
mono-methylarginine (MMA). The difference between the two families is that 
Type I RPMTs function to further catalyze asymmetric dimethylation where 
both two methyl groups are covalently attached to the same nitrogen atom of 
the guanidine group. This family includes PRMT1, PRMT3, PRMT4, PRMT6 
and PRMT8, producing asymmetric dimethylarginine (ADMA). Whereas 
Type II RPMTs catalyze symmetric dimethylation to generate symmetric 
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di-methylarginine (SDMA) where two methyl groups are attached to two 
different nitrogen atoms of the guanidine group. This family contains PRMT5 
and PRMT9 (Bedford, 2007; Yang & Bedford, 2013). 
    It is found that nearly 2% of the arginine residues are dimethylated in the 
liver cell nucleus. This modification has been implicated to participate in 
various critical biological processes, including transcriptional regulation, 
RNA metabolism, chromatin remodelling, signaling transduction and cell 
proliferation etc (Bedford & Clarke, 2009; Boffa et al., 1977). 
 
Figure B6 The dimethylation pathway catalyzed by PRMTs (© 2012 Esse et al., by 
permission). 
 
1.1.5.1 Dimethylation of Arginine 121 in the Complex I NUCM 
subunit 
    Residue Arg121 is located in the NUCM subunit of Complex I from Y. 
lipolytica. It became the first candidate residue for investigation in this 
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project. Some of its distinctive characteristics make it attractive to study the 
effect on the reduction potential of cluster N2. 
    First of all, R121 is in close proximity to cluster N2 (~5 Å) (Figure B7a), 
and well-conserved among several species from E. coli to human, but 
surprisingly absent in T. thermophilus (Figure B7c). Another special feature 
of this residue is that it is dimethylated in human, bovine, yeast and some of 
the bacteria but not in E.coli (Figure B7b). As for the fact that the N2 potential 
is both much lower in T. thermophilus and E.coli than other species, Hirst 
and Roessler (2016) suggested that the presence of this modification on the 
arginine residue influences the reduction potential of cluster N2.   
 
Figure B7 The arginine residue in the NUCM subunit of Complex I. a. The position 
of R121 residue (in Y. lipolytica Complex I numbering) relative to N2. Figure modified from 
the bovine Complex I structure (© 2016 Hirst and Roessler, adapted with permission); b. The 
evidence from mass spectroscopy that R85 in the human 49KDa subunit is dimethylated as 
indicated by the red line (© 2013 Carroll et al., by permission); c. Sequence alignments 
showing the conservation of the arginine residue among several species. the red dots 






1.1.5.2 The function of arginine dimethylation in Complex I 
    There are some functional studies on the R121 residue from different 
spices. J. E. Walker’s group published two papers in 2013 on the topic of R85 
dimethylation (the corresponding residue of R121 in human). One shows that 
R85 can be symmetrically dimethylated at its ω–NG, NG’ atoms of the 
guanidine group (Carroll et al., 2013). In another paper, it is confirmed that 
NDUFAF7 is the methyltransferase which is responsible for dimethylating the 
R85 residue in the human NDUFS2 subunit (corresponding to the 49KDa in 
bovine Complex I) (Rhein et al., 2013). NDUFAF7 belongs to the type II 
PRMTs. Suppression of NDUFAF7 causes the severe decrease of OCR (rate of 
consumption of oxygen) linked to Complex I. Moreover, the expression of 
both NDUFS7 (corresponding to PSST in bovine Complex I) and ND1 subunit 
is reduced, indicating that NDUFAF7 is required for the assembly of Complex 
I. Consistent with this, MidA, the homologous protein of human NDUFAF7 in 
Dictyostelium discoideum, has been identified as the methyltransferase 
required for the assembly of mitochondrial Complex I (Carilla-Latorre et al., 
2010). Downregulation of MidA in HEK294T cells results in a decreased level 
of Complex I. From Tocilescu’s PhD thesis (2009), the Complex I content of 
R121K mutant in Y. lipolytica is only about 38% compared to WT, indicating 
that the assembly of Complex I is affected in this mutant.  
    Our collaborator Judy Hirst’s group in Cambridge has proven that R121 in 
Yarrowia is also dimethylated (private correspondence), which is in 
accordance with what has been observed in another yeast species P. pastoris 
(Carroll et al., 2013), making it possible for us to do further study on this 
modification.  
1.1.6 EPR spectroscopy theory  
    Electron paramagnetic resonance (EPR) or electron spin resonance (ESR) 
is widely used to detect the unpaired electron in paramagnetic species. In 
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1945, EPR phenomenon was discovered by the former Soviet Union physicist 
E. Zavoisky from chemicals which have paramagenetic properties, like MnCl2, 
CuCl2 etc. Since then, the development of EPR technique started to flourish 
and more advanced EPR approaches have been established. Because of its 
unique advantage compared to other spectroscopy, such as high sensativity, 
low sample volume etc., EPR has been widely applied to many fields involved 
in physics, cheimstry, biology, medical research etc.  
    EPR is a way to detect the energy transduction between different energy 
level when a paramagnetic substance is being excited in the provided 
magnetic field. Taking the free electron with a spin angular momentum 
S=±1/2 as an example, when applying an increasing magnetic field H, the 
spin energy level of the electron starts to split into two energy levels. This 
energy splitting is called electron Zeeman effect (Hagen, 2008; Brustolon, 
2009) (Figure B8). 
 
Figure B8 The energy splitting (Zeeman effect) of a free electron in an applied 
magnetic field H. 
 
    The higher level state α, with the magnetic quantum number Ms=+1/2, 






βe is the Bohr magnetón 
ge is the Landé factor (or simply called g factor) of a free electron  
 
As an important EPR parameter, g factor reflects the contribution from 
electron spin angular momentum as well as the orbital angular momentum to 
its intrinsic magnetic moment. For a free electron which only carries the spin 
angular momentum, ge=2.0023.  
Similarly, the energy of the lower enegy level β with the magnetic 
quantum number Ms=-1/2 is:  
Eβ =-1/2geβeH 
Thus, the difference between the two energy levels is:  
ΔE=Eα -Eβ= geβeH 
    For a free electron, ge and βe are all constants. Therefore the energy 
separation ΔE is proportional to the applied external magnetic field H. 
    If an electromagnetic wave with the radiation frequency ν is 
perpendicularly applied to the H, and the electromagnetic radiation energy 
meets the below equation:  
hν= geβeH 
    The electron spin in the lower energy level β could then absorb this 
energy and transit to the higher energy level α. This resonance is thus called 
the electron magnetic resonance. The equation above is the foundation of 
EPR spectroscopy.  
To achieve the resonance, in principle, we could either keep the magnetic 
field constant and change the frequency of the electromagnetic radiation 
(“frequency sweep”), or alternatively apply an electromagnetic wave with a 
constant frequency and change the magnetic field (“field sweep”). Due to the 
current limitation of the microwave techniques, the latter “field sweep” 
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method is widely applied to most of the EPR spectrometers. X-band is the 
most commonly used microwave band in EPR at a frequency of 9.75 GHz. In 
this case, The resonance field at g=2 is 0.348 T. 
    In this chapter, X-band continuous wave EPR (CW-EPR) is used to study 
cluster N2 from different Complex I mutants.  
1.1.7 Aims of this research 
    Some studies have suggested that the undetectable N2 EPR signal in 
the T. thermophilus Complex I is probably caused by the low potential of 
cluster N2 (Hinchliffe et al., 2006; Meinhardt et al., 1990) and the adaption to 
use menaquinone instead of ubiquinone (Mooser et al., 2006). Another 
observation worth noticing is that ubiquinone is switched from menaquinone 
to semiquinone under anaerobic conditions, suggesting a possible 
explanation that the potential of cluster N2 in E. coli is lower than those in 
other species (Ingledew & Poole, 1984). Table B5 compares the reported N2 
midpoint potentials from different species. 
  
Table B4 The reported N2 midpoint potential value from different species 
Species Em (mV) at pH7 References 
E. coli -220 Leif et al., 1995 
T. thermophilus N2 not observed 
Meinhardt et al., 1990; 
Hinchliffe et al., 2006 
Y. lipolytica 
WT: -140 Zwicker et al., 2006； 
Le Breton et al., 2007 H226M: -220 




    Investigating how Arg121 affects the potential of cluster N2 is the main 
topic of this chapter. Site-directed mutagenesis is employed to mutate Arg121 
into either a similar residue or a different one. To study the dimethylation 
property of Arg121, the best way is to find the homologous gene of human 
NDUFAF7 in Y. lipolytica and then erase the modification by knocking this 
gene out. 
Combined with the above molecular biology techniques, EPR 
spectroscopy will be the ultimate approach to study cluster N2 in this project, 
providing more information on the local environment of cluster N2 and 

























Excella E25 shaker (New Bruswick) 
Innova 44R shaker (New Bruswick) 
Centrifuge:  
Centrifuge 5424 (eppendorf) 
Centrifuge 5810R (eppendorf) 
Universal 320R (Hettich) 
Avanti J-30I equipped with JA1000 rotor (Beckman Coulter)  
OptimaTM L-100XP Ultracentrifuge equipped with Ti 45 or Ti 70 rotor 
(Beckman Coulter) 
Column: 
Self-packed Ni-NTA column (50 mL, filled with Ni SepharoseTM 6 Fast Flow, 
GE Healthcare) 





Cary 100 UV-Vis spectrophotometer (Aglient)  
WPA Biowave II Spectrophotometer (Biochrom) 
EPR spectrometer: Elexsys E500 spectrometer (Bruker) equipped with ER 
4118X-MS2 resonator (Bruker);  
Protein purifier: AKTApurifierTM (GE Healthcare) 
pH meter: 3510 pH Meter (JENWAY) 
Autoclave: tactrol 2 (Priorclave) 
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Electroporator: Gene Pulser XcellTM (Biorad) equipped with Gene Pulser® 
Cuvette (Biorad, 0.2 cm gap) 
Electrphoresis: Mini-PROTEIN® Tetra System (Biorad) 
Thermocycler: T100TM Thermal Cycler (Biorad) 
Peristaltic pump: P-1 (Pharmacia Fine Chemials) 
Concentrator: Amicon® Utra-15 Centrifugal Filters (Merk Millipore) 
1.2.1.2 Chemicals 
Bovine Serum Albumin (BSA), Benzamidine hydrochloride hydrate, Tris 
(Trizma® Base), imidazole, Potassium ferricyanide (III), 6-aminocaproic 
acid, Lyticase, Menadione, PMSF, MOPS sodium salt, HEPES, Glycerol, 
Sodium phosphate monobasic, Lithium acetate dihydrate, NADH, Coenzyme 
Q1 (Sigma-Aldrich); 
CHAPS (Alfa Aesar); 
EDTA (VWR CHEMICALS); 
Sodium dithionite (Merck KGaA); 
Asolectin (Avanti® Polar Lipids); 
n-Dodecyl β-maltoside (DDM) (GLYCON Bioch); 
Decylubiquinone (UQ), Piericidin A, Rotenone (CAYMAN CHEMICAL); 
cOmplete, EDTA-free protease inhibitor cocktail tablets (ROCHE); 
Sodium chloride (Fisher Chemical); 
Agar, YPD broth, LB broth, sorbitol (Formedium). 
1.2.1.3 Antibiotics 
Ampicillin sodium, Hygromycin B (Formedium) 
1.2.1.4 Kits 
E.Z.N.A® Yeast DNA Kit (OMEGA BIO-TEK, D3370)； 
E.Z.N.A.® Gel Extraction Kit (OMEGA BIO-TEK, D2500); 
QIAprep Spin Miniprep Kit (QIAGEN, 27104)； 
Pierce® BCA Protein Assay Kit (Thermo Scientific, 23225); 
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In-Fusion® HD Cloning Kit (Takara). 
1.2.1.5 Enzymes 
OneTaq MasterMix, Q5 Polymerase MasterMix, T4 ligase (NEB); 
Restriction Enzyme: NheI-HF, EcoRI-HF, BamHI, DpnI (NEB). 
1.2.1.6 Plasmids 
Name Insertion Source 
pINA443 YlURA3 U. Brandt 
pUC19-YALI0D12859g YALI0D12859g this work 
pUC19-ΔYALI0D12859g::YlURA3 
YALI0D12859g partially replaced by 
YlURA3 
this work 
pUB26-NUCM  NUCM  J. Hirst 
pUB26-NUCM-R121M NUCM carrying R121M mutation J. Hirst 
pUB26-NUCM-R121K  NUCM carrying R121K mutation this work 
1.2.1.7 Bacterial trains 
E.coli: Stellar™ Competent Cells (Clontech); 
Y. lipolytica: WT (GB10 background); Δnucm (GB10 background). 
1.2.2 Methods 
1.2.2.1 Molecular biology related methods 
A. Site-directed mutagenesis (SDM) 
    The pUB26-NUCM (WT) and pUB26-NUCM-R121M plasmid as well as 
the corresponding Y. lipolytica strains were kindly given from Hirst’s Group 
(MBU, Cambridge). The pUB26-NUCM-R121K mutant was made based on 
the above plasmid using the following site-directed mutagenesis method by 
introducing lysine (AAG) to replace the arginine 121 site in NUCM CDS.  
    1) The Primer design 
The method to achieve the site-directed mutagenesis is generally 
replicating the whole plasmid by using a pair of primers near the expected 
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mutated site. In general, the primers were designed to have 3’ “G/C” clamps 
and were modified with 5’-phosphorylation. In this case, the forward primer 
contains the mutated nucleotides (AAG instead of CGA). The reverse primer 
is a short sequence coming from the upstream of the mutated site. The primer 
sequences are listed in Appendix VI.  
2) PCR 
    Q5 polymerase (NEB) was chosen to replicate the whole plasmid carrying 
the point mutation. The typical elongation time is ~40 s/kb. The reaction 
system and condition are shown as follows. If necessary, gradient annealing 
temperature can be attempted to optimize the best condition. When the PCR 
was finished, run a 1% TAE agarose gel at 80 V to make sure a visible PCR 
product can be generated (gel extraction is not necessary).  
25 µL reaction system: 
5ÍQ5 buffer (NEB) 5 µL 
10 mM dNTPs  0.5 µL 
10 µM Fwd Primer 1.25 µL 
10 µM Rev Primer 1.25 µL 
Plasmid (20 ng/µL) 1 µL 
H2O                                           15.75 µL 
Q5 DNA polylmerase (NEB)          0.25 µL 
PCR program: 
1) 98 °C  00:30 
2) 98 °C  00:10 
3) 60-70 °C 00:30              
4) 72 °C  05:30           go to step 2 (24Ícycles) 
5) 72 °C  05:00 





The below reaction was prepared in a PCR tube and incubated for 2 
hours at RT (or using a thermal cycler at 25 °C). Then the sample was heated 
at 65 °C for 20 min to inactivate T4 ligase using a thermal cycler. 
PCR product (directly from the PCR reaction)     5 µL 
10ÍT4 DNA ligase buffer (NEB)      2 µL 
H2O                                           15 µL 
T4 DNA ligase (NEB) 1 µL 
4) DpnI digestion 
    1 µL DpnI was added to the ligation solution at 37°C for 15 min. After 
digestion, the reaction was heated at 80°C for 20 min to inactivate DpnI using 
a thermal cycler. 
5) Transformation 
    All the above solution was transferred to the Stellar™ Competent Cells 
following manufacturer’s instruction (Clontech, protocol PT5055-2). The 
transformed cells were spread onto ampicillin-containing plates at 37 °C 
overnight.  
6) Sequencing 
    Several colonies were picked from the above plates to make small culture 
and then the plasmid was extracted for sequencing. Primers used for 
sequencing the pUB26-NUCM plasmid (including the one carrying the point 
mutation) are shown below: 
  Sequencing the NUCM insertion direction: n49knc1; 49-2.5; 
  Sequencing the CDS: NUCM-R (reverse); 49-1 (forward). 






B. Gene cloning  
    The gene cloning was conducted in a similar way to what’s described in 
part A of 1.2.2.1 to amplify the gene by Q5 polymerase, but extend the cycle 
number to 30.  
    The gene insertion into pUC19 plasmid and the replacement of the target 
gene by YlURA3 gene were all achieved by the In-Fusion cloning technology 
using In-Fusion® HD Cloning Kit (Takara).  
    In brief, the gene-specific primer for gene amplification is designed with 
an extra 15 bp extension that is homologous to the end of the linearized vector. 
By PCR, each end of the gene was added with this 15 bp vector sequence. The 
In-Fusion enzyme could fuse this gene fragment and the linearized vector by 
homologous recombination from the overlaps, thus achieving the gene 
insertion into the vector.   
    The detailed information of the primer sequence is in Appendix VI. 
C. Yeast genome extraction 
    The genome extraction from yeast cells was performed following 
manufacturer’s instruction of the E.Z.N.A® Yeast DNA Kit (OMEGA 
BIO-TEK). 
D. Yeast plasmid extraction 
    Since yeast cells are hard to break, an extra cell wall digestion was needed. 
The cell pellet was collected from 3 mL yeast culture by centrifuge, and then 
resuspended in 500 µL TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA) 
containing 40 µL 5,000 unit/mL lyticase (SIGMA, L4025) at 30°C for 1h to 
digest the cell wall. After lyticase digestion, the plasmid extraction was 




    Note that the plasmid extracted by this method is not visible by DNA gel. 
But if transferred into E.coli cells, the plasmid can be further simply extracted 
at a notably amount and is qualified enough for either DNA gel or sequencing.  
E. Yeast transformation and colony PCR 
The transformation of the plasmid into the corresponding Y. lipolytica 
strain was followed by the method below slightly modified from Wang et al., 
2011. Here is a brief procedure.  
    Yeast strain was inoculated into 20 mL starter cultures of 2ÍYPD and left 
shaking at 30°C overnight. When the OD600 of this starter culture reached to 
13-18, another 100 mL of 2×YPD was inoculated using this 20 mL starter 
culture to an OD600 of 0.1 and incubated by shaking at 30°C overnight. When 
the OD600 of the 100 mL culture reached to 1-2.5, the cell pellet was harvested 
at 5000 g for 5 mins and resuspended into 8 mL competence buffer (10 mM 
Tris-HCl, pH 7.5, 0.6 M sorbitol, 150 mM Li-Acetate). The cells were 
incubated in competence buffer for 1 hour at R.T. with occasional mixing and 
then harvested again as before. Note that from now on, all subsequent steps 
should be done on ice or in the cold room. The cells were resuspended and 
washed in 3 mL ice-cold 1 M sorbitol. The washing step was repeated 3 times 
with the final resuspension into 5 mL ice-cold 1 M sorbitol. The cells were 
kept on ice untill ready for transformation.  
    In a cooled electroporation cuvette with a 2 mm gap, at least 1 µg of DNA 
(5 ug would be best) was mixed with 200 uL competent yeast cells thoroughly 
with the pipette. The mixture was electroporated with 1.5 kV, 200 ohms and 
25 µF (Using the exponential protocol in the BIORAD electroporator. This 
protocol should give a pulse length at around 4.6 ms). Then 1 mL RT 2ÍYPD 
was immediately added to the cells. The cells were then transferred into a 1.5 
mL Eppendorf tube and incubated for 2-3 hours by shaking at 30°C. After 
incubation, the cells were plated onto the required selection plates.  
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    For the transformation of pUB26-derived plasmids, a final concentration 
of 150 µg/ml hygromycin was required in the selection medium. To make sure 
the plasmid was successfully transferred into the yeast cells, a control plate 
pasted with electro-shocked competent cells without plasmid was needed. 
Several relatively larger single colonies were picked respectively from the 
plate for colony PCR (Small colonies that were similar to what was growing in 
the control plate usually come from the background, but not positive 
transformants). Each single colony was resuspended in 40 µl TE buffer and 
then treated at 95°C for 20min in a PCR cycler. Then normal colony PCR was 
conducted using this crude sample as the template. If necessary, the mutated 
site can be again sequenced to make sure the yeast carries the correct point 
mutation. In this case, the plasmid is needed to be extracted from the yeast 
following the method described in section D from 1.2.2.1.  
1.2.2.2 Microbiology and protein related methods 
A. Standard large-scale Y.lipolytica growth procedure 
    A tiny amount of yeast glycerol stock was inoculated into 50 ml 2ÍYPD 
(pH 5.5) in a 250 ml conical flask. Hygromycin is added at a final 
concentration of 50 µg/mL in the medium if Y.lipolytica mutation is needed 
to grow. The flask was incubated at 30°C by shaking at 225 rpm until OD600 
was around 10-20. 2 mL of this culture was transferred into a 2 L flask 
containing 500 mL 2ÍYPD, and left for shaking until the cell density reaches 
to 20-30. The cells were harvested at 5000 g for 15 min and kept at -80°C. 
B. Protein quantification 
The quantification of either isolated Complex I or total protein from the 
membrane is followed by the manufacturer’s instruction of Pierce® BCA 





C. Membrane Preparation from Y. lipolytica 
Required solutions: 
Breaking buffer (pH 7.2): 20mM MOPS-Na, 400 mM Sorbitol, 5 mM EDTA, 5 
mM Benzamidine hydrochloride hydrate, 5 mM 6-aminocaproic acid, 2 % 
BSA  
Washing buffer (pH 7.2): 20mM MOPS-Na, 400 mM Sorbitol, 5 mM 
Benzamidine hydrochloride hydrate, 5 mM 6-aminocaproic acid 
Resuspension buffer (pH 7.45): 20 mM NaH2PO4, 50 mM NaCl 
1) Cell disruption 
    The yeast cell pellet was defrosted at 4°C overnight. The disruptor 
(Emulsiflex Avestin C3) was pre-chilled to 4°C. Approximately 50 g cells were 
resuspended in 100 mL ice-cold breaking buffer (containing 2 mL fresh 200 
mM PMSF). The resuspended cells were disrupted at 25-30 Kps for ~15 
rounds. The cells were frequently checked under microscopy.  
    Alternatively, if Dyno-mill is chosen to disrupt the cells, normally 500 g 
cells were resuspended in 1 L ice-cold breaking buffer (containing 4 mL fresh 
200 mM PMSF) for the disruption. The cells were disrupted by pumping 
through the system twice at 8-10 rpm/min. 
2) Ultracentrifugation 
    The disrupted cells were collected at 5700 g in 4°C for 30mins to get rid of 
the cell debris. The supernatant was transferred to the ultracentrifuge 
(Beckman Coulter) at a speed of 208,000 g for 1 hour at 4°C. The membrane 
pellet was collected and resuspended in ice-cold washing buffer using a glass 
homogenizer and then re-spin at 208,000 g at 4°C for 1 hour. This step was 
repeated to wash the membrane thoroughly. The pellet was finally 
resuspended in ice-cold resuspension buffer and divided into 20-25 mL 
aliquots then kept at -80°C. 
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D. General protein purification of Complex I from Y. lipolytica 
membrane 
Required solutions: 
2% asolectin/CHAPS stock (25mL): Weight out 500 mg CHAPS, and dissolve 
in 25 mL of buffer (containing 20mM NaH2PO4, 400 mM NaCl, 52 mM 
imidazole). This solution is homogenized using a glass homogenizer to make 
the 2 % stock (syringe through a 0.22 µm filter before use) 
Buffer A (pH 7.2): 20mM NaH2PO4, 400 mM NaCl, 52 mM imidazole, 0.1% 
DDM, 0.02% asolectin/CHAPS (filtered and degassed before use; the filtered 
DDM and asolectin/CHAPS should be added freshly before loading to the 
column) 
Buffer B (pH 7.2): 20mM NaH2PO4, 400 mM NaCl, 140 mM imidazole, 0.1% 
DDM, 0.02% asolectin/CHAPS (filtered and degassed before use; the filtered 
DDM and asolectin/CHAPS should be added freshly before loading to the 
column) 
Gel Filtration buffer (pH 7.45): 20 mM Na-MOPS, 150 mM NaCl, 0.05% 
DDM, 10% glycerol (filtered and degassed before use; the filtered DDM 
should be added freshly before loading to the column) 
Neutralised (pH 7.5) 1M imidazole 
    All the steps below should be performed on ice or in a cold room. 
1) Membrane dissolution  
    Approximately 20-50 mL mitochondrial membrane pellet was thawed in 
RT water if frozen. The membrane was ultra-centrifuged at 208,000 g for 30 
mins at 4°C. The pellet was homogenized in resuspension buffer (from part C 
of 1.2.2.2) to a finally concentration of 20 mg/mL. Two EDTA-free protease 
inhibitor cocktail tablets (ROCHE) were added into this solution. 10% DDM 
was added dropwise to a 2:1 ratio of DDM: protein by stirring. The membrane 
was solubilized for 30 mins. The supernatant was collected at 208,000 g at 
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4°C for 1 hour. The solid NaCl was added to a final concentration of 400 mM 
and imidazole was added to 20 mM from 1M neutralised stock.  
2) Protein purification 
    The above sample was loaded onto a pre-equilibrated 50 mL Ni-NTA 
column which was connected to the AKTApurifierTM. The impurities were 
washed by 100% Buffer A. Complex I was eluted by 100% Buffer B. All the 
fractions from the Complex I peak were collected and concentrated by using a 
Millipore 15 (50,000 MWCO) concentrator. The concentrated protein was 
injected onto the pre-equilibrated Superose 6 increase column at a flow rate 
of 0.5 mL/min. Complex I peak was then concentrated as described above to 
5-20 mg/mL and frozen as 10-20 µL aliquots in dry ice or liquid nitrogen and 
kept at -80°C. 
E. Potentiometric titration 
Required solutions: 
TIP 7 buffer: 50 mM HEPES, 50 mM Na2HPO4, 150 mM NaCl, 0.03% DDM, 
30% glycerol 
5/10/20/40 mM gradient sodium dithionite 
5/10/20/40 mM gradient K3Fe(CN)6 solutions 
    The potentiometric titration of Complex I by the reductant sodium 
dithionite (SDT) or the oxidant K3Fe(CN)6 under anaerobic condition is 
mainly followed what’s described in Wright et al., 2016 (Figure B9). Here is a 
brief description.  
    First, the protein was exchanged into TIP7 buffer using the Millipore 15 
(30,000 MWCO) concentrator at 4°C. Then the below apparatus was 
prepared in the glovebox where an anaerobic environment was maintained. 
The apparatus was chilled to 4°C by connecting to a water bath. The 
electrodes connected to the PSTrace 4.6 Software were assembled onto the 
cell in order to record the current potential. All the redox potentials of the 
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sample recorded here were relative to the Ag/AgCl reference electrode and 
were needed to convert to the standard hydrogen electrode (SHE). At least 
140 µl protein sample was added into the cell with two tiny stirring balls 
(2mm diameter). The following mediators were added to the protein as well: 
Indigotrisulfonate, Methylene Blue, Benzyl Viologen, Indigodisulfonate, 
Anthraquinone-2-sulfonic acid. The final concentration of each mediator was 
the same as the protein. The solution was stirred at full speed for at least 15 
min for degassing.  
 
Figure B9 The schematic of the apparatus for the potentiometric titration (© 
2016 Wright et al., by permission). 
Several SDT and K3Fe(CN)6 solutions with gradient concentration (5-40 
mM) were made respectively in the glovebox. Substoichiometric amounts of 
either the reductant or oxidant were added to the protein samples to achieve 
different degrees of potential. Each sample (~10 µL) with a certain potential 
was transferred into the EPR tube and fast-frozen in the liquid nitrogen. The 





G. EPR spectroscopy 
    All the EPR samples were measured in X-band continuous-wave mode 
(CW) using an ER 4118X-MS2 resonator (Bruker) in an Elexsys E500 
spectrometer (Bruker) equipped with a cryostat system (Cryogenic Ltd., UK). 
The detailed EPR condition for each measurement is shown in the legend of 
the corresponding spectrum in the result part.  
    For the titrated samples, the sample without adding any 
reductant/oxidant was used as the background. For all the other individual 
samples, the corresponding buffer was used as the background. 
The EPR data were analyzed and simulated by EasySpin software 




















1.3 Results  
1.3.1 The measurement of N2 redox potential in wide 
type Complex I from Y. lipolytica 
    The purification of Complex I from Y. lipolytica has been established in 
our lab. The His-tagged wild type Complex I was successfully purified by 
Ni-affinity chromatography followed with gel filtration.  
    In order to make sure that the purified Complex I functions well, the N2 
redox potential of Y. lipolytica wild type Complex I was measured. The 
reported N2 midpoint potential (Em,7) of the wild type Complex I in Y. 
lipolytica at pH 7 is -140 mV (vs Standard Hydrogen Electrode (SHE)) 
(Zwicker et al., 2006). Other reported value from various species can be 
found in Table B5 in section 1.1.7. 
    The potentiometric titration of the wild type protein was carried out 
under anaerobic conditions in the glovebox. The protein potential was 
controlled by adding substoichiometric amounts of sodium dithionate (SDT) 
and the plot in Figure B10a below shows the recorded potential data (vs SHE). 
The samples with different degrees of potential were measured by CW-EPR 
(Figure B10b). Then the EPR data was simulated and the integral area of N2z 
was used to fit to the one-electron Nernst curve (Figure B10c). The result 
shows that the Em,7 of N2 from the wild type Complex I is -137.8±4 mV, which 
is in line with the reported data (Zwicker et al., 2006), indicating that the 





Figure B10 The measurement of N2 redox potential in the wild type Complex I 
from Y. lipolytica. a. The titration trace of the WT Complex I potential (vs SHE) by adding 
different amount of sodium dithionate at 4°C under anaerobic conditions. b. The CW-EPR 
spectra of the samples from the titrations. The black spectra indicate the experimental data. 
The red dashed spectra indicate the simulated spectra. The vertical dotted lines indicate the 
corresponding Fe-S cluster. The asterisk indicates the signal of unknown impurity from the 
EPR tube. EPR measurement condition: temperature, 25 K; microwave frequency, 7 GHz; 
microwave power, 2 mW. c. The one-electron Nernst curve of the titration data. The integral 
area of N2z from Figure b is used to fit for the curve.   
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1.3.2 The research of the R121M variant 
    The R121M mutation in NUCM gene from Y. lipolytica was first studied 
by EPR. The R121M variant was successfully purified by Ni-affinity 
chromatography followed by gel filtration. The SDS-PAGE gel indicates the 
clear bands of each core subunit compared with WT protein (Figure B11). 
 
Figure B11 SDS-PAGE gel of WT and R121M Complex I from Y. lipolytica. 
 
    The SDT-reduced R121M protein was then measured by CW-EPR. 
Compared to the WT spectrum, no N2 signal is visible in the R121M protein 
(Figure B12 bottom spectrum). The isolated spectrum of individual Fe-S 
cluster has also been simulated. Again, we cannot simulate any N2 signal 
contributing to the overall R121M spectrum, indicating that the absence of 
this residue results in a severe effect on cluster N2. The lack of N2 signal also 
makes it impossible to measure the midpoint potential of N2 in this mutant. 
The g value of each cluster has been summarized in Table B6 together with 
previously published data. The g values from this work are consistent with the 





Figure B12 CW-EPR spectra of fully reduced WT and R121M Complex I. 
Experimental spectra of fully reduced R121M Complex I protein are shown in black.  
Simulated spectra are shown in red. All samples were reduced by SDT. EPR measurement 
condition: temperature, 15 K; microwave frequency, 7 GHz; microwave power, 2 mW. 
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Table B5 g values from the simulated CW-EPR spectra in this work and the 
comparison with published data 
Fe-S 
cluster 
g values g values g values g values 
gz gy gx gz gy gx gz gy gx gz gy gx 
N1 2.020 1.943 1.94 2.018 1.945 1.933 2.02 1.95 1.93 2.024 1.943 1.939 
N2 2.053 1.929 1.925 2.051 1.926 1.918    2.056 1.928 1.920 
N3 2.030 1.924 1.860 2.031 1.930 1.861       
N4 2.103 1.939 1.894 2.104 1.931 1.892 2.10-2.11 1.93 1.89 2.107 1.931 1.888 
N5 2.065 (1.93) (1.90) 2.062 1.93 ~1.89 2.06 1.93 1.89    
Reference 
Djafarzadeh et al., 
2000 
Kerscher et al., 2001; 
Kerscher et al., 2002; 
Garofano et al., 2003 
Summarized by 
Yakovlev et al., 2007 
This work 
 
    From the observation, two hypotheses were proposed to explain the loss 
of the N2 signal in R121M. The potential of R121M could probably decrease to 
a much lower level that SDT could not achieve. Then we tried to use EuDTPA 
as a more powerful reductant to lower the protein potential as much as 
possible (Reda et al., 2008; Roessler et al., 2012), but failed. Another idea is 
that the spin state of N2 is possibly changed to a higher degree in the R121M 
variant. To test if there are any high-spin signals of N2 in R121M, the mutated 
protein was measured under a much lower magnetic field. Unfortunately, 





Figure B13 Experimental CW-EPR spectra of fully reduced R121M Complex I at 
lower magnetic field. EPR measurement condition: temperature, 5 K; microwave 
frequency, 7 GHz; microwave power, 20 mW. 
 
1.3.3 The research on the R121K variant  
    Due to the severe effect from the R121M mutant, another variant R121K 
was chosen for our next study. The structure of lysine is most close to arginine, 
and both side chain groups are positively charged. Thus, the R121K mutation 
was expected to have a mild effect on cluster N2.  
    The R121K mutation in Y. lipolytica has been previously reported. The 
Complex I content in mitochondrial membrane carrying the R121K mutation 
is only 38±2% compared to the WT. The EPR characterizations of this mutant 
have only been reported from the crude samples (the entire mitochondrial 
membrane containing the mutated complex) and no N2 signal was detected 
(Tocilescu, PhD thesis, 2009). To have a clearer idea, this mutant was made 
in this study again and the isolated protein was purified for EPR 
investigation. 
The mutant has been successfully generated by the method described in 
section 1.2.2.1. The complex was then expressed and purified. Unfortunately, 
the CW-EPR spectrum of the isolated R121K Complex I again shows no N2 
signal (Figure B14), similar to that of the R121M variant.  
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The study on the R121M and R121K mutants both indicates the 
importance of R121 residue for N2 function. Apparently R121 cannot be 
simply replaced by a similar residue to complement the deficiency. Due to 
lack of the EPR signals from both mutants, advanced pulse EPR approach 
cannot be employed for our further investigation. Therefore, the study of the 
dimethylation of R121 residue became the next interest of this project.  
 
Figure B14 Experimental CW-EPR spectra of fully reduced R121K Complex I 
compared with WT and R121M at 15K. EPR measurement condition: microwave 
frequency, 7 GHz; microwave power, 2 mW. 
 
1.3.4 Making the NDUFAF7 homolog gene knock-out in Y. 
lipolytica   
1.3.4.1 YALI0D12859g is homologous to human NDUFAF7 in 
Y. lipolytica by bioinformatic analysis 
As discussed in the introduction, human NDUFAF7 is the 
methyltransferase responsible for dimethylating residue R85 in the human 
NDUFS2 subunit (corresponding to NUCM subunit in Y. lipolytica) (Rhein et 
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al., 2013). To find the homologs of human NDUFAF7 in Y. lipolytica, several 
bioinformatics analyses were attempted by sequence alignment from 
different databases, briefly described below: 
    1) Using NDUFAF7 protein sequence as query 
    When using NDUFAF7 as the keyword, two Y. lipolytica proteins were 
found from the Uniprot database, Q6C0X9 and Q6C998. If using human 
NDUFAF7 protein sequence as query in the KEGG Y. lipolytica genome 
database(http://www.genome.jp/kegg-bin/show_genomemap_top?org_id
=yli), the most likely hit is yli:YALI0D12859g given that it has the highest 
score. This sequence is annotated as Q6C998. 
    2) Using NDUFAF7 nucleotide sequence as query 
    To further search for the sequences within larger database in NCBI, the 
human NDUFAF7 (NCBI Reference Sequence: NM_144736.4) gene CDS 
sequence was used as query in the Y. lipolytica (taxid:4952) database by 
BLASTX. Only two protein sequences are found, YALI0D12859p and 
YALIA101S12e01288g1_1. They are only differed by two residues. When 
aligning the sequences in pair, YALI0D12859p and Q6C998 are exactly the 
same. 
    If using the same human NDUFAF7 gene sequence as query in the Y. 
lipolytica CLIB122 (taxid:284591) database, only YALI0D12859p was found 
and it makes no difference with previous results shown above. Using the 
whole mRNA sequence of NDUFAF7 gave the same results. In conclusion, 
from the nucleotide sequence of human NDUFAF7 gene, only one protein 
Q6C998 was found. 
    From the above information, Q6C998 encoded by YALI0D12859g is most 
likely the homologous protein of human NDUFAF7 in Y. lipolytica. Sequence 
alignment shows that the two proteins share 31.9% identity and 47.6% 




Figure B15 Sequence alignment of NDUFAF7 and Q6C998 protein. The identical 
residue pairs from both proteins are indicated in red shade while the residue pairs sharing 
high similarity (>80%) are indicated in grey shade. 
   
1.3.4.2 The method to make the NDUFAF7 homolog gene 
knock-out in Y. lipolytica   
    To knock out the NDUFAF7 homolog gene in Y. lipolytica, the URA3 gene 
encoding Orotidine 5'-phosphate decarboxylase (ODCase) was chosen to 
replace the target gene YALI0D12859g. URA3 gene has been widely used in 
yeast engineering. ODCase plays an important role in the synthesis 
of pyrimidine ribonucleotides (Flynn & Reece, 1999). Loss of ODCase activity 
severely affects the normal growth unless uracil or uridine is added to the 
media, making it easier for the screening by this auxotrophy. Figure B16 
briefly describes the method designed for replacing the target gene with the 




Figure B16 Schematic representation of the method to replace the target gene 
with marker gene by homologous recombination. In this study, the marker gene is 
URA3, and the target gene is YALI0D12859g. 
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    Following the original method reported from Brandt's 
group (Kashani-Poor et al., 2001) (using URA3 to replace NUGM), the target 
gene YALI0D12859g together with its ~1000bp upstream sequence and 
~1000bp downstream sequence was cloned and then inserted into the pUC19 
plasmid at the BamHI site. Since NcoI and EcoRV are located near the 
beginning and the end of the ORF of the target gene respectively, they were 
chosen to double digest this gene in order to cut off most of the ORF (Figure 
B17a, the 1.2Kb fragment). Then the marker gene YlURA3 (originated from 
plasmid pINA443) was reversely inserted into this gap.  
The whole map of this newly generated plasmid is shown in Figure 
B17c.  The 4kb ΔYALI0D12859g::YlURA3 fragment was cut off from the 
plasmid by EcoRI and HindIII  (Figure B17b) from the plasmid. This 4K 
fragment is used for the transformation into Y. lipolytica to achieve the 
homologous recombination. All the ligations were done by in-fusion cloning.  
    Though the plasmid has been successfully generated, unfortunately, the 
transformation into Y. lipolytica gave no positive strains by several trials. 
Even for those strains with URA3 gene insertion, the marker gene is 
off-targeted to other gene loci rather than YALI0D12859g. Apart from the 
off-target problem, another explanation is that YALI0D12859g may have very 
important function to the cell survival, thus knocking out the gene would be 
lethal to Y. lipolytica.  





Figure B17 The making of pUC19-ΔYALI0D12859g::YlURA3 plasmid. a. Double 
digestion of pUC19-YALI0D12859g. Lane 1, control plasmid without treatment. Lane 2, 
plasmid digested by NcoI and EcoRV. Arrow indicates the 1.2Kb ORF fragment. b. Double 
digestion of pUC19-ΔYALI0D12859g::YlURA3 plasmid by EcoRI and HindIII. Arrow 








1.4 Conclusion and discussion 
    In this chapter, the function of R121 residue in NUCM subunit from 
Complex I is studied by combining site-directed mutagenesis with EPR 
spectroscopy.  
    By CW-EPR spectroscopy, the signal of cluster N2 is absent from both 
R121M and R121K mutations and the possibility that cluster N2 changes to a 
higher spin state has been excluded. These findings indicate the importance 
of R121 to maintain the normal function of N2 in Complex I. Unfortunately, 
the lack of EPR signal of N2 cluster from both R121M and R121K variants 
makes it impossible for further advanced EPR studies. 
    We then turned to focus on the possible effect of dimethylation state of 
residue R121 on N2 cluster. To erase the dimethylation on this residue, the 
gene responsible for this modification was searched by bioinformatics. 
Homologous recombination method is chosen to knock this gene out. Most of 
the CDS sequence of this gene (YALI0D12859g) has been replaced by the 
marker gene YlURA3 and inserted into the pUC19 plasmid. Unfortunately, by 
several transformations, the gene knockout is still unsuccessful with a high 
off-target rate observed. Since previous reports have demonstrated that this 
gene has great effects on complex I assembly or stability (Carilla-Latorre et al., 
2010; Rhein et al., 2013), the deficiency of this gene would probably greatly 
affect the yeast viability.  
Instead of the conventional homologous recombination method to knock 
this gene out, deleting part of the gene or making frameshift mutation by the 
CRISPR-CAS9 technique would probably be an alternative way.  
To conclude, R121 from NUCM subunit is one of the key residues that 
affect the direct environments around cluster N2. However, appropriate 




The above work was done by the early of 2017. Until recently, the EPR 
data from this work was published as part of the support to the cryo-EM 
structure of NUCM-R121M complex I (Hameedi et al., 2021). In this structure, 
the R121M mutation causes the missing of the N2 cluster. The nearby 
quinone-binding site is also disordered. It indicates the key roles of R121 in 
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Appendix VIII  
The primers used in Appendix VII 
 
Table B6 Primers used for making and sequencing the NUCM point mutation 
Primer Name Sequence (5’-3’) 
R121LYS-F CTGCACAAGGGAACCGAGAAGC 
R121LYS-R CAGACCGACGTGGGGGTC 





Table B7 Primers used for making and sequencing the YALI0D12859g-related 
constructs 





12859-homo-F ggtacccggggatccCTTCCCGTCTCCATCCTTGT  
12859-homo-R gactctagaggatccAGTTCATCGATCTGTTTGTG 
12859-seq-F TGGCGGCGTAGATAATAGCTC 
12859-seq-R TATTGACCGACAACCACCGCG 
 
 
 
 
